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Summary 
The National Cervical Screening Program (NCSP) aims to reduce cervical cancer cases, as 
well as illness and death from cervical cancer in Australia, through an organised approach to 
cervical screening aimed at detecting and treating high-grade abnormalities before possible 
progression to cervical cancer. The target group is women aged 20–69. 
This report is the latest in the Cervical screening in Australia series, which is published 
annually to provide regular monitoring of national participation and performance for the 
NCSP. While the previous report covered 2009–2010, this report provides data for the  
2010–2011 period of participation in the NCSP, as well as the latest available cervical cancer 
incidence and mortality data (from sources outside the NCSP).  
The following statistics refer to the latest data available for women aged 20–69. 
How many women were diagnosed with, or died from, cervical cancer?  
There were 631 new cases diagnosed in 2009, and 152 women died from cervical cancer in 
2010. This is equivalent to 9 new cases and 2 deaths per 100,000 women, respectively. 
Incidence and mortality have both halved since the NCSP was introduced in 1991, remaining 
at their historic lows of 9 new cases and 2 deaths per 100,000 women since 2002. 
The incidence of cervical cancer in Aboriginal and Torres Strait Islander women was more 
than twice that of non-Indigenous women, and mortality of Aboriginal and Torres Strait 
Islander women was 5 times the non-Indigenous rate. 
How many women participated in the National Cervical Screening Program? 
In 2010–2011, more than 3.6 million women participated in the NCSP. This was 57% of 
women in the target population (after adjustment to exclude those without a cervix). 
Participation was similar across remoteness areas, with the highest participation of 58% in 
Inner regional and the lowest of 55% in Remote areas. 
There were greater differences in participation across socioeconomic status of residence, and 
a clear trend of increasing participation with increasing socioeconomic status from 52% in 
areas of lowest socioeconomic status to 63% in areas of highest socioeconomic status.  
Participation by Aboriginal and Torres Strait Islander women is not available due to 
Indigenous status information not being collected on pathology forms, although there is 
evidence that this population group is under-screened. 
How many women rescreened early or after a reminder letter? 
Only 13% of women with a negative Pap test in 2010 rescreened earlier than recommended. 
Of the women sent a 27-month reminder letter by a cervical cytology register in 2010,  
32% rescreened within 3 months.  
How many high-grade abnormalities were detected? 
In 2011, for every 1,000 women screened, 8 women had a high-grade abnormality detected 
by histology, providing an opportunity for treatment before possible progression to cancer. 
Peak high-grade abnormality detection was for women aged 25–29, a shift from the historic 
age group of 20–24, as a result of a decrease in high-grade abnormalities in younger women. 
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Data at a glance 
The following table provides a comparison of national data against key NCSP performance 
indicators for women in the target age group, 20–69. Summary statistics for the latest 
reporting period are compared with those from the previous reporting period. 
Definitions for these performance indicators are given under each indicator in Section 2.  
Key performance indicators for the National Cervical Screening Program, women aged 20–69, 
previous and latest data 
 Previous data  Latest data Change 
Performance indicator Reporting period Statistic  Reporting period Statistic  
Participation 2008–2009 58.9%  2010–2011 57.2%  
Rescreening       
  Early rescreening 2009 cohort 14.0%  2010 cohort 13.3%  
  Rescreening after reminder letter Letters sent 2009 31.7%  Letters sent 2010 31.5%  
Cytology       
  Unsatisfactory 2010 2.1%  2011 2.1%  
  Negative 2010 92.6%  2011 92.3%  
  No endocervical component 2010 21.1%  2011 21.4%  
  Low-grade abnormalities 2010 3.9%  2011 4.1%  
  High-grade abnormalities 2010 1.4%  2011 1.5%  
Histology       
  Histology tests per 100 cytology tests 2010 3.6%  2011 3.7%  
  Low-grade abnormalities 2010 17.2%  2011 17.4%  
  High-grade abnormalities 2010 25.9%  2011 25.9%  
  High-grade abnormality detection rate 2010 8.5  2011 8.4  
Correlation       
  PPV of high-grade squamous cytology 2009 70.0%  2010 69.8%  
  PPV of high-grade endocervical cytology 2009 71.2%  2010 73.5%  
Incidence 2008 9.3  2009 8.9  
Mortality 2009 1.9  2010 2.0  
Notes  
1. All data are for women aged 20–69; age-standardised proportions and rates are shown where available (crude rates are shown otherwise). 
2. Previous data refers to the previous non-overlapping reporting period, which for participation is 2008–2009, rather than 2009–2010. 
3. Participation is the per cent of eligible women in population. 
4. Early rescreening is the per cent of women with a negative cervical cytology test in February 2010 who rescreened within 21 months. 
5. Rescreening after reminder letter is the per cent of women sent a reminder letter who rescreened within 3 months. 
6. Cytology is per cent of all cytology tests. 
7. Histology is the per cent of all histology tests. 
8. High-grade abnormality detection rate is the number of women with a high-grade abnormality detected by histology per 1,000 women 
screened. 
9. PPV is the positive predictive value, calculated as the proportion of cytology results of possible or definite high-grade that were confirmed on 
histology to be a high-grade abnormality or cervical cancer. 
10. Incidence is the number of new cases per 100,000 women; mortality is the number of deaths per 100,000 women.
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Section 1 Introduction  
This report 
The first section of this report presents an overview of cervical cancer in Australia, and 
outlines the process of cervical screening and the development and management of the 
National Cervical Screening Program (NCSP). It also details the performance indicators used 
for monitoring the NCSP, and provides a brief overview of technical issues that should be 
considered when interpreting information in this report. 
The second section of this report presents the latest national data against the seven NCSP 
performance indicators. Data included in this report are for the 2010–2011 period of 
participation in the NCSP, supplemented by cervical cancer incidence and mortality data 
from national databases outside the NCSP, for which the latest data available are for 2009 
and 2010, respectively. To aid in interpretation of these data, the start of each performance 
indicator delivers a summary that includes its definition and rationale, followed by key 
results to provide readers with an indication of the main findings. More detailed analyses, as 
well as background information where appropriate, follow this summary material.  
More detailed data than those shown within this report are available in Cervical screening in 
Australia 2010–2011: supplementary data tables. These can also be downloaded for free from the 
AIHW website <http://www.aihw.gov.au/publications>. 
Cervical screening in Australia 2010–2011 is part of an annual series. Earlier editions and any 
published subsequently can be downloaded for free from the AIHW website 
<http://www.aihw.gov.au/publications>. The website also includes information on 
ordering printed copies. 
Overview  
What is cervical cancer? 
Cancer is a group of several hundred diseases 
in which abnormal cells are not destroyed 
naturally by the body but instead multiply 
and spread out of control. Cancers are 
distinguished from each other by the specific 
type of cell involved and the place in the 
body in which the disease began.  
Cervical cancer affects the cells of the uterine 
cervix, which is the lower part  
(or ‘neck’) of the uterus where it joins the 
inner end of the vagina. Like other cancers, 
cervical cancer is a disease where normal cells 
change, begin to multiply out of control, and 
form a growth or tumour.  
 
Anatomy: the female reproductive system 
(cervix, ovaries, uterus) 
© National Cancer Institute 2013. 
Source: <http://visualsonline.cancer.gov>. 
Reproduced with permission of the copyright owner. 
 2  Cervical screening in Australia 2010–2011 
Cervical cancer may arise from the squamous cells that cover the outer surface of the cervix 
(known as squamous cell carcinoma) or from the glandular cells in the cervical canal (known 
as adenocarcinoma). In Australia in 2009, 65% of cervical cancers were squamous cell 
carcinoma and 26% were adenocarcinoma (adenosquamous and other cervical cancers made 
up the remainder). 
How common is cervical cancer in Australia? 
Cervical cancer is the 12th most common cancer affecting Australian women (excluding 
basal and squamous cell carcinoma of the skin), with 7 new cases of cervical cancer 
diagnosed per 100,000 women in the population in 2009 (the latest available data). It is also 
the 19th most common cause of cancer-related death, with 2 deaths per 100,000 women in 
2010. 
Cervical cancer incidence and mortality are both higher in Aboriginal and Torres Strait 
Islander women, with incidence more than twice, and mortality 5 times, that of non-
Indigenous women (AIHW & AACR 2010) (for more details see Indicators 6 and 7). 
What causes cervical cancer? 
During the last decade there has been a greater understanding of the natural history of 
cervical cancer. It is now recognised that cervical cancer is a rare outcome of persistent 
infection with human papillomavirus (HPV), and that infection with a high-risk HPV type is 
necessary, although not sufficient, for the development of cervical cancer (Bosch et al. 2002; 
Walboomers et al. 1999).  
Currently 15 high-risk types of HPV are recognised. HPV types 16, 18, and 45 are most 
predominantly associated with cervical cancer, with HPV types 16 and 18 detected in 70–80% 
of cases of cervical cancer in Australia (Brotherton 2008).  
However, infection with one or more of the 40 genital HPV types is extremely common, with 
infection rates of this sexually transmitted infection peaking in women in young adulthood 
(the period following sexual debut). Most HPV infection is asymptomatic and cleared by the 
immune system within a year; however, in up to 10% of women the infection can persist, and 
in a very small number of women, persistent infection with high-risk HPV may eventually 
lead to cervical cancer. 
How do we screen for cervical cancer? 
Cells in the cervix exhibit changes or abnormalities before any progression to cancer occurs. 
These abnormalities are graded depending on how much of the lining of the cervix these 
abnormal cells occupy—low-grade abnormalities are contained in the top layer of the lining 
of the cervix while high-grade abnormalities occupy more layers.  
Low-grade abnormalities are caused by acute infection with HPV and most will regress 
without treatment within a short period of time. High-grade abnormalities usually occur 
after persistent infection with HPV. The probability of a high-grade abnormality progressing 
to cancer increases with age and the extent of abnormality, but cancer is still a very rare 
outcome (NHMRC 2005)—studies suggest that only 12% of the precursor to squamous cell 
carcinoma of the cervix progresses to cancer (Ostor 1993). Cervical screening aims to detect 
and treat these precancerous abnormalities in cervical cells before their potential progression 
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to cervical cancer, thereby reducing cervical cancer incidence as well as morbidity and 
mortality from this disease. 
Cervical screening uses cytology from the Papanicolaou smear, or ‘Pap test’, as the screening 
tool. During a Pap test, cells are collected from the transformation zone of the cervix—the 
area of the cervix where the squamous cells from the outer opening of the cervix and 
glandular cells from the endocervical canal meet. This is the site where most cervical 
abnormalities and cancers are detected. For conventional cytology, these cells are transferred 
onto a slide, and sent to a pathology laboratory for assessment. Collected cells are then 
examined under a microscope to look for 
abnormalities. 
While cervical cytology, the examination of 
the cells collected from the cervix, is a very 
useful tool, it should be stressed that it is not 
diagnostic (unlike cervical histology, which 
is the examination of tissue collected from 
the cervix through a biopsy to confirm the 
presence of an abnormality). As a screening 
tool, the aim of cervical cytology is to 
identify those individuals who may have a 
cervical abnormality (as indicated by the 
presence of abnormal cells in the specimen 
collected) and therefore require further 
diagnostic testing. Since the Pap test collects 
an arbitrary sample of cells from the surface 
of the cervix at an arbitrary point in time, 
and requires a level of judgment in the 
interpretation of sampled cells, cervical 
cytology cannot accurately reveal all 
abnormalities that may exist in the cervical 
tissue in situ.  
While the ability of cervical cytology to accurately identify those women who do not have 
disease (that is, the specificity) is very high—estimates range from 62% to 98% in an 
International Agency for Research on Cancer (IARC) review—the ability to detect disease in 
those women who truly have the disease (that is, the sensitivity) of a single cervical cytology 
test is only moderate in contrast (40–86%) (IARC 2005). The strength of cervical screening 
comes from repeating the cervical cytology test at agreed rescreening intervals, which allows 
the accurate detection of precancerous abnormalities over the long pre-invasive stage of 
squamous cervical cancers (Dickinson 2002). The recognition of cervical screening as a 
program of rescreening at regular intervals rather than as a single opportunistic test was an 
important distinction (Dickinson 2002). 
Why screen for cervical cancer? 
The initial aim of an organised approach to screening was to further reduce the incidence 
and mortality of cervical cancer beyond the reductions attributable to the opportunistic 
cervical screening available in Australia since the mid-1960s (Dickinson 2002). This aim has 
been realised, with an estimated 70% of squamous cell carcinomas of the cervix (around 
1,200 cases) prevented in 1998 as a result of Australia’s cervical screening program (Mitchell 
Terminology 
Incidence: the number of new cases of 
cervical cancer diagnosed per 100,000 
women in a year. 
Morbidity: illness. 
Mortality: the number of deaths from 
cervical cancer per 100,000 women in a 
year. 
Cytology: the examination of cells from the 
cervix (usually collected by a Pap test) 
through a microscope.  
Histology: the examination of tissue from 
the cervix (usually collected by a biopsy) 
through a microscope. Histology is more 
accurate than cytology because it allows 
the examination of cells and other 
structures, as they would appear in situ. 
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2003), a finding supported by more recent analyses of incidence and mortality trends 
(Canfell 2006; Luke et al. 2007). Indeed the relatively low incidence and mortality of cervical 
cancer in Australia compared with other countries (Ferlay et al. 2010) has been largely 
attributed to Australia’s cervical screening program and its successful implementation in 
1991 (NHMRC 2005).  
How is cervical screening managed in Australia? 
In 1991, the Australian Health Ministers’ Advisory Council (AHMAC) accepted 
recommendations made by the Screening Evaluation Steering Committee in the Australian 
Institute of Health report Cervical cancer screening in Australia: options for change (AHMAC 
1991) that saw the establishment of the Organised Approach to Preventing Cancer of the 
Cervix, Australia’s cervical screening program. Now known as the National Cervical 
Screening Program, it operates as a joint program of the Australian Government and state 
and territory governments, targeting women aged 20–69. A statement of the current national 
policy for cervical screening in Australia appears in the box below, while contact details for 
the state and territory and Australian Government components of the NCSP are provided in 
Appendix B. 
National policy for Australia’s National Cervical Screening Program 
The National Cervical Screening Program recommends that all women aged 18 to 69 years, 
who have ever been sexually active, whether vaccinated or unvaccinated, should have 
cervical screening by Pap smears. Their policy states that: 
‘Routine screening with Pap smears should be carried out every two years for women who 
have no symptoms or history suggestive of cervical pathology.  
All women who have ever been sexually active should start having Pap smears between the 
ages of 18 and 20 years, or one or two years after first having sexual intercourse, whichever 
is later.  
Pap smears may cease at the age of 70 years for women who have had two normal Pap 
smears within the last five years. Women over 70 years who have never had a Pap smear, or 
who request a Pap smear, should be screened.’ 
Source: DoHA 2011a. 
Since cervical screening is not provided by a dedicated service, but is part of primary health 
care, all women who choose to have a Pap test through any health care provider are 
considered to be part of the National Cervical Screening Program. Being part of the NCSP 
means that there are standards for laboratories that interpret Pap test results, evidence-
driven guidelines to aid in the management of women after they receive Pap test results, as 
well as dedicated cervical cytology registers or ‘Pap test registers’ that act as a ‘safety net’ for 
participating women as well as encouraging regular Pap tests.  
Cervical cytology registers fulfil many important roles, including sending reminder letters to 
women overdue for screening, providing a safety net for women who have not had follow-
up of an abnormal result, and providing cytology laboratories and cervical cytology 
providers with previous results for a woman to allow a more detailed evaluation of present 
findings. State and territory cervical cytology registries also provide data on the 
epidemiology and natural history of precancerous lesions, as well as providing data for 
national monitoring of the NCSP. These registers are key to the NCSP and were established 
along with the program in 1991. 
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High-quality cervical cytology in Australian pathology laboratories has also been a key 
component of the screening program, facilitated through the development of National 
Pathology Accreditation Advisory Council (NPAAC) Performance measures for Australian 
laboratories reporting cervical cytology (NPAAC 2006). 
The National Health and Research Council’s (NHMRC) Screening to prevent cervical cancer: 
guidelines for the management of asymptomatic women with screen detected abnormalities (NHMRC 
2005) provides recommendations for the management of women with an abnormal Pap test 
result. They enable practitioners and clinicians to manage the abnormalities detected by Pap 
tests according to evidence-based information which guides best practice. 
How do we monitor the National Cervical Screening Program? 
Performance indicators 
The effectiveness of the NCSP has been monitored since 1996–1997 using performance 
indicators developed to monitor what were originally defined as essential aspects of the 
program. Full definitions of the original performance indicators can be found in Breast and 
cervical cancer screening in Australia 1996–1997 (AIHW 1998). New performance indicators 
were developed following a review that considered changes to both the NCSP and the 
cervical screening environment to ensure the NCSP continued to be monitored optimally. 
These new performance indicators were officially endorsed in September 2009 by the 
Screening Subcommittee of the Australian Population Health Development Principal 
Committee for use by the NCSP, and appeared for the first time in Cervical screening in 
Australia 2008–2009.  
The table below lists the current performance indicators for the NCSP (more information 
about each indicator is available in Section 2 of this report). 
Performance indicators for the National Cervical Screening Program 
1  Participation The percentage of women aged 20–69 who have a 
Papanicolaou smear or ‘Pap test’ in a 2-year period 
2  Rescreening  
   2.1  Early rescreening The proportion of women who have another Pap test within  
21 months of a negative Pap test result  
   2.2  Rescreening after 27-month cervical cytology  
   register reminder letter 
The proportion of women who have a Pap test within  
3 months of being sent a 27-month reminder letter 
3  Cytology The number of Pap test results in each result category  
4  Histology The number of histology results in each result category 
(including the number of women with a high-grade histology 
for every 1,000 women screened) 
5  Cytology-histology correlation A measure of how well cytology correlates with histology 
performed not more than 6 months after the cytology test 
6  Incidence The number of new cases of cervical cancer 
7  Mortality The number of deaths from cervical cancer 
Standards 
While there are no official standards for NCSP performance indicators, in places in this 
report, NPAAC standards in Performance measures for Australian laboratories reporting cervical 
cytology (NPAAC 2006) have been used to provide a benchmark for the data presented. 
 6  Cervical screening in Australia 2010–2011 
These are used as a guide to interpretation only, since this is a different purpose to that for 
which these standards were developed, and differences in definitions and data may exist. 
What does the HPV vaccine mean for cervical screening? 
What is the HPV vaccine? 
Following the recognition that infection with HPV is necessary for the development of 
cervical cancer, HPV vaccination was introduced in Australia in April 2007 as part of the 
National Immunisation Program. There are currently two HPV vaccines registered for use in 
Australia—Gardasil® and Cervarix®, both of which are prophylactic vaccines, which means 
they need to be administered prior to HPV infection.  
These HPV vaccines protect against high-risk HPV types 16 and 18. As noted earlier, HPV 
types 16 and 18 are the two main high-risk HPV types that can lead to cervical cancer, these 
detected in 70–80% of cervical cancers in Australia (Brotherton 2008). Gardasil also protects 
against HPV types 6 and 11, which are commonly associated with genital warts in males and 
females. Gardasil is the HPV vaccine currently used for the National HPV Vaccination 
Program. 
The National HPV Vaccination Program was first introduced on 1 April 2007 as a program 
for females; at its inception it comprised an ongoing program for females aged 12–13 
administered through schools, as well as a catch-up program for females aged 13–26 between 
2007 and 2009, with females aged 13–17 vaccinated through schools and females aged 18–26 
vaccinated through the community (NHVPR 2011). From February 2013, the current school-
based program for females aged 12-13 was extended to males aged 12–13, with a catch-up 
program in 2013 and 2014 for males aged 14–15 (DoHA 2013a). 
Data on the vaccination coverage of participants in the National HPV Vaccination Program 
are collected and reported by the National HPV Vaccination Program Register (NHVPR), 
with full data on vaccination coverage estimates available online (DoHA 2013b).  
A standard indicator proposed to measure HPV vaccine coverage trends internationally 
(WHO 2010), 71.2% of Australian females aged 15 in 2011 were vaccinated with three doses 
of HPV vaccine by age 15 (DoHA 2013b). 
What are the expected effects of the HPV vaccine? 
The National HPV Vaccination Program aims to reduce incidence of HPV-related cancers 
and disease, including cervical cancer. The HPV vaccine, by preventing the HPV infection 
that can lead to 70–80% of cervical cancer (Brotherton 2008), has the potential to reduce the 
incidence of cervical cancer below the already low levels that cervical screening has achieved 
in Australia.  
Importantly, there is potential for the HPV vaccine to reduce the incidence of 
adenocarcinomas as well as cervical cancers in Aboriginal and Torres Strait Islander women 
in a way that cervical screening alone has not been able to achieve (Budd & Sturrock 2010). 
This is because incidence of adenocarcinoma has not fallen to the same degree as incidence of 
squamous cell carcinoma, which is generally considered to be due to sampling and 
interpretation limitations of cervical screening for glandular lesions. As a result, this 
previously rare cancer now comprises around a quarter of all cervical cancers diagnosed 
(Blomfield & Saville 2008) (see Indicator 6). Aboriginal and Torres Strait Islander women also 
have a higher incidence of cervical cancer than non-Indigenous women, which is likely 
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related to Aboriginal and Torres Strait Islander women participating to a lesser degree in 
cervical screening (Binns & Condon 2006; Coory 2002) (see Indicator 6).  
It is important to note, however, that the HPV vaccine does not preclude the need for 
cervical screening. This is because the HPV vaccine only covers 2 of the high-risk HPV types, 
infection with which can lead to cervical cancer, and the HPV vaccine may not be effective in 
women exposed to HPV prior to being vaccinated. Thus cervical screening and the HPV 
vaccine should be seen as a two-pronged approach to the prevention of cervical cancer, and 
vaccinated women should either commence or continue participating in cervical screening 
according to the current NCSP policy (Budd & Sturrock 2010). 
Data  
Data sources 
The main sources of data for the NCSP performance indicators are the state and territory 
cervical cytology registers. Analyses of these data allow monitoring of participation, 
rescreening, cytology, histology, and the cytology-histology correlation (Indicators 1–5). State 
and territory cervical cytology registers are ‘live’ registers. As such, the data within this 
report can only be viewed as being an accurate depiction of the data held by the registers at a 
particular moment in time, since any results or clinical information received by the cervical 
cytology registers subsequent to data provision to the AIHW are unable to be captured. Data 
in this report can be considered accurate as at July 2012. 
Additional to these sources are the AIHW Australian Cancer Database, which is the source of 
cervical cancer incidence data (Indicator 6), and the National Mortality Database, which is 
the source of cervical cancer mortality data (Indicator 7). More details on data sources and 
classifications are provided in Appendix C. 
Note that for each performance indicator, the latest available national data are used, which 
differ depending on both the data source and specifications of each performance indicator. 
Aboriginal and Torres Strait Islander women 
Of the performance indicators used to monitor the NCSP, only incidence and mortality can 
be disaggregated by Indigenous status.  
Cervical cytology registers receive data from pathology laboratories, which means that they 
are limited to those data available on the pathology form accompanying the cervical sample 
and result. Since there is currently no national mechanism for the collection of Indigenous 
status on pathology forms, state and territory cervical cytology registers are currently unable 
to collect Indigenous status. Thus participation, rescreening, cytology and histology trends 
specific to Aboriginal and Torres Strait Islander women cannot be monitored, and the effects 
of initiatives to increase their participation cannot be measured nationally. 
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Reporting women with symptoms 
In principle, women who have symptoms that could indicate the presence of cervical cancer 
(such as abnormal bleeding) at the time of their cervical cytology test should be excluded 
from all performance indicators, since any testing of symptomatic women will be diagnostic 
in nature, rather than true screening.  
In theory, a mechanism exists to remove symptomatic women from the data, as these women 
are able to be identified by the recommendation code RS Symptomatic-Clinical management 
required (included in the National Cervical Cytology Coding Sheet introduced in July 2006).  
However, in 2008–2009, the proportion of women with the RS code was found to vary across 
states and territories from 0.02% through to 2.38% of women screened. These variations were 
too large to reflect any genuine differences in women with symptoms, and concluded to be 
due to inconsistent use of this code nationally. Thus, at this time, RS code is of insufficient 
quality to exclude symptomatic women at the national level.  
All data presented in this report therefore include both symptomatic and asymptomatic 
women. 
Terminology and concepts  
Reporting periods 
This report presents monitoring data over 1-year, 2-year, 3-year and 5-year reporting 
periods. Participation data are presented over a 2-year period in line with the recommended 
2-year screening interval of the NCSP, as well as over a 3-year and 5-year period. Most other 
data are presented for a single calendar year, with the exception of some incidence and 
mortality data, which are presented over a 5-year period to improve stability and 
comparability of rates due to small numbers. 
Age groups 
Data are presented for women aged 20–69 who, as the target group of the NCSP, are the 
primary focus of this report. Detailed data for these, as well as for women under 20 and 70 
and over, can be accessed in Cervical screening in Australia 2010–2011: supplementary data 
tables. 
Crude versus age-standardised 
This report presents crude and age-standardised rates. Crude is the ‘true’ proportion or rate, 
and is appropriate when a single year or reporting period is reported (for example, crude 
participation in 2010–2011 was found to be 56.8%). However, comparisons over time or 
across states/territories or population subgroups require that crude rates are age-
standardised to remove the underlying differences in age-structure over time or between 
groups. These allow analysis of trends and differentials, and are therefore preferentially 
reported in these situations (for example, age-standardised participation in 2010–2011 was 
57.2%). 
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Statistical significance 
Statistical analyses are useful tools that aid in the interpretation of data. In this report, 95% 
confidence intervals* were used to determine if a statistically significant difference exists 
between compared values: where the confidence intervals do not overlap, the difference 
between rates is greater than that which could be explained by chance and is regarded as 
statistically significant. Because overlapping confidence intervals does not imply that the 
difference between two rates is definitely due to chance, it can only be stated that no 
statistically significant differences were found, and not that no differences exist. 
Differences that are described as ‘significant’ refer to a statistically significant difference. 
Judgment should, however, be exercised in deciding whether or not the difference is of any 
practical or clinical significance. This is particularly relevant to a national dataset, the 
analysis of which can result in statistically significant differences that may not be of any 
clinical significance or policy relevance. 
 
*The use of confidence intervals for non-sample data  
The AIHW is reviewing the provision of confidence intervals when data arise from sources 
that provide information on all subjects rather than from a sample survey. This review will 
include analysis of the methods used to calculate confidence intervals, as well as the 
appropriateness of reporting confidence intervals for such data. It aims to ensure that 
statistical methods used in AIHW reports remain robust and appropriately inform 
understanding and decision-making.  
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Section 2 Performance indicators 
Indicator 1 Participation 
What you need to know about participation 
Definition: The percentage of women screened in a 2-year period for women aged 20–69.  
Rationale: Through increased participation in cervical screening, more cervical abnormalities 
can be detected and treated that could otherwise develop into cervical cancer. Thus high 
participation is required for the National Cervical Screening Program (NCSP) to achieve its 
major objective of reducing cervical cancer incidence, morbidity and mortality. 
Guide to interpretation: As the target group of the NCSP, data are predominantly reported 
for women aged 20–69, but some data are also shown for women under 20 and those 70 and 
over (although the definition of ‘participation’ strictly refers to women aged 20–69). 
Participation is measured over 2 years to align with the NCSP’s recommended screening 
interval. Participation is based on the number of women screened, and not the number of 
cytology tests performed. 
Participation rate calculations should, in principle, exclude women from the denominator 
who are unlikely to require screening. In practice, the only group that can be reliably 
removed are women who have had a total hysterectomy. This is achieved using national 
‘hysterectomy fractions’ that are based on hysterectomy incidence data derived from the 
AIHW National Hospitals Morbidity Database (see Appendix C).  
The most recent participation data are for the 2010–2011 reporting period. 
What the data tell us about participation 
 Trend   
Participation in the NCSP was steady at 59% for all 2-year periods from 2004–2005 to  
2008–2009, before a slight decrease to 58% in 2009–2010, and to 57% in the latest reporting 
period 2010–2011.  
 
2010–2011 
In 2010–2011, a total of 3,794,354 women participated in the NCSP, of whom 3,641,198 were 
aged 20–69.  
This is 56.8% of women in the target age group, which, when age-standardised to allow 
analysis of trends and differentials, equates to a participation rate of 57.2% for 2010–2011.  
Less than 3 percentage points separated the highest participation of 57.6% and 57.4 in Inner 
regional areas and Major cities from the lowest of 54.8% in Remote areas. 
Participation showed a clear trend of increasing participation with increasing 
socioeconomic status, from 52.0% in areas of lowest socioeconomic status to 62.9% in areas 
of highest socioeconomic status. 
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Detailed analyses 
Participation in 2010–2011 
In 2010–2011, 3,794,354 women participated in the NCSP (that is, had at least 1 cervical 
cytology test over the 2 years), of whom 3,641,198 were aged 20–69. These 3,641,198 women 
represent 56.8% of those aged 20–69 in the population with an intact cervix (the target 
population), which, when age-standardised to allow analysis of trends and differentials, 
equates to a participation rate of 57.2%.  
Participation trends 
Figure 1.1 shows the trend in participation in the NCSP nationally, from 1996–1997, when 
reporting began, to 2010–2011, the most recent national data available. These data, and 
associated caveats, are provided in more detail in Table 1.1, below. 
 
     Note: Rates from before 2004–2005 should not be directly compared with those after this reporting period (see Table 1.1).  
    Source: AIHW analysis of state and territory cervical cytology register data. 
   Figure 1.1: Participation of women aged 20–69 in the National Cervical Screening Program,  
   1996–1997 to 2010–2011 
Since the reporting of truly national data began in 1999–2000 (due to the inclusion of 
previously unreported Queensland data in this period), participation in the NCSP by women 
aged 20–69 with an intact cervix has remained remarkably steady—61% of these women 
participated between 1999–2000 and 2003–2004, and 59% participated between 2004–2005 
and 2008–2009, with this apparent 2 percentage point drop in participation due to a different 
method of estimating the number of women in the population with an intact cervix between 
2003–2004 and 2004–2005, rather than representing a real decline. 
There was a slight decline in participation in 2009–2010 and 2010–2011 to 57.9% and 57.2%, 
respectively, made more conspicuous by a minor peak in participation in the 2006–2007 and 
2007–2008 reporting periods that immediately preceded these. It is reasonable to consider 
that this minor peak is primarily due to the introduction of the National HPV Vaccination 
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Program on 1 April 2007, which appears to have resulted in a greater number of women 
participating in cervical screening in 2007 in particular. Whether this was due to the 
vaccination program acting as a ‘reminder’ for women to screen, or whether this was due to 
opportunistic screening of women who presented to their health care provider for 
vaccination is not clear, but the age groups of <20, 20–24 and 25–29 (which include the ages 
of 12 to 26 which were the focus of the vaccination program in 2007–2009) all demonstrated a 
transient increase in 2007, suggesting that the latter was likely a factor in the overall 
participation peak in reporting periods that include the year 2007. 
This decline from 58.9% in 2008–2009 to 57.2% in 2010–2011 occurred despite an increase in 
the number of women participating, since the concurrent 3.3% increase in the adjusted 
population between these 2 periods is greater (Table 1.1). 
Table 1.1: Number and age-standardised rate of women aged 20–69 participating in the National 
Cervical Screening Program, 1996–1997 to 2010–2011 
Reporting period Participants(b) Population(c) Adjusted population(d) AS rate(e) 95% CI 
1996–1997(a) 2,563,107 4,769,763 4,186,906 61.0 60.9–61.1 
1997–1998(a) 2,653,504 4,823,334 4,227,203 62.6 62.5–62.6 
1998–1999(a) 2,716,364 4,874,748 4,264,927 63.4 63.4–63.5 
1999–2000 3,244,329 6,041,447 5,278,596 61.3 61.2–61.3 
2000–2001 3,262,931 6,122,480 5,339,538 61.0 60.9–61.1 
2001–2002 3,296,409 6,211,365 5,406,559 60.9 60.9–61.0 
2002–2003 3,318,354 6,307,398 5,479,418 60.6 60.6–60.7 
2003–2004 3,354,519 6,404,756 5,553,880 60.5 60.5–60.6 
2004–2005 3,407,219 6,504,478 5,798,435 58.8 58.7–58.8 
2005–2006 3,452,092 6,613,589 5,889,613 58.7 58.6–58.7 
2006–2007 3,549,524 6,727,196 5,985,311 59.4 59.4–59.5 
2007–2008 3,599,919 6,850,603 6,090,649 59.3 59.2–59.3 
2008–2009 3,638,941 6,988,894 6,210,936 58.9 58.8–58.9 
2009–2010 3,635,929 7,118,905 6,323,240 57.9 57.8–57.9 
2010–2011 3,641,198 7,226,614 6,413,446 57.2 57.1–57.2 
(a) Since the Queensland Health Pap Smear Register began operations in February 1999, Queensland data are excluded from both the 
participants and population data for the 1996–1997, 1997–1998 and 1998–1999 reporting periods. 
(b)  Participants are the number of women aged 20–69 screened in each 2-year reporting period. Number of women screened includes all 
women screened in each jurisdiction, not just those women resident in each jurisdiction, with the exception of Victoria and the Australian 
Capital Territory, for which only residents of the jurisdiction (and immediate border residents) are included.  
(c)  Population is the average of the Australian Bureau of Statistics (ABS) estimated resident population for women aged 20–69 for the 2 years. 
(d)  Adjusted population is the average of the ABS estimated resident population for women aged 20–69 for the 2 years, adjusted to include only 
women with an intact cervix using age-specific hysterectomy fractions. Reporting periods 1996–1997 to 2003–2004 use hysterectomy 
fractions derived from the 2001 ABS National Health Survey; reporting periods 2004–2005 to 2010–2011 use hysterectomy fractions 
derived from the AIHW National Hospitals Morbidity Database. 
(e)  Age-standardised (AS) rate is the number of women aged 20–69 screened in each 2-year reporting period as a percentage of the ABS 
estimated resident population for women aged 20–69, adjusted to include only women with an intact cervix as described above,  
age-standardised to the Australian population at 30 June 2001. 
Note: Rates from 1996–1997 to 2003–2004 cannot be directly compared with rates from 2004–2005 onwards due to a different source of 
hysterectomy fractions used to adjust the population. 
Source: AIHW analysis of state and territory cervical cytology register data. 
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Participation by age 
In 2010–2011, 96.0% of women participating in the NCSP were aged 20–69 (the target age 
group), with 2.7% under 20, and 1.3% aged 70 or over. Participation was highest for women 
aged 45–49 at 63.0%, followed by women aged 50–54 at 62.6% (Table 1.2). 
Table 1.2: Participation by age, 2010–2011  
Age group 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 
Women 334,336 419,220 435,404 464,527 444,963 425,158 378,138 311,591 261,433 166,428 
Crude rate 42.6 51.9 58.1 60.3 61.6 63.0 62.6 60.3 57.7 50.4 
Note: Crude rate is the number of women screened in 2010–2011 as a percentage of the ABS estimated resident population for women aged 20–
69, adjusted to include only women with an intact cervix using age-specific hysterectomy fractions derived from the AIHW National Hospitals 
Morbidity Database. 
Source: AIHW analysis of state and territory cervical cytology register data. 
Note that, while participation among women aged 20–24 is both low and decreasing (falling 
from 45.3% in 2008–2009 to 42.6% in 2010–2011), Australia is one of the few countries that 
screen this age group. 
Participation by state and territory 
In 2010–2011, participation across all states and territories was within 3.4 percentage points 
of the national average of 57.2%, ranging from 53.5% to 60.3% (Table 1.3, Figure 1.2). The 
decrease in national participation from 2008–2009 to 2010–2011 occurred in all states and 
territories. 
 
Source: AIHW analysis of state and territory cervical cytology register data; data for figure are available in Table A1. 
Figure 1.2: Participation of women aged 20–69, by state and territory, 2010–2011   
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Table 1.3: Participation of women aged 20–69, by state and territory, 2010–2011  
State/territory NSW Vic Qld WA SA Tas ACT NT Australia 
Women 1,149,414 962,122 704,267 371,246 276,276 78,857 63,329 35,687 3,641,198 
AS rate 56.1 60.3 55.3 55.6 59.7 55.6 57.6 53.5 57.2 
95% CI 56.0–56.2 60.2–60.4 55.2–55.5 55.4–55.7 59.5–60.0 55.2–56.0 57.2–58.1 52.9–54.1 57.1–57.2 
Notes 
1. Direct comparisons between the states and territories of Australia are not advised due to the substantial differences that exist between the 
jurisdictions, including population, area, geographic structure, policies and other factors. 
2. Age-standardised (AS) rate is the number of women screened in 2010–2011 as a percentage of the ABS estimated resident population for 
women aged 20–69, adjusted to include only women with an intact cervix using age-specific hysterectomy fractions derived from the AIHW 
National Hospitals Morbidity Database, age-standardised to the Australian population at 30 June 2001. 
Source: AIHW analysis of state and territory cervical cytology register data. 
Participation by location of residence 
Table 1.4: Participation of women aged 20–69, by remoteness area, 2010–2011 
Remoteness 
area Major cities Inner regional 
Outer 
regional Remote Very remote Australia 
Women 2,577,444 677,216 307,989 49,638 27,421 3,641,198 
AS rate 57.4 57.6 56.0 54.8 56.0 57.2 
95% CI 57.3–57.5 57.4–57.7 55.8–56.2 54.3–55.3 55.3–56.7 57.1–57.2 
Notes  
1. Women were allocated to a remoteness area using their residential postcode according to the Australian Standard Geographic Classification 
for 2006. 
2. Caution is required when examining differences across remoteness area (see Appendix C). 
3. Age-standardised (AS) rate is the number of women screened in 2010–2011 as a percentage of the ABS estimated resident population for 
women aged 20–69, adjusted to include only women with an intact cervix using age-specific hysterectomy fractions derived from the AIHW 
National Hospitals Morbidity Database, age-standardised to the Australian population at 30 June 2001. 
4. Participation by remoteness area in 2010–2011 is not comparable with previous reporting periods (see Appendix C).  
Source: AIHW analysis of state and territory cervical cytology register data. 
Participation in the NCSP was similar across remoteness areas (Figure 1.3A), with less than 3 
percentage points separating the highest participation of 57.6% and 57.4 in Inner regional 
areas and Major cities from the lowest of 54.8% in Remote areas (Table 1.4). The relatively high 
participation of 56.0% in Very remote areas is of note. 
Table 1.5: Participation of women aged 20–69, by socioeconomic status, 2010–2011 
Socioeconomic 
status 
1 
(lowest)  
2 3 4 5  
(highest) Australia 
Women 618,974 671,965 726,038 773,152 827,984 3,641,198 
AS rate 52.0 54.0 56.4 58.3 62.9 57.2 
95% CI 51.9–52.2 53.8–54.1 56.3–56.6 58.1–58.4 62.7–63.0 57.1–57.2 
Notes  
1. Women were allocated to a socioeconomic status using their residential postcode according to the Socio-Economic Indexes for Areas 
(SEIFA) Index of Relative Socio-Economic Disadvantage for 2006. 
2. Caution is required when examining differences across socioeconomic status (see Appendix C). 
3. Age-standardised (AS) rate is the number of women screened in 2010–2011 as a percentage of the ABS estimated resident population for 
women aged 20–69, adjusted to include only women with an intact cervix using age-specific hysterectomy fractions derived from the AIHW 
National Hospitals Morbidity Database, age-standardised to the Australian population at 30 June 2001. 
4. Participation by socioeconomic status in 2010–2011 is not directly comparable with previous reporting periods (see Appendix C).  
Source: AIHW analysis of state and territory cervical cytology register data. 
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Participation showed greater differences across socioeconomic status of location of residence, 
and a clear trend of increasing participation with increasing socioeconomic status (Figure 
1.3B), from 52.0% of women residing in areas of lowest socioeconomic status to 62.9% of 
women residing in areas of highest socioeconomic status (a difference of 10.9 percentage 
points) (Table 1.5).  
Participation of Aboriginal and Torres Strait Islander women 
Participation in cervical screening cannot be measured nationally for Aboriginal and Torres 
Strait Islander women since, as detailed in the introduction, cervical cytology registers 
depend on, and are limited to, information on pathology forms, which do not currently 
include Indigenous status.  
There is evidence, however, that Aboriginal and Torres Strait Islander women are  
underscreened. Coory et al. (2002) and Binns & Condon (2006) estimated participation in 
communities with high proportions of Aboriginal and Torres Strait Islander women in 
Queensland and the Northern Territory, respectively. These researchers found that, on 
average, participation by Aboriginal and Torres Strait Islander women was close to 18 
percentage points below that for the respective jurisdiction, with both studies showing 
considerable variation between communities or regions. 
It has been recognised that Aboriginal and Torres Strait Islander women face cultural, 
linguistic and physical barriers to cervical screening (DoHA 2004). State and territory 
cervical screening programs have developed initiatives to increase participation in cervical 
screening by Aboriginal and Torres Strait Islander women such as the employment of 
Aboriginal and Torres Strait Islander Health Workers, with the Australian Government 
component of the NCSP supporting these through the development of principles, standards 
and guidelines for screening Aboriginal and Torres Strait Islander women (DoHA 2004). 
However, without being able to measure participation in cervical screening by Indigenous 
status, it is not known to what extent initiatives are reaching their desired aim. 
The study above illustrates the value of an evidence base. Binns and Condon (2006) 
demonstrated that Northern Territory cervical screening program initiatives resulted in very 
A 
 
B  
 
Note: Bars on columns represent 95% confidence intervals. 
Source: AIHW analysis of state and territory cervical cytology register data. 
 Figure 1.3: Participation of women aged 20–69, by remoteness area (A), and by socioeconomic 
 status (B), 2010–2011 
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high rates of participation in some regions of this jurisdiction, providing an opportunity to 
adapt these successful initiatives to other regions and communities. Such an evidence base, 
not currently available nationally, is fundamental in assessing the status of cervical screening 
in Aboriginal and Torres Strait Islander women nationally, as well as guiding further 
improvements in cervical screening participation in Aboriginal and Torres Strait Islander 
women. 
Participation measured over greater lengths of time 
Measuring participation over a 3-year and 5-year period, rather than a 2-year period, 
demonstrated that 70.1% of women aged 20–69 participated in the NCSP at least once in the 
3-year period 2009–2011, and 83.4% had at least one Pap test in the 5-year period 2007–2011 
(Table 1.6). 
Table 1.6: Participation of women aged 20–69, by state and territory, over 2 years (2010–2011),  
3 years (2009–2011) and 5 years (2007–2011) 
State/territory NSW Vic Qld WA SA Tas ACT NT Australia 
2010–2011 56.1 60.3 55.3 55.6 59.7 55.6 57.6 53.5 57.2 
2009–2011 69.0 73.3 68.2 67.8 73.0 69.2 71.9 68.1 70.1 
2007–2011 83.9 85.2 81.6 79.3 84.7 82.2 88.0 84.4 83.4 
Notes 
1. Direct comparisons between the states and territories of Australia are not advised due to the substantial differences that exist between the 
jurisdictions, including population, area, geographic structure, policies and other factors. 
2. Age-standardised (AS) rate is the number of women screened as a percentage of the ABS estimated resident population for women aged 
20–69, adjusted to include only women with an intact cervix using age-specific hysterectomy fractions derived from the AIHW National 
Hospitals Morbidity Database, age-standardised to the Australian population at 30 June 2001. 
3. Confidence intervals are available in Cervical screening in 2010–2011: supplementary data tables. 
Source: AIHW analysis of state and territory cervical cytology register data. 
The increase from 2-year to 3-year participation may be, in part, due to state and territory 
cervical cytology registers reminding women to rescreen 27 months after a previously 
negative cytology test (see Indicator 2.2 for more information), since this reminder has the 
potential to increase the attendance of women within 3 years of their previous cytology test 
(Queensland Health 2012). In this respect, 3-year participation may provide a more accurate 
indication of the proportion of women who participate regularly in cervical screening. 
The age structure changes when participation is measured over greater lengths of time, with 
a proportionally greater number of women in the younger age groups included when 
participation is measured over 3 years or 5 years compared with participation measured over 
a 2-year period (Figure 1.4).  
Along with this change, the age group with the highest participation shifts from women 
aged 45–49 for the 2-year period 2010–2011 and the 3-year period 2009–2011 to women aged 
30 to 39 for the 5-year period 2007–2011 (Figure 1.4). The age group with the lowest 
participation also changes from women aged 20–24 for the 2-year period 2010–2011 and the 
3-year period 2009–2011 to women aged 65–69 for the 5-year period 2007–2011 (Figure 1.4). 
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Source: AIHW analysis of state and territory cervical cytology register data; data for figure are available in Table A1. 
Figure 1.4: Participation of women aged 20–69, by age, over 2 years (2010–2011), 3 years (2009–2011), 
and 5 years (2007–2011) 
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Indicator 2.1 Early rescreening 
What you need to know about early rescreening 
Definition: The proportion of women rescreening, by number of rescreens, within  
21 months of a negative cytology test, for women aged 20–69. 
Rationale: A low proportion of women rescreening early is desirable, since compliance with 
the recommended screening interval is important in maintaining the cost effectiveness of the 
cervical screening program. 
Guide to interpretation: This indicator is calculated as the proportion of a cohort of women 
with negative cytology in the index month of February who had a repeat cytology test of any 
result in the following 21 months. Women with an abnormality in the preceding  
36 months are excluded, as are repeat cytology tests that are a valid repeat of an 
unsatisfactory cytology test. 
The most recent early rescreening data are for the index month of February 2010. This small 
lag in data availability is because 21 months needs to have passed since a woman’s last 
negative cytology test to know whether or not she has rescreened within this interval. 
What the data tell us about early rescreening 
 Trend 
The proportion of women rescreening early decreased from 14.0% for the 2009 cohort to 
13.3% for the 2010 cohort, which is a positive trend.  
 
2010 cohort 
Of all women aged 20–69 with a negative cytology test in February 2010, 13.3% rescreened 
early (within 21 months). 
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Detailed analyses 
Early rescreening in the 2010 cohort 
Of the 155,514 women aged 20–69 who had negative cytology in February 2010 with no 
abnormalities in the preceding 36 months, the majority did not rescreen early, with 134,824 
women (86.7%) having no repeat cytology tests within 21 months of this negative cytology 
test. In comparison, 20,690 women (13.3%) did rescreen early—20,026 had one repeat 
cytology test, 622 had two repeat cytology tests, and 42 women had three or more repeat 
cytology tests within 21 months of this negative cytology test (Table 2.1). 
This means that 13.3% of women are rescreening early unnecessarily (although some number 
of these women may have symptoms or another clinically valid reason that would make 
early rescreening appropriate). 
Table 2.1: Number and proportion of women aged 20–69 rescreening early following a negative 
cervical cytology test, by number of early rescreens, 2010 cohort  
Early rescreens Number of women Per cent of women 
0 134,824  86.7  
1 20,026  12.9  
2 622  0.4  
3+ 42  0.0  
Note: Women with a cytological or histological abnormality in the preceding 36 months are excluded from entering the cohort; repeat cytology tests 
that are a valid repeat of an unsatisfactory cytology test are excluded from this count. 
Source: AIHW analysis of state and territory cervical cytology register data.  
Early rescreening trends 
The proportion of women rescreening early has decreased every year from the 1997 cohort 
through to the 2010 cohort (Figure 2.1). While overall there has been a substantial decrease 
from 46.7% to 13.3%, there have been two changes to the definition of early rescreening (one 
for the 1999 cohort onwards and one for the 2008 cohort onwards) that affect direct 
comparisons. 
More recently (and directly comparable since the same definition of early rescreening has 
been applied) the proportion of women rescreening early decreased from 15.1% for the 2008 
cohort to 13.3% for the 2010 cohort. A decrease in the proportion of women rescreening early 
is a positive finding, since modelling has shown that a decrease in early rescreening reduces 
the cost of a screening program without changing its effectiveness (Creighton et al. 2010). 
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Source: AIHW analysis of state and territory cervical cytology register data.  
Figure 2.1: Proportion of women aged 20–69 rescreening early following a negative cervical 
cytology test, 1996 to 2010 cohorts 
Early rescreening by state and territory 
The proportion of women rescreening early varied across states and territories between 9.5% 
and 14.4% (Table 2.2). 
Table 2.2: Proportion of women aged 20–69 rescreening early following a negative cervical cytology 
test, by state and territory, 2010 cohort  
State/territory NSW Vic Qld WA SA Tas ACT NT Australia 
Per cent 14.4  13.3  13.2  12.4  11.7  9.5  10.8  13.0  13.3  
Source: AIHW analysis of state and territory cervical cytology register data.  
  
         0.0
         5.0
        10.0
        15.0
        20.0
        25.0
        30.0
        35.0
        40.0
        45.0
        50.0
Year
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Women rescreening early (per cent)
Indicator definition changed 
Indicator definition changed 
  Cervical screening in Australia 2010–2011 21 
Indicator 2.2 Rescreening after 27-month 
reminder letter 
What you need to know about rescreening after a reminder letter 
Definition: The proportion of women who are sent a 27-month cervical cytology register 
reminder letter (a letter sent when the register has no record of a woman having had repeat 
cytology within 27 months of a previously negative cytology test), who rescreen within  
3 months, for women aged 20–69. 
Rationale: This indicator measures the effectiveness of this reminder letter in prompting 
women to rescreen. Thus a high proportion of women rescreening within 3 months of the  
27-month cervical cytology register reminder letter is desirable. 
Guide to interpretation: Calculations are based on the number of women who are sent a 
letter, which is not necessarily the number of women who received a letter (for example, if a 
woman has changed address), which cannot be determined. To be counted as rescreened 
within 3 months, women need to have a cytology test within 3 months of being sent a 
reminder letter. 
The most recent data are for women sent a reminder letter in 2010. This small lag in data 
availability is because 3 months needs to have passed since a woman was sent a 27-month 
reminder letter in a particular calendar year to know whether or not she has rescreened 
within this interval. 
What the data tell us about rescreening after a reminder letter 
 Trend 
The proportion of women sent a letter and who rescreened within 3 months barely changed 
between 2009 (31.7%) and 2010 (31.5%).  
 
Letters sent in 2010 
31.5% of women sent a 27-month cervical cytology register reminder letter in 2010 
rescreened within 3 months of being sent this letter, indicating that this letter acts as a 
prompt for many women. 
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Detailed analyses 
Rescreening after 27-month reminder letters sent in 2010 
In 2010, 27-month cervical cytology register reminder letters were sent to 888,269 women. Of 
these, 280,064 women (31.5%) rescreened within 3 months (Table 2.3). This indicates that the 
reminder letter acts as a prompt to rescreen for many women (although it is not possible to 
know from these data if barriers exist that contributed to the proportion of women who did 
not rescreen within 3 months).  
Table 2.3: Women aged 20–69 rescreening within 3 months of 27-month cervical cytology register 
reminder letter, by state and territory, letters sent in 2010  
State/territory NSW Vic Qld WA SA Tas ACT NT Australia 
No. sent letter 318,224  233,945  195,360  86,687  . .  25,607  20,184  8,262  888,269  
No. rescreened 93,449  78,310  65,488  26,643   . .  8,612  5,775  1,787  280,064  
Per cent 29.4  33.5  33.5  30.7   . .  33.6  28.6  21.6  31.5  
Note: Data are not available for South Australia, which at present does not have a 27-month cervical cytology register reminder letter sent to 
women (these are sent to practitioners, with a 30-month reminder letter sent to women, neither of which are directly comparable). 
Source: AIHW analysis of state and territory cervical cytology register data.  
Rescreening after 27-month reminder letter by state and territory 
The proportion of women who rescreened within 3 months of being sent a reminder letter 
was around 30% in most states and territories, although was notably lower (21.6%) in the 
Northern Territory (Figure 2.2). 
 
Source: AIHW analysis of state and territory cervical cytology register data. 
Figure 2.2: Proportion of women aged 20–69 rescreening within 3 months of the 27-month cervical 
cytology register reminder letter, by state and territory, letters sent in 2010 
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Indicator 3 Cytology 
What you need to know about cytology 
Cytology means ‘study of cells’ and, in the context of cervical screening, refers to cells from 
the cervix that are collected and examined for abnormalities. Cervical cytology using the 
conventional Papanicolaou smear (‘Pap test’) is the primary screening tool of the National 
Cervical Screening Program (NCSP). 
Definition: The proportion of cytology test results that were unsatisfactory, negative, had no 
endocervical component, or detected an abnormality in a 12-month period.  
Rationale: Annual monitoring of cytology report categories by various stratifications may 
reveal emerging positive or negative trends that need to be addressed. In addition, it is 
anticipated that the ability to monitor national trends in squamous and endocervical 
component report categories will allow the earliest indications possible of any effects from 
the human papillomavirus (HPV) vaccine introduced in 2007, which will be of relevance to 
the NCSP.  
Guide to interpretation: The most recent cytology data are for the year 2011. 
What the data tell us about cytology 
Trends 
 The proportion of cytology tests that were unsatisfactory and negative barely changed 
between 2010 (2.1% and 92.6%) and 2011 (2.1% and 92.3%, respectively) 
 The (age-standardised) proportion of cytology tests with an endocervical component 
present decreased significantly each year from 82.1% in 2004 to 78.6% in 2011. This overall 
decrease included a slight decrease from 78.9% in 2010 to 78.6% in 2011.  
 The proportion of cytology tests reported as abnormal, after decreasing from 6.7% in 
2004 to 5.3% in 2010, increased to 5.6% in 2011. 
The increase between 2010 and 2011 appeared to be due to an increase in possible low-
grade squamous intraepithelial lesions (and to a lesser extent possible high-grade squamous 
intraepithelial lesions), atypical endocervical cells of uncertain significance, and possible 
high-grade endocervical glandular lesions. 
 
Cytology in 2011 
More than 2 million cytology tests were performed in 2011, with 2,065,618 for women aged 
20–69. For these women:  
•  2.1% of cytology tests were unsatisfactory 
•  92.3% of cytology tests were negative 
•  An endocervical component was present in 78.6% of cytology tests 
•  A definite or possible high-grade abnormality was reported in 1.5% of cytology tests. 
• An abnormality was reported in 5.6% of cytology tests. 
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More information about cytology  
Cervical cytology using the conventional Papanicolaou smear (Pap test) is the primary 
screening tool of the NCSP. Cytology means ‘study of cells’, and, in the context of cervical 
screening, refers to cells from the cervix that are collected and examined for abnormalities. 
The objective of a Pap test is to sample cells from the transformation zone of the cervix 
(CDHSH 1993), which is the area of the cervix in which the squamous and endocervical cells 
(also known as glandular cells) meet (between the ‘original’ and ‘current’ squamocolumnar 
junctions), and the site where cervical abnormalities and cancer are usually found. 
The NCSP developed the National Cervical 
Cytology Coding Sheet based on the 
Australian Modified Bethesda System 2004 
for reporting cervical cytology, introduced 
along with revised guidelines for the 
management of asymptomatic women with 
screen-detected abnormalities in July 2006 
(NHMRC 2005). This coding sheet allows 
pathologists to report on both the 
squamous and endocervical components of 
the cervical cytology sample (as well as a 
third category for non-cervical 
abnormalities and a recommendation code 
that are not reported here), which together 
give an overall cervical cytology result. This 
overall cytology result may indicate a 
squamous abnormality, an endocervical 
abnormality, or (more rarely) concurrent 
squamous and endocervical abnormalities. 
The squamous cell and endocervical 
component reporting categories of the 
National Cervical Cytology Coding Sheet 
are shown in Table 3.1. 
Table 3.1: Cytology reporting categories of the National Cervical Screening Program 
Squamous cell Endocervical component 
SU Unsatisfactory EU Unsatisfactory 
 E0 No endocervical component 
S1 Negative E1 Negative 
S2 Possible low-grade squamous intraepithelial lesion  
S3 Low-grade squamous intraepithelial lesion E2 Atypical endocervical cells of uncertain significance 
S4 Possible high-grade squamous intraepithelial lesion E3 Possible high-grade endocervical glandular lesion 
S5 High-grade squamous intraepithelial lesion E4 Adenocarcinoma in situ 
S6 High-grade squamous intraepithelial lesion with 
  possible microinvasion/ invasion 
E5 Adenocarcinoma in situ with possible microinvasion/ 
  invasion 
S7 Squamous cell carcinoma E6 Adenocarcinoma 
Note: There is a further endocervical component result of E- that has been omitted since this code indicates a vaginal vault smear,  
which is not included in the cervical cytology results presented. 
Figure 3.1: Anatomy: cells of the cervix 
© National Cancer Institute 2013. 
Source: <http://visualsonline.cancer.gov>. 
Reproduced with permission of the copyright owner. 
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Detailed analyses 
Cytology in 2011 
In 2011, there were 2,149,798 cervical cytology tests performed, 2,065,618 (96.1%) of these for 
women aged 20–69 (Table 3.2). Most cytology tests were performed for women aged 25–49, 
with a peak of 260,198 tests performed for women aged 35–39 (Figure 3.2A), this being 12.5% 
of all cytology tests performed in 2011.  
Cytology trends 
Historically, looking at all years from 2004 to 2011, the greatest number of cytology tests was 
performed in 2007 (2,093,417 for women aged 20–69). This was a 3% increase on the number 
of cytology tests performed in 2006, which is the greatest year-to-year increase seen between 
2004 and 2011 (Table 3.2). This is likely due to the introduction of the National HPV 
Vaccination Program on 1 April 2007, either acting as a ‘reminder’ for women to have a Pap 
test, or through opportunistic screening for women attending their health care provider for 
immunisation. With girls aged up to 30 seeing a 5.7% increase from 2006 to 2007, it seems 
likely that the latter was a factor, since the introduction of the vaccination program included 
a catch-up program for girls and women aged from 12 to 26. 
In addition, there appears to be a cohort effect, whereby the number of cytology tests is 
relatively higher every second year, in odd years, which may be related to the 2-yearly 
screening interval of the NCSP.  
More recently, the number of cytology tests performed for women aged 20–69 increased 
from 2,025,860 in 2010 to 2,065,618 in 2011. This increase occurred across most age groups, 
being largest for women aged 60 to 69 (Table 3.2). 
Table 3.2: Number of cytology tests by age, 2004 to 2011  
Age group 
(years) 2004 2005 2006 2007 2008 2009 2010 2011 
<20 68,245 69,841 65,189 67,861 63,668 60,813 55,511 56,159 
20–24 199,197 207,671 203,531 215,454 203,540 202,951 192,175 195,602 
25–29 237,905 239,628 235,385 249,461 242,116 249,852 240,510 247,362 
30–34 286,845 287,736 270,412 268,829 258,449 259,995 246,489 253,185 
35–39 269,733 274,984 273,274 283,760 281,047 281,300 264,471 260,198 
40–44 270,055 269,546 259,880 259,723 250,963 252,387 245,041 252,666 
45–49 233,472 239,200 239,884 248,203 243,146 246,688 236,829 235,860 
50–54 193,660 196,175 196,236 201,663 202,073 206,118 205,915 211,883 
55–59 153,891 159,849 163,546 166,087 165,893 168,806 168,579 172,415 
60–64 102,437 106,608 112,240 122,356 129,177 134,622 139,035 144,153 
65–69 70,827 73,281 75,700 77,881 79,390 83,835 86,816 92,294 
70+ 32,321 31,075 30,188 29,925 28,353 28,005 27,750 28,014 
All ages 2,118,780 2,155,682 2,125,522 2,191,238 2,147,848 2,175,383 2,109,131 2,149,798 
Ages 20–69 2,018,022 2,054,678 2,030,088 2,093,417 2,055,794 2,086,554 2,025,860 2,065,618 
Source: AIHW analysis of state and territory cervical cytology register data.  
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Unsatisfactory cytology in 2011  
In 2011, of the 2,065,618 cytology tests performed for women aged 20–69, 42,760 (2.1%) were 
unsatisfactory (Table 3.4). 
Unsatisfactory cytology is defined as a cervical cytology test where the squamous result is 
SU Unsatisfactory and the endocervical result is EU Unsatisfactory or where the squamous 
result is SU Unsatisfactory and the endocervical result is either E0 No endocervical 
component or E1 Negative.  
While not a true result per se, unsatisfactory cytology means that due to the unsatisfactory 
nature of the cells sampled, the pathologist is unable to determine a clear result. This may 
be due to either too few or too many cells, or the presence of blood or other factors 
obscuring the cells, or to poor staining or preservation. The absence of an endocervical 
component is not considered sufficient grounds to deem a cervical cytology sample 
unsatisfactory (NPAAC 2006). 
Unsatisfactory cytology trends 
The proportion of cervical cytology tests considered unsatisfactory remained relatively 
constant, at 2.1% of all cytology tests for most years from 2004 to 2011 (Table 3.3). 
Table 3.3: Unsatisfactory cytology tests in women aged 20–69, 2004 to 2010 
 2004 2005 2006 2007 2008 2009 2010 2011 
Number 42,124 41,042 42,720 44,912 43,223 43,104 42,096 42,760 
Crude rate 2.1 2.0 2.1 2.2 2.1 2.1 2.1 2.1 
AS rate 2.1 2.0 2.1 2.2 2.1 2.1 2.1 2.1 
95% CI 2.1–2.1 2.0–2.0 2.1–2.1 2.1–2.2 2.1–2.1 2.1–2.1 2.1–2.1 2.1–2.1 
Note: Crude rate is the number of unsatisfactory cytology tests as a proportion of the total number of cytology tests; age-standardised (AS) 
rate is the number of unsatisfactory cytology tests as a proportion of the total number of cytology tests age-standardised to the Australian 
population at 30 June 2001. 
Source: AIHW analysis of state and territory cervical cytology register data.  
The National Pathology Accreditation Advisory Council (NPAAC) Performance measures for 
Australian laboratories reporting cervical cytology (NPAAC 2006) includes a recommended 
standard for the proportion of specimens reported as unsatisfactory as between 0.5% and 
5.0% of all specimens reported.  
Box 3.1: National Pathology Accreditation Advisory Council (NPAAC) Performance 
measures for Australian laboratories reporting cervical cytology 
Performance measure 1 
Proportion of specimens reported as unsatisfactory. 
Recommended standard 
Between 0.5% and 5.0% of all specimens reported as unsatisfactory. 
Calculated value for 2011 
2.1%  
The proportion of cytology tests that were unsatisfactory, 2.1% in 2011 (Table 3.3), falls 
within these benchmark standards (Box 3.1) and would therefore be considered appropriate. 
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Unsatisfactory cytology by age 
The proportion of cytology tests that were unsatisfactory in 2011 was around 2% for all ages 
20–69. Unsatisfactory cytology tests fell from 2.3% of tests for women aged under 30 to a low 
of 1.8% for women aged 45–49. The proportion then increased with increasing age to a high 
of 2.6% for women aged 70 and over (Figure 3.2B). It has been suggested that the increase in 
unsatisfactory tests in older women may be related to physiological changes in post-
menopausal women resulting in atrophic epithelial cells in the sample (Bateson 2009). 
Unsatisfactory cytology by state and territory  
In 2011, the majority of states and territories had unsatisfactory cytology tests comprising 
between 2.1% and 2.4% of all cytology tests. The exceptions to this were New South Wales 
with 1.7%, Western Australia with 1.8%, and the Australian Capital Territory with 1.3% of all 
cytology tests being unsatisfactory (Table 3.4).  
Table 3.4: Unsatisfactory cytology tests in women aged 20–69, by state and territory, 2011 
 NSW Vic Qld WA SA Tas ACT NT Australia 
Number 11,084 12,346 9,830 3,893 3,601 1,078 440 488 42,760 
Crude rate 1.7 2.3 2.4 1.8 2.3 2.4 1.3 2.4 2.1 
AS rate 1.7 2.3 2.4 1.8 2.3 2.4 1.3 2.4 2.1 
95% CI 1.7–1.7 2.2–2.3 2.4–2.5 1.8–1.9 2.3–2.4 2.3–2.6 1.2–1.4 2.2–2.6 2.1–2.1 
Note: Crude rate is the number of unsatisfactory cytology tests as a proportion of the total number of cytology tests; age-standardised (AS) rate is 
the number of unsatisfactory cytology tests as a proportion of the total number of cytology tests age-standardised to the Australian population at 
30 June 2001. 
Source: AIHW analysis of state and territory cervical cytology register data.  
  
All cytology tests 
 
Unsatisfactory cytology tests 
 
Source: AIHW analysis of state and territory cervical cytology register data; data for figures are available in Table A1. 
Figure 3.2: Proportion of cytology tests, and proportion of unsatisfactory cytology tests, by age, 2011 
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Negative cytology in 2011 
Most cervical cytology tests have a negative result, indicating that no abnormalities were 
detected. In 2011, of the 2,065,618 cytology tests performed for women aged 20–69, 1,908,291 
(92.4%) were negative (92.3% age-standardised) (Table 3.5). 
Negative cytology is defined as a cervical cytology test where the squamous result is  
S1 Negative and the endocervical result is either E0 No endocervical component or  
E1 Negative. 
Negative cytology trends 
The proportion of negative cytology tests remained steady from 2006 to 2011 at between 92% 
and 93% of all cytology tests performed for women aged 20–69 (Table 3.5).  
Table 3.5: Negative cytology tests in women aged 20–69, 2004 to 2011 
 2004 2005 2006 2007 2008 2009 2010 2011 
Number 1,839,464 1,872,910 1,857,552 1,922,592 1,891,705 1,931,682 1,876,881 1,908,291 
Crude rate 91.2 91.2 91.5 91.8 92.0 92.6 92.6 92.4 
AS rate 91.3 91.3 91.6 91.9 92.1 92.6 92.6 92.3 
95% CI 91.1–91.4 91.1–91.4 91.4–91.7 91.8–92.1 91.9–92.2 92.5–92.7 92.5–92.7 92.2–92.5 
Note: Crude rate is the number of negative cytology tests as a proportion of the total number of cytology tests; age-standardised (AS) rate is the 
number of negative cytology tests as a proportion of the total number of cytology tests age-standardised to the Australian population at 30 June 
2001. 
Source: AIHW analysis of state and territory cervical cytology register data.  
 
 
 
Source: AIHW analysis of state and territory cervical cytology register data; data for figures are available in Table A1. 
Figure 3.3: Proportion of cytology tests that were negative by age, 2011 
          50
          60
          70
          80
          90
         100
Age group (years)
<2
0
20
–2
4
25
–2
9
30
–3
4
35
–3
9
40
–4
4
45
–4
9
50
–5
4
55
–5
9
60
–6
4
65
–6
9
70
+
Per cent
  Cervical screening in Australia 2010–2011 29 
Negative cytology by age 
In 2011, the proportion of cytology tests that were negative was lowest for women under 25, 
at just above 84% of cytology tests, thereafter increasing with increasing age, peaking at 
96.3% for women aged 65–69 (Figure 3.3). 
Negative cytology by state and territory 
The proportion of cytology tests that were negative was similar across states and territories, 
ranging between 90.9% and 94.2% for women aged 20–69 in 2011 (Table 3.6). 
Table 3.6: Negative cytology tests in women aged 20–69, by state and territory, 2011 
 NSW Vic Qld WA SA Tas ACT NT Australia 
Number 608,251 496,477 373,982 193,564 144,182 40,876 32,646 18,313 1,908,291 
Crude rate 93.5 91.1 92.7 91.3 93.0 92.4 94.0 90.7 92.4 
AS rate 93.3 90.9 92.8 91.5 92.9 92.3 94.2 91.4 92.3 
95% CI 
93.1–
93.6 
90.7–
91.2 
92.5–
93.1 
91.1–
91.9 
92.4–
93.4 
91.4–
93.2 
93.1–
95.2 
90.0–
92.8 
92.2– 
92.5 
Note: Crude rate is the number of negative cytology tests as a proportion of the total number of cytology tests; age-standardised (AS) rate is the 
number of negative cytology tests as a proportion of the total number of cytology tests age-standardised to the Australian population at 30 June 
2001. 
Source: AIHW analysis of state and territory cervical cytology register data.  
No endocervical component in 2011 
The presence of endocervical cells in a cervical cytology sample, while not required for a 
sample to be considered satisfactory (NPAAC 2006), indicates that the transformation zone is 
likely to have been sampled (the site where most cervical abnormalities and cancer are 
detected) (CDHSH 1993). Additionally, the presence of endocervical cells is necessary to 
detect endocervical abnormalities and adenocarcinoma where these are present. 
In 2011, of the 2,065,618 cytology tests performed for women aged 20–69, 440,411 (21.3%) had 
no endocervical component (21.4% age-standardised) (Table 3.7).  
A cytology test with no endocervical component is defined as a cervical cytology test with 
any squamous result and an endocervical result of E0 No endocervical component, meaning 
that no endocervical cells are present in the sample, and thus only the squamous cells in the 
sample can be assessed for the presence of abnormalities or cancer. 
No endocervical component trends 
The number of cervical cytology tests with no endocervical component increased 
disproportionately to the increase in the number of cytology tests between 2004 and 2011. 
While the overall increase in the number of cytology tests for women aged 20–69 from 2004 
to 2011 was only 2.4%, the number of cytology tests with no endocervical component 
increased 25.6% over the same period (from 350,670 to 440,411). This is reflected in the steady 
increase in the proportion of cytology tests with no endocervical component from 17.4% in 
2004 to 21.3% in 2011 for women aged 20–69 (Table 3.8). This trend holds after age-
standardisation—from 17.9% in 2004 to 21.4% of cytology tests in 2011 (Table 3.7). 
The 2007–2009 National Cancer Prevention Policy of Cancer Council Australia (2007) states 
that ‘presence of an endocervical component in 80% of Pap tests is generally considered 
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acceptable’. In this context, the 2011 crude rate of 21.3%, which indicates the presence of an 
endocervical component in 78.7% of cytology tests, is slightly outside this desired range.  
Table 3.7: Cytology tests with no endocervical component in women aged 20–69, 2004 to 2011 
 2004 2005 2006 2007 2008 2009 2010 2011 
Number 350,670 379,531 387,918 406,736 407,942 418,527 424,077 440,411 
Crude rate 17.4 18.5 19.1 19.4 19.8 20.1 20.9 21.3 
AS rate 17.9 19.0 19.5 19.8 20.2 20.3 21.1 21.4 
95% CI 17.8–17.9 18.9–19.0 19.5–19.6 19.8–19.9 20.1–20.2 20.3–20.4 21.0–21.1 21.4–21.5 
Note: Crude rate is the number of cytology tests with no endocervical component as a proportion of the total number of cytology tests;  
Age-standardised (AS) rate is the number of cytology tests with no endocervical component as a proportion of the total number of cytology 
tests age-standardised to the Australian population at 30 June 2001. 
Source: AIHW analysis of state and territory cervical cytology register data.  
No endocervical component by age 
Younger women had a lower proportion of cytology tests with no endocervical component, 
with between 17.1% and 18.1% of all cytology tests performed for women aged between 20 
and 39 lacking endocervical cells in 2011 (Figure 3.4). In contrast, an endocervical component 
was absent from more than 20% of cytology tests for women aged 45–49, from 30% of 
cytology tests for women aged 60–64, and from 36% of cytology tests performed in women 
aged 70 and over (Figure 3.4). 
This trend aligns with the movement of the transformation zone with age; the proportion of 
women with a transformation zone located on the ectocervix has been found to decrease 
from 94% of women under 25 to just 2% of women older than 64 (Autier et al. 1996). These 
figures hold up well with the observed data, when it is considered that sampling of the 
 
 
Source: AIHW analysis of state and territory cervical cytology register data; data for figures are available in Table A1. 
Figure 3.4: Proportion of cytology tests with no endocervical component by age, 2011 
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transformation zone is required for endocervical cells to be present in a cervical cytology 
sample, and that a transformation zone high up in the endocervical canal is likely to be more 
difficult to sample that a transformation zone on the ectocervix. 
No endocervical component by state and territory 
In 2011, the proportion of cytology tests for which there was no endocervical component 
ranged considerably between 18.9% and 30.5% (age-standardised) across states and 
territories for women aged 20–69 (Table 3.8). 
Table 3.8: Cytology tests with no endocervical component in women aged 20–69, by state and 
territory, 2011 
 NSW Vic Qld WA SA Tas ACT NT Australia 
Number 122,365 136,470 75,789 48,516 31,916 13,620 6,963 4,772 440,411 
Crude rate 18.8 25.0 18.8 22.9 20.6 30.8 20.1 23.6 21.3 
AS rate 18.9 25.1 18.9 23.4 20.4 30.5 20.3 24.9 21.4 
95% CI 
18.8–
19.0 
24.9–
25.2 
18.8–
19.1 
23.1–
23.6 
20.2–
20.7 
30.0–
31.0 
19.9–
20.8 
24.2–
25.7 
21.4– 
21.5 
Note: Crude rate is the number of cytology tests with no endocervical component as a proportion of the total number of cytology tests; age-
standardised (AS) rate is the number of cytology tests with no endocervical component as a proportion of the total number of cytology tests age-
standardised to the Australian population at 30 June 2001. 
Source: AIHW analysis of state and territory cervical cytology register data.  
Abnormalities detected by cytology in 2011 
In 2011, there were 115,026 abnormalities (low-grade, high-grade or cancer) detected in the 
2,065,618 cytology tests for women aged 20–69 (5.6 abnormalities per 100 cytology tests). Of 
these abnormalities, 84,540 (73.5%) were low-grade and 30,253 (26.3%) were high-grade, 
cancer making up the remainder (Table 3.9). 
Abnormality trends 
Low-grade abnormalities decreased steadily from their peak of 114,257 in 2005  
to 78,510 in 2010 for women aged 20–69 (a decrease from 5.5 to 3.9 per 100 cytology tests,  
age-standardised). However, in contrast to this trend, the number of low-grade 
abnormalities increased from 78,510 in 2010 to 84,540 in 2011 (a slight increase from 3.9 to 4.1 
per 100 cytology tests, age-standardised) (Table 3.9). 
High-grade abnormalities remained steady at 1.3 or 1.4 per 100 cytology tests for all years 
from 2004 to 2010, and although the increase to 1.5 in 2011 is not large, 2011 had the highest 
number of high-grade abnormalities detected—above 30,000 for the first time (Table 3.9). 
The NPAAC Performance measures for Australian laboratories reporting cervical cytology (NPAAC 
2006) includes recommended standards for the proportion of specimens reported as possible 
and definite high-grade abnormalities of at least 0.7%, and for the proportion of cytology 
tests reported as abnormal of less than 14.0%. It further recommends that the ratio of 
possible high-grade to definite high-grade abnormalities to be less than 1.5:1. Although these 
standards were developed for a different purpose, they provide a useful benchmark.  
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Box 3.2: National Pathology Accreditation Advisory Council (NPAAC) Performance 
measures for Australian laboratories reporting cervical cytology 
Performance measure 2b 
(i)  Proportion of specimens reported as definite and possible high-grade abnormality. 
(ii) Proportion of specimens reported as abnormal. 
Recommended standard 
(i)  Not less than 0.7% reported as definite or possible high-grade abnormality 
(ii) Not more than 14.0% reported as abnormal. 
Calculated value for 2011 
(i) 1.5% 
(ii) 5.6% 
Calculation of these performance measures using cytology detection data for 2011 gave 
results of 1.5%, 5.6% and 0.8:1, respectively (Box 3.2), which would all be considered within 
the standards set for these measures. 
Table 3.9: Abnormalities detected by cytology in women aged 20–69, 2004 to 2011 
 2004 2005 2006 2007 2008 2009 2010 2011 
Low-grade abnormalities 
Number 109,814 114,257 103,841 97,916 92,013 83,933 78,510 84,540 
Crude rate 5.4 5.6 5.1 4.7 4.5 4.0 3.9 4.1 
AS rate 5.4 5.5 5.1 4.6 4.5 4.0 3.9 4.1 
95% CI 5.3–5.4 5.4–5.5 5.0–5.1 4.6–4.6 4.4–4.5 4.0–4.0 3.9–3.9 4.1–4.2 
High-grade abnormalities 
Number 26,975 26,534 26,165 28,297 29,176 28,054 28,491 30,253 
Crude rate 1.3 1.3 1.3 1.4 1.4 1.3 1.4 1.5 
AS rate 1.3 1.3 1.3 1.3 1.4 1.3 1.4 1.5 
95% CI 1.3–1.3 1.2–1.3 1.2–1.3 1.3–1.3 1.4–1.4 1.3–1.3 1.4–1.4 1.4–1.5 
All abnormalities (low-grade, high-grade, and cancer)   
Number 137,010 141,016 130,234 126,442 121,400 112,188 107,261 115,026 
Crude rate 6.8 6.9 6.4 6.0 5.9 5.4 5.3 5.6 
AS rate 6.7 6.7 6.3 5.9 5.9 5.4 5.3 5.6 
95% CI 6.6–6.7 6.7–6.8 6.3–6.4 5.9–6.0 5.8–5.9 5.3–5.4 5.3–5.4 5.6–5.6 
Notes 
1. Low-grade abnormalities are cytology test results S2, S3 and E2; high-grade abnormalities are cytology results S4, S5, S6, E3,  
E4 and E5. All abnormalities are cytology results S2, S3, S4, S5, S6, S7, E2, E3, E4, E5 and E6 (see Table 3.1). 
2. Crude rate is the number of low-grade, high-grade, or all abnormalities detected by cytology as a proportion of the total number  
of cytology tests; age-standardised (AS) rate is the number of low-grade, high-grade, or all abnormalities detected by cytology as a 
proportion of the total number of cytology tests age-standardised to the Australian population at 30 June 2001. 
3. This is the number of abnormalities detected, not the number of abnormal cytology tests – in a small proportion of cytology tests there may 
be more than one abnormality detected, both of which will be counted. 
Source: AIHW analysis of state and territory cervical cytology register data.  
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Box 3.3: Detection of abnormalities 
While cervical abnormalities are present in a proportion of women in the population at any 
one time, abnormalities can only be detected if these women have a Pap test. Thus, while 
data on the detection of abnormalities can reflect underlying incidence of abnormalities in 
the population, these data only show how many abnormalities are found through cervical 
screening, and not how many abnormalities are present. 
Does a change in detection mean a change in occurrence of disease? 
The distinction between incidence and detection is important in the context of abnormality 
trends, since trends in the number and proportion of abnormalities detected by cervical 
cytology are influenced by many factors from which incidence is sheltered. 
Trends in underlying prevalence of disease certainly play a role, but because we are looking 
only at abnormalities detected in screened women, the number of abnormalities detected is 
also a function of the number of women screened, how many times they screen, and 
whether or not screened women are representative of women in the population generally. 
Further, abnormalities in women who do not have a Pap test cannot be ‘seen’, and so while 
these abnormalities contribute to the underlying prevalence of cervical disease in the 
population, they do not contribute to the abnormalities detected. 
Changes to the cervical screening program can also change detection rates. Management 
guidelines implemented in 2006 may have resulted in changes in the detection of 
abnormalities, especially low-grade abnormalities, even in the absence of concurrent 
changes to underlying prevalence. A further factor is the vaccine against HPV introduced in 
2007, which ultimately is predicted to reduce abnormalities in the underlying population 
(Goldie 2004).  
Therefore, if fewer women have a Pap test, the ‘pool’ of women in which abnormalities can 
be detected gets smaller; likewise, if the number of women with an abnormality decreases, 
then the number of abnormalities detected will decrease in reflection of this underlying 
trend. In this way, either changes to the screening program or changes to the underlying 
prevalence can result in a decrease in the detection of abnormalities, but it is not always 
possible to know which of these may be the primary factor resulting in the change – indeed 
it has been acknowledged that it may be difficult to distinguish HPV vaccination effects on 
abnormality detection from effects related to changes in cervical screening (WHO 2010). 
Abnormalities by age 
Figure 3.5 shows the age distribution of all low-grade abnormalities combined, and the age 
distribution of all high-grade abnormalities combined. 
Abnormalities are most common in younger women, due to HPV infections that occur 
frequently after sexual debut. Low-grade abnormalities are highest in women under 20 and 
in those aged 20–24 (Figure 3.5), while high-grade abnormalities are relatively low in women 
under 20 and peak in women aged 20–29 (Figure 3.5). Detection of both low-grade and high-
grade abnormalities then decreases with increasing age, only increasing slightly in women 
aged 70 or over (Figure 3.5). 
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Squamous abnormalities detected by cytology in 2011 
In 2011 there were 115,026 abnormalities detected by cytology in women aged 20–69.  
Of these, 113,321 were squamous in origin—83,719 low-grade, 29,447 high-grade and  
155 squamous cell carcinoma. This was 5.5 squamous abnormalities per 100 cytology tests in 
that year (Table 3.10). 
A squamous abnormality is defined as a squamous result of S2 Possible low-grade 
squamous intraepithelial lesion, S3 Low-grade squamous intraepithelial lesion, S4 Possible 
high-grade squamous intraepithelial lesion, S5 High-grade squamous intraepithelial lesion, 
S6 High-grade intraepithelial lesion with possible microinvasion/invasion or S7 Squamous 
cell carcinoma, regardless of the corresponding endocervical result for that cytology test. 
The most frequently detected squamous abnormalities in 2011 were possible low-grade 
squamous intraepithelial lesions (S2), with 49,443 abnormalities comprising 43.6% of 
squamous abnormalities, followed by low-grade squamous intraepithelial lesions (S3), with 
34,276 comprising 30.2%. Possible high-grade squamous intraepithelial lesions (S4) and high-
grade squamous intraepithelial lesions (S5) were the next most frequent, at 11.5% and 14.2% 
of squamous abnormalities, respectively. High-grade intraepithelial lesions with possible 
microinvasion/invasion (S6) and squamous cell carcinoma (S7) were both very rare 
squamous abnormalities at just 0.3% and 0.1% of squamous abnormalities, respectively, for 
women aged 20–69 (Table 3.10). 
Squamous abnormality trends 
Squamous abnormalities followed the same trend noted for low-grade, high-grade and all 
abnormalities in the earlier section ‘Abnormality trends’. Overall, squamous abnormalities 
decreased from 133,392 (6.5 per 100 cytology tests) in 2004 to 105,692 (5.3 per 100 cytology 
tests) in 2010, before increasing to 113,321 (5.5 per 100 cytology tests) in 2011 (Table 3.10). 
Low-grade abnormalities 
 
High-grade abnormalities 
 
Source: AIHW analysis of state and territory cervical cytology register data; data for figures are available in Table A1. 
Figure 3.5: Abnormalities detected by cytology by age, 2011 
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However, this trend was not common to all squamous abnormalities. Possible low-grade 
squamous intraepithelial lesions (S2) decreased steadily from 2005 to 2010, increasing again 
in 2011, similar to the overall trend. In contrast, low-grade squamous intraepithelial lesions 
(S3) decreased steadily from 2004 to 2011 (although comprising a constant 1.7 per 100 
cytology tests in 2009, 2010 and 2011).  
Table 3.10: Squamous abnormalities detected by cytology in women aged 20–69, by squamous 
category, 2004 to 2011 
Squamous category 2004 2005 2006 2007 2008 2009 2010 2011 
S2 Possible low-grade squamous intraepithelial lesion   
Number 55,981 59,788 55,431 54,262 51,147 47,290 43,485 49,443 
Per 100 cytology tests 2.8 2.9 2.7 2.6 2.5 2.3 2.1 2.4 
Per cent of squamous abnormalities 42.0 43.4 43.4 43.6 42.8 42.8 41.1 43.6 
S3 Low-grade squamous intraepithelial lesion   
Number 51,947 52,545 47,038 42,502 39,846 35,897 34,311 34,276 
Per 100 cytology tests 2.6 2.6 2.3 2.0 1.9 1.7 1.7 1.7 
Per cent of squamous abnormalities 38.9 38.1 36.8 34.2 33.4 32.5 32.5 30.2 
S4 Possible high-grade squamous intraepithelial lesion   
Number 9,481 8,679 9,456 10,727 11,500 11,494 12,088 13,020 
Per 100 cytology tests 0.5 0.4 0.5 0.5 0.6 0.6 0.6 0.6 
Per cent of squamous abnormalities 7.1 6.3 7.4 8.6 9.6 10.4 11.4 11.5 
S5 High-grade squamous intraepithelial lesion   
Number 15,407 16,199 15,342 16,438 16,491 15,505 15,317 16,117 
Per 100 cytology tests 0.8 0.8 0.8 0.8 0.8 0.7 0.8 0.8 
Per cent of squamous abnormalities 11.6 11.8 12.0 13.2 13.8 14.0 14.5 14.2 
S6 High-grade squamous intraepithelial lesion with possible microinvasion/ invasion   
Number 422 447 318 316 290 287 313 310 
Per 100 cytology tests 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Per cent of squamous abnormalities 0.3 0.3 0.2 0.3 0.2 0.3 0.3 0.3 
S7 Squamous cell carcinoma   
Number 154 148 150 154 126 141 178 155 
Per 100 cytology tests 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Per cent of squamous abnormalities 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 
All squamous abnormalities   
Number 133,392 137,806 127,735 124,399 119,400 110,614 105,692 113,321 
Crude rate 6.6 6.7 6.3 5.9 5.8 5.3 5.2 5.5 
AS rate 6.5 6.6 6.2 5.8 5.8 5.3 5.3  5.5 
95% CI 6.5–6.5 6.5–6.6 6.2–6.2 5.8–5.9 5.7–5.8 5.2–5.3 5.2–5.3 5.5–5.6 
Note: Crude rate is the number of each squamous abnormality or of all squamous abnormalities combined detected by cytology as a proportion of 
the total number of cytology tests; age-standardised (AS) rate is the number of all squamous abnormalities combined detected by cytology as a 
proportion of the total number of cytology tests age-standardised to the Australian population at 30 June 2001. 
Source: AIHW analysis of state and territory cervical cytology register data.  
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Possible high-grade squamous intraepithelial lesions (S4) increased from 2005 to 2011, 
although remained a constant 0.5 or 0.6 per 100 cytology tests, whereas high-grade 
squamous intraepithelial lesions (S5) have remained relatively steady both in number and as 
a per cent of cytology tests across all years from 2004 to 2011.  
The rarer high-grade intraepithelial lesions with possible microinvasion/invasion (S6) and 
squamous cell carcinoma (S7) have fluctuated, but not contributed greatly to overall trends. 
Thus it would seem that the overall increase in squamous abnormalities between 2010 and 
2011 was primarily driven by an increase in possible low-grade intraepithelial lesions, and to 
a lesser extent possible high-grade intraepithelial lesions, and has occurred despite a 
decrease in the number of low-grade intraepithelial lesions. 
The increase in possible low-grade intraepithelial lesions in 2011 is in opposition to the trend 
for the years before 2011, and is an unexpected finding. Trends for individual states and 
territories were examined to assess how widespread this trend was—of note almost all states 
and territories experienced a clear increase in possible low-grade squamous intraepithelial 
lesions in 2011 following a decrease from 2009 to 2010. The reason for this comprehensive 
and sudden increase in this type of abnormality is unclear. 
Squamous abnormalities by age 
While low-grade and high-grade squamous abnormalities (both possible and definite) all 
peaked in younger women before decreasing sharply with increasing age, for low-grade 
squamous intraepithelial lesions this peak occurred in women under 20 and in those aged 
 
 
 
Note: S2 = possible low-grade squamous intraepithelial lesion; S3 = low-grade squamous intraepithelial lesion; S4 = possible high-grade 
squamous intraepithelial lesion; S5 = high-grade squamous intraepithelial lesion; S6 = high-grade squamous intraepithelial lesion with possible 
microinvasion/invasion; S7 = squamous cell carcinoma.  
Source: AIHW analysis of state and territory cervical cytology register data. 
Figure 3.6: Squamous abnormalities detected by cytology in women by age, 2011 
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20–24, whereas for high-grade intraepithelial lesions this peak occurred in women aged 20–
24 and 25–29, with lower rates seen in women under 20. These four squamous abnormalities 
were at their lowest in women aged 65–69 (Figure 3.6). In contrast, detection of high-grade 
squamous abnormalities with possible microinvasion/invasion (S6) and squamous cell 
carcinoma (S7) was very rare in younger women (to illustrate, from the 499,123 cytology tests 
performed for women under 30, there were just 9 cases of squamous cell carcinoma 
detected). 
Endocervical abnormalities detected by cytology in 2011 
In 2011, there were 115,026 abnormalities detected by cytology in women aged 20–69.  
Of these 1,705 were endocervical (glandular) in origin—821 atypical endocervical cells of 
uncertain significance, 806 high-grade, and 78 adenocarcinoma. This was 0.08 endocervical 
abnormalities per 100 cytology tests in that year (Table 3.11). 
An endocervical abnormality is defined as an endocervical result of E2 Atypical 
endocervical cells of uncertain significance, E3 Possible high-grade endocervical glandular 
lesion, E4 Adenocarcinoma in situ, E5 Adenocarcinoma in situ with possible 
microinvasion/invasion or E6 Adenocarcinoma, regardless of the corresponding squamous 
result for that cytology test. 
The most frequently detected endocervical abnormalities in 2011 were those categorised as 
‘atypical endocervical cells of uncertain significance’ (E2). This category represents abnormal 
glandular cells in a cervical cytology sample where the degree of abnormality is not 
sufficient for a diagnosis of adenocarcinoma in situ to be made (NHMRC 2005). Almost half 
of endocervical abnormalities were categorised in this way, comprising 48.2% of all 
endocervical abnormalities detected in 2011. 
Possible high-grade endocervical glandular lesions (E3) and adenocarcinoma in situ (E4) 
were the next most frequent endocervical abnormalities, at 29.3% and 16.6% of endocervical 
abnormalities, respectively. Adenocarcinoma in situ with possible microinvasion/invasion 
(E5) was rare at 1.3%, and adenocarcinoma (E6) slightly more frequent at 4.6% of 
endocervical abnormalities in 2011 for women aged 20–69 (Table 3.11). 
Although endocervical abnormalities are far rarer than squamous abnormalities, of the 
endocervical abnormalities that do occur, cervical cancer makes up a far greater proportion, 
with adenocarcinoma comprising 4.6% of endocervical abnormalities in 2011, compared with 
squamous cell carcinoma, which comprised just 0.1% of squamous abnormalities in that 
year. 
Endocervical abnormality trends 
Similar to squamous abnormalities, and following the same trend noted for low-grade, high-
grade and all abnormalities in the earlier section ‘Abnormality trends’, the overall number of 
endocervical abnormalities decreased from 3,618 in 2004 to 1,569 in 2010, before increasing to 
1,705 in 2011. However, the proportion of endocervical abnormalities between 2009 and 2011 
was relatively stable at around 0.08 per 100 cytology tests (Table 3.11). 
Of the endocervical abnormalities, this trend was common to atypical endocervical cells of 
uncertain significance (E2) and possible high-grade endocervical glandular lesions (E3). 
Atypical endocervical cells of uncertain significance decreased from 1,886 in 2004 to 714 in 
2010, and then increased to 821 in 2011 – although comprising the same per cent of cytology 
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tests in 2009 to 2011 (Table 3.11). A change in the management guidelines for this 
abnormality in 2006 may account for the overall decrease from 2006 to 2010 (current 
Guidelines recommend this be managed as a high-grade abnormality, whereas previous 
Guidelines recommended this be managed as a low-grade abnormality), but the reason for 
the apparent reversal of this trend in 2011 is not clear. 
Similarly, possible high-grade endocervical glandular lesions decreased from 1,344 in 2004 to 
435 in 2010, before increasing to 500 in 2011 (Table 3.11). 
Table 3.11: Endocervical abnormalities detected by cytology in women aged 20–69, by endocervical 
category, 2004 to 2011 
Endocervical category 2004 2005 2006 2007 2008 2009 2010 2011 
E2 Atypical endocervical cells of uncertain significance   
Number 1,886 1,924 1,372 1,152 1,020 746 714 821 
Per cent of cytology tests 0.09 0.09 0.07 0.06 0.05 0.04 0.04 0.04 
Per cent of endocervical 
abnormalities 52.1 59.9 54.9 56.4 51.0 47.4 45.5 48.2 
E3 Possible high-grade endocervical glandular lesion   
Number 1,344 887 724 510 562 461 435 500 
Per cent of cytology tests 0.07 0.04 0.04 0.02 0.03 0.02 0.02 0.02 
Per cent of endocervical 
abnormalities 37.1 27.6 29.0 25.0 28.1 29.3 27.7 29.3 
E4 Adenocarcinoma in situ   
Number 276 274 283 277 299 283 305 283 
Per cent of cytology tests 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 
Per cent of endocervical 
abnormalities 7.6 8.5 11.3 13.6 15.0 18.0 19.4 16.6 
E5 Adenocarcinoma in situ with possible microinvasion/invasion   
Number 45 48 42 29 34 24 33 23 
Per cent of cytology tests 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Per cent of endocervical 
abnormalities 1.2 1.5 1.7 1.4 1.7 1.5 2.1 1.3 
E6 Adenocarcinoma   
Number 67 77 78 75 85 60 82 78 
Per cent of cytology tests 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Per cent of endocervical 
abnormalities 1.9 2.4 3.1 3.7 4.3 3.8 5.2 4.6 
All endocervical abnormalities   
Number 3,618 3,210 2,499 2,043 2,000 1,574 1,569 1,705 
Crude rate 0.18 0.16 0.12 0.10 0.10 0.08 0.08 0.08 
AS rate 0.17 0.15 0.12 0.10 0.10 0.07 0.08 0.08 
95% CI 
0.17–
0.18 
0.15–
0.16 
0.12–
0.13 
0.09–
0.10 
0.09–
0.10 
0.07–
0.08 
0.07–
0.08 
0.08–
0.09 
Note: Crude rate is the number of each endocervical abnormality or of all endocervical abnormalities combined detected by cytology as a 
proportion of the total number of cytology tests; age-standardised (AS) rate is the number of all endocervical abnormalities combined detected by 
cytology as a proportion of the total number of cytology tests age-standardised to the Australian population at 30 June 2001. 
Source: AIHW analysis of state and territory cervical cytology register data.  
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In contrast, high-grade endocervical glandular abnormalities have remained relatively 
steady both in number and as a per cent of cytology tests across all years from 2004 to 2011. 
The rarer high-grade endocervical glandular abnormalities with possible microinvasion/ 
invasion (E5) and adenocarcinoma (E6) have not greatly affected the overall trends. 
Thus it would seem that the overall increase in endocervical abnormalities between 2010 and 
2011 has been primarily driven by an increase in atypical endocervical cells of uncertain 
significance  and possible high-grade endocervical glandular lesions. 
The small numbers in individual states and territories make it difficult to ascertain how 
widespread these trends may be nationally. 
Endocervical abnormalities by age 
Endocervical abnormalities are rarely detected in women under 20. Atypical endocervical 
cells of uncertain significance (E2) peaked at age 25–29. Possible high-grade glandular 
abnormalities (E3) also peaked at age 25–29, whereas adenocarcinoma in situ (E4) peaked at 
age 30–34 (Figure 3.7). 
While the detection of all other endocervical abnormalities is very low in women aged 70 or 
over, there is a relatively large increase apparent in the detection of both possible high-grade 
(E3) and adenocarcinoma (E6) in this age group. However, these findings are based on a very 
small number of abnormalities, and so should be interpreted with caution. 
 
 
 
 
Note: E2 = atypical endocervical cells of uncertain significance; E3 = possible high-grade endocervical glandular lesion;  
E4 = adenocarcinoma in situ; E5 = adenocarcinoma in situ with possible microinvasion/invasion; E6 = adenocarcinoma. 
Source: AIHW analysis of state and territory cervical cytology register data. 
Figure 3.7: Endocervical abnormalities detected by cytology in women by age, 2011 
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Indicator 4 Histology 
What you need to know about histology 
Cervical histology is the examination of tissue from the cervix through a microscope, and is 
the primary diagnostic tool of the National Cervical Screening Program (NCSP).  
Definition: The proportion of histology test results that were negative or detected an 
abnormality in a 12-month period. High-grade abnormality detection is defined as the 
number of women with a high-grade abnormality detected per 1,000 women screened. 
Rationale: Annual monitoring of histology report categories by various stratifications may 
reveal emerging positive or negative trends that need to be addressed, including effects from 
the human papillomavirus (HPV) vaccine introduced in 2007. 
In addition, the high-grade abnormality detection rate is an indicator of how well the NCSP 
detects high-grade abnormalities. Detection of high-grade abnormalities, which have a 
greater probability of progressing to invasive cancer than do low-grade abnormalities, 
provide an opportunity for treatment before possible progression to cervical cancer. 
Guide to interpretation: High-grade abnormality detection rate is per 1,000 women screened 
because this measure is based on the number of women, not the number of tests. 
The most recent histology data are for the year 2011. 
What the data tell us about histology 
 Trends 
Between 2010 and 2011, the (age-standardised) detection of high-grade abnormalities in 
women aged 20–69 decreased slightly from 8.5 to 8.4 per 1,000 women screened.  
Detection in women under 20 continued to decrease between 2010 and 2011, from 7.8 to 7.1 
per 1,000 women screened.  
A decrease in high-grade abnormalities detected in women aged 20–24 in 2011 also 
contributed to a shift in the historical peak from women aged 20–24 to women aged 25–29 
in 2011. 
 
Histology in 2011 
There were 79,026 cervical histology tests performed in 2011, with 75,589 for women 20–69. 
For every 1,000 women screened, 8.4 women had a high-grade abnormality detected by 
histology, providing an opportunity for treatment before possible progression to cervical 
cancer. 
The ratio of high-grade squamous abnormalities to squamous cell carcinoma was 40.5:1 
compared with the ratio of high-grade endocervical abnormalities to adenocarcinoma of 
2.9:1. 
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More information about histology  
Histology is the primary diagnostic tool of the NCSP. Because cytology is only a screening 
tool, confirmation of disease is required before any treatment is initiated, both to ensure 
treatment is appropriate and to avoid unnecessary treatment in women where the cytology 
has predicted disease that is not present. While colposcopy is used as part of this process, in 
Australia it is considered best practice to confirm high-grade disease with histology prior to 
treatment (NHMRC 2005).  
Because histology is used to diagnose disease, either as follow-up for screen-detected 
abnormalities in asymptomatic women as per the national guidelines, or because it is 
clinically indicated even in the absence of a cytological abnormality being detected, histology 
is performed for only a subset of screened women. Further, more women have histology 
following a cytology result of high-grade disease or cancer than following negative or low-
grade cytology results. Thus, while histology can tell us much about true disease, it can only 
do so for the subset of women in which histology is performed.  
Note that histology may also be performed for reasons other than to confirm or follow-up 
suspected cervical disease, and that the national guidelines introduced in July 2006 changed 
recommendations for the subsets of women that were recommended to have colposcopy and 
biopsy following a screen-detected abnormality. 
Unlike cytology, which has nationally consistent reporting through the Australian Modified 
Bethesda System 2004 (AMBS 2004), state and territory cervical cytology registers have 
different coding systems for histology. In order to report histology in a way that is 
meaningful, states and territories have worked together with the AIHW to develop a 
national histology coding system for the NCSP, with the individual histology codes used in 
each state and territory mapped to these national codes. 
The squamous and endocervical reporting categories of the NCSP national histology coding 
system are shown in Table 4.1.  
Table 4.1: Histology reporting categories of the National Cervical Screening Program 
Squamous Endocervical 
HSU Unsatisfactory HEU Unsatisfactory 
HS01 Negative HE1 Negative 
HS02 Low-grade squamous abnormality  HE02 Endocervical atypia 
HS03.1 High-grade squamous abnormality, cervical 
intraepithelial neoplasia (CIN) not otherwise specified 
(NOS) 
HE03.1 High-grade endocervical abnormality, 
endocervical dysplasia 
HS03.2 High-grade squamous abnormality, CIN II HE03.2 High-grade endocervical abnormality, 
adenocarcinoma in situ 
HS03.3 High-grade squamous abnormality, CIN III  
HS04.1 Squamous cell carcinoma, microinvasive HE04.1 Adenocarcinoma, microinvasive 
HS04.2 Squamous cell carcinoma, invasive HE04.2 Adenocarcinoma, invasive 
 HE04.3 Adenosquamous carcinoma 
 HE04.4 Carcinoma of the cervix (other) 
Note: there is a further result of HE03.3 to allow the collection of mixed high-grade histology (carcinoma in situ/adenocarcinoma in situ)  
that has been omitted since this category is not included in the cervical histology results presented.  
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Detailed analyses 
Histology in 2011 
In 2011, there were 79,026 cervical histology tests performed, 75,589 (95.7%) of these for 
women aged 20–69 (Table 4.2). Most histology tests were performed for women aged 20 to 
49, with a peak of 12,940 tests for women aged 25–29 (Figure 4.1A), this being 16.4% of all 
histology tests in 2011. 
It is reasonable to expect an increase in the number of histology tests in 2011, since there was 
a marked increase in the number of abnormalities detected by cytology in that year, 
including the highest number of high-grade abnormalities ever detected, for which the 
Guidelines recommend subsequent histology to confirm the presence of high-grade disease 
prior to treatment. 
Histology trends 
The number of cervical histology tests performed for women aged 20–69 decreased from 
76,276 in 2004 to between 72,000 and 73,000 for most years between 2006 and 2009. However, 
in 2011 there was a 4.6% increase in the number of histology tests, from 72,234 in 2010 to 
75,589 in 2011. The number of histology tests increased between 2010 and 2011 for all age 
groups except for under 20 and 20–24, for which there was a decrease. The greatest increase 
was an 11.5% increase for women aged 40–44 (Table 4.2). 
This appears to be a direct result of the increased detection of high-grade abnormalities in 
2011 compared with 2010, noted in the earlier Cytology section, since the greatest increase in 
the number of high-grade abnormalities was also for women aged 40–44 (a 19.2% increase 
from 2010), and there was a also a mirroring of the decrease in women under 20 and 20–24 
noted above. 
Table 4.2: Number of histology tests by year, 2004 to 2011  
Age group 
(years) 2004 2005 2006 2007 2008 2009 2010 2011 
<20 3,462 3,386 2,909 2,296 2,089 1,689 1,454 1,380 
20–24 13,247 13,572 12,655 11,967 12,136 11,187 10,519 10,089 
25–29 12,858 12,854 12,490 12,364 12,621 12,625 12,690 12,940 
30–34 11,387 11,224 10,448 9,975 9,989 10,009 9,839 10,635 
35–39 9,314 9,056 8,716 8,819 9,037 8,985 8,753 9,259 
40–44 9,391 9,017 8,671 8,309 8,249 8,280 8,265 9,218 
45–49 8,266 7,998 7,878 8,107 8,202 8,348 8,584 8,681 
50–54 5,386 5,226 5,043 5,290 5,382 5,623 5,742 6,259 
55–59 3,277 3,249 3,318 3,271 3,374 3,441 3,562 3,892 
60–64 1,817 1,921 1,953 2,102 2,324 2,395 2,600 2,802 
65–69 1,333 1,253 1,347 1,397 1,478 1,501 1,680 1,814 
70+ 1,705 1,708 1,533 1,523 1,728 1,817 1,915 2,057 
All ages 81,448 80,466 76,972 75,423 76,612 75,904 75,611 79,026 
Ages 20–69 76,276 75,370 72,519 71,601 72,792 72,394 72,234 75,589 
Source: AIHW analysis of state and territory cervical cytology register data.  
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Histology as a proportion of cytology  
Trends in histology are heavily dependent on cytology trends, since histology is used to 
diagnose abnormalities predicted by cytology. The number of histology tests per 100 
cytology tests has been reported to take into account changes in the number of cytology tests 
when interpreting the number of histology tests. 
In 2011, for all women aged 20–69, there were 3.7 histology tests for every 100 cytology tests 
performed. Within this age range, it was highest for women aged 20–24 and 25–29, 
indicating that, for every 100 cytology tests, women aged 20 to 29 had the greatest number of 
histology tests performed. This equated to 5.2 histology tests for every 100 cytology tests, 
decreasing to 3.0 histology tests for every 100 cytology tests by the time women reach 50–54, 
with only 2.0 histology tests for every 100 cytology tests for women aged 65–69 (Figure 4.1B). 
Histology as a proportion of cytology closely follows the detection of high-grade 
abnormalities by cytology, with two exceptions: women under 20 appear to have fewer 
histology tests than would be expected by the number of high-grade cytology abnormalities 
detected, and women aged 40–54 appear to have a greater number of histology tests than 
would be expected if these were solely due to follow-up of high-grade cytology. 
Hysterectomies for benign conditions may contribute to the latter. 
Negative histology in 2011 
In 2011, of the 75,589 histology tests performed, 36,117 (47.8%) were negative.   
A negative histology result is defined as any histology test that is not unsatisfactory and 
where there is no evidence of HPV infection, intraepithelial pre-neoplasia or intraepithelial 
neoplasia. Note that there is no requirement for both squamous and endocervical 
components to be sampled and to be negative; a histology result that only samples the 
squamous component and the squamous component is negative, or a histology result that 
only samples the endocervical component and the endocervical component is negative, are 
both counted as negative histology tests.  
Women aged 20–24 had the lowest proportion of histology tests that were negative (23.6%), 
increasing with increasing age, with 81.7% of all histology tests performed for women aged 
A 
 
B  
 
Source: AIHW analysis of state and territory cervical cytology register data; data for figures are available in Table A1. 
Figure 4.1: Proportion of histology tests by age (A) and histology tests per 100 cytology tests  
by age (B), 2011 
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70 and over negative (Figure 4.2). The high proportion of negative histology tests in older 
women is likely related to cervical histology from hysterectomies due to benign conditions, 
since cervical cytology registers are sent all cervical histology results, including benign 
conditions unrelated to abnormalities. 
Abnormalities detected by histology in 2011 
In 2011, there were 38,122 abnormalities (low-grade, high-grade or cancer) detected in the 
75,589 histology tests for women aged 20–69 (50.4 per 100 histology tests). Of these 
abnormalities, 14,566 (38.3%) were low-grade and 22,676 (59.6%) were high-grade, cancer 
making up the remainder (Table 4.3). 
Abnormality trends 
Low-grade abnormalities detected by histology decreased from 20,239 in 2004 to  
14,018 in 2010 for women aged 20–69 (a decrease from 23.0 to 17.2 per 100 histology tests, 
age-standardised), rising slightly to 14,566 in 2011, although with a similar rate of 17.4 (Table 
4.3). The overall decrease, across all age groups, is in line with expected changes in detection 
of low-grade abnormalities resulting from changes to the recommended management of 
women with low-grade abnormalities as part of the current NHMRC Guidelines introduced 
in 2006 (Box 4.1), although the 2011 data suggests the trend may have stabilised following 
this change (2012 data are required to see if this is true). 
  
 
 
  
 
Source: AIHW analysis of state and territory cervical cytology register data; data for figures are available in Table A1. 
Figure 4.2: Proportion of negative histology tests by age, 2011 
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Box 4.1: Interpretation of abnormality trends 
The detection of abnormalities by histology is affected by the same factors as the detection 
of abnormalities by cytology, but is also influenced by the detection of abnormalities by 
cytology itself, since most histology occurs as a consequence of an abnormality being 
detected by cytology, and is thus expected to increase and decrease in line with cytological 
abnormality detection trends. 
Prior to the introduction of the current NHMRC Guidelines, the recommended 
management for women with a low-grade abnormality detected by cytology was 
colposcopy, which often resulted in a biopsy. The current Guidelines no longer recommend 
colposcopy for the majority of women with a low-grade abnormality detected by cytology, 
which is expected to result in a decrease in both the number of histology tests, and the 
proportion of histology tests with a result of low-grade abnormality.  
However, cervical screening is a complex environment—factors do not exist in isolation, 
and pinpointing the precise cause of trends is difficult. The change in Guidelines is 
probably the main driving factor behind histology trends, but in addition to any apparent 
decrease in detection of abnormalities in the screening population, there may also be a true 
decrease in prevalence emerging in the broader population, since the introduction of the 
HPV vaccine in 2007 is expected to reduce the incidence of low-grade and high-grade 
abnormalities, which would be reflected in the detection of these abnormalities by cytology 
and histology. 
Table 4.3: Abnormalities detected by histology in women aged 20–69, 2004 to 2011 
 2004 2005 2006 2007 2008 2009 2010 2011 
Low-grade abnormalities        
Number 20,239 19,576 18,003 16,602 15,347 14,576 14,018 14,566 
Crude rate 26.5 26.0 24.8 23.2 21.1 20.1 19.4 19.3 
AS rate 23.0 22.2 21.4 20.2 18.4 17.6 17.2 17.4 
95% CI 22.7–23.4 21.9–22.6 21.1–21.8 19.9–20.6 18.1–18.7 17.3–17.9 16.9–17.5 17.1–17.7 
High-grade abnormalities        
Number 19,681 20,200 20,063 21,067 22,102 22,031 22,104 22,676 
Crude rate 25.8 26.8 27.7 29.4 30.4 30.4 30.6 30.0 
AS rate 21.2 22.0 22.9 24.4 25.2 25.4 25.9 25.9 
95% CI 20.9–21.5 21.6–22.3 22.6–23.3 24.1–24.8 24.8–25.5 25.0–25.7 25.6–26.3 25.5–26.2 
All abnormalities (low-grade, high-grade and cancer)   
Number 40,653 40,603 38,825 38,476 38,325 37,380 36,940  38,122 
Crude rate 53.3 53.9 53.5 53.7 52.7 51.6 51.1 50.4 
AS rate 45.5 45.8 45.8 46.2 45.1 44.4 44.4 44.6 
95% CI 45.0–46.0 45.3–46.2 45.3–46.3 45.7–46.7 44.7–45.6 43.9–44.9 44.0–44.9 44.1–45.0 
Notes 
1. Low-grade abnormalities are histology test results HS02 and HE02; high-grade abnormalities are histology results HS03 and HE03. 
All abnormalities are histology test results HS02, HS03, HS04, HE02, HE03 and HE04 (see Table 4.1).  
2. Crude rate is the number of low-grade, high-grade, or all abnormalities detected by histology as a proportion of the total number of 
histology tests; age-standardised (AS) rate is the number of low-grade, high-grade, or all abnormalities detected by histology as a  
proportion of the total number of histology tests age-standardised to the Australian population at 30 June 2001. 
3. This is the number of abnormalities detected, not the number of abnormal histology tests – in a small proportion of histology tests there may 
be more than one abnormality detected, both of which will be counted. 
Source: AIHW analysis of state and territory cervical cytology register data.  
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In contrast, the detection of high-grade abnormalities by histology increased from 19,681 in 
2004 to 22,676 in 2011 for women aged 20–69 (an increase from 21.2 to 25.9 per 100 histology 
tests, age-standardised) (Table 4.3).  
Although the (age-standardised) detection rate did not change between 2010 and 2011, there 
were differences between age groups, with an increase in the detection rate for women aged 
35 and over, and a decrease in the detection of high-grade abnormalities in women aged 34 
and under – with the largest decrease in women aged 20–24. This decrease may be due to the 
introduction of the National HPV Vaccination Program in 2007, as demonstrated by an 
ecological study of Victorian Cervical Cytology Register data, which showed a decrease in 
incidence of histologically confirmed high-grade cervical abnormalities of 0.38% 
(95%CI 0.61–0.16) for women under 18 when comparing the pre- and post-vaccination 
periods (Brotherton et al., 2011). 
Age-trend data, while not shown in this report, are available in associated supplementary 
data tables. 
Abnormalities by age 
Figure 4.3A shows the age distribution of all low-grade abnormalities combined, and  
Figure 4.3B the age distribution of all high-grade abnormalities combined. 
Similar to abnormalities detected by cytology, abnormalities detected by histology were most 
common in younger women (HPV infections occur more frequently in the first years after 
sexual debut). However, because low-grade cytology is not routinely followed-up with 
histology under the current NHMRC Guidelines (NHMRC 2005), low-grade histology 
occurred less frequently than high-grade histology. The age distribution of these detected 
abnormalities is a straight line, with low-grade abnormalities highest in women under 20, 
thereafter decreasing steadily with increasing age (Figure 4.3A). 
The age-distribution of high-grade abnormalities was different, being highest in women 
aged 20–34, followed by women under 20, then those aged 35–39, and thereafter decreasing 
sharply with increasing age (Figure 4.3B). 
Low grade abnormalities 
 
 
High grade abnormalities 
 
 
Source: AIHW analysis of state and territory cervical cytology register data; data for figures are available in Table A1. 
Figure 4.3: Abnormalities detected by histology by age, 2011 
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High-grade abnormality detection rate in 2011 
The number of women with a high-grade abnormality detected by histology per 1,000 
women screened (the high-grade abnormality detection rate) is reported separately, since 
this is a historical rate that provides different information to the number of high-grade 
abnormalities detected, reported above.  
High-grade abnormalities of the cervix include cervical intraepithelial neoplasia (CIN) that 
has been graded as moderate (CIN II) or severe (CIN III), or for which the grade has not been 
specified, as well as endocervical dysplasia and adenocarcinoma in situ. High-grade 
abnormalities have a greater probability of progressing to invasive cancer than do low-grade 
abnormalities (although it should be noted that high-grade abnormalities do not always 
progress, with one study suggesting that at least 80% of high-grade abnormalities regress 
spontaneously (Raffle et al. 2003)). Detection of high-grade abnormalities provides an 
opportunity for treatment before cancer can develop, thus the NCSP aims to detect high-
grade abnormalities in line with its broader aim to reduce the incidence of cervical cancer. 
In 2011, there were 16,641 women with a high-grade abnormality detected by histology, 
which, when presented as a proportion of the 1,984,259 women screened in that year, 
equates to a high-grade abnormality detection rate of 8.4 for women aged 20–69 (Table 4.4). 
This means that, for every 1,000 women screened, 8.4 had a high-grade abnormality found, 
providing an opportunity for treatment before possible progression to cervical cancer. 
High-grade abnormality detection rate trends 
Table 4.4: High-grade abnormality detection rate by age, 2004 to 2011  
 2004 2005 2006 2007 2008 2009 2010 2011 
<20 14.5 13.2 13.2 11.6 10.8 8.9 7.8 7.1 
20–24 20.3 20.2 19.9 18.9 21.3 19.9 19.7 17.4 
25–29 17.7 17.7 17.7 17.8 19.3 19.0 19.9 19.4 
30–34 11.6 11.6 11.6 11.5 12.7 12.8 13.6 14.0 
35–39 7.1 7.0 7.2 7.3 7.8 7.6 8.3 9.0 
40–44 4.6 4.4 4.7 4.7 4.8 4.7 4.9 5.5 
45–49 3.1 3.1 3.2 3.2 3.3 3.3 3.5 3.8 
50–54 1.7 1.7 1.9 1.9 2.0 1.9 2.1 2.2 
55–59 1.5 1.6 1.5 1.4 1.3 1.3 1.7 1.7 
60–64 1.2 1.4 1.2 1.2 1.3 1.2 1.2 1.4 
65–69 1.0 1.0 1.4 1.3 1.3 1.1 1.1 1.1 
70+ 3.1 3.0 2.8 2.4 2.6 2.6 3.4 2.7 
Ages 20–69   
Crude rate 7.9 7.9 7.8 7.8 8.4 8.1 8.4 8.4 
AS rate 7.7 7.7 7.8 7.7 8.3 8.1 8.5 8.4 
95% CI 7.6–7.9 7.6–7.8 7.6–7.9 7.5–7.8 8.2–8.5 8.0–8.2 8.3–8.6 8.3–8.6 
Note: Crude rate is the number of women with a high-grade abnormality detected by histology per 1,000 women screened; age-standardised (AS) 
rate is the number of women with a high-grade abnormality detected by histology per 1,000 women screened, age-standardised to the Australian 
population at 30 June 2001. 
Source: AIHW analysis of state and territory cervical cytology register data.  
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The number of women aged 20–69 with a high-grade abnormality detected by histology per 
1,000 women screened, after remaining at approximately 7.7 for all years from 2004 to 2007, 
increased to above 8 in 2008, where it remained from 2008 to 2011 (Table 4.4). 
However, in contrast with the overall trend of increasing detection over time, there has been 
a steady decrease in high-grade abnormality detection in women under 20. Highest at 14.5 in 
2004, this decreased to 7.1 women with high-grade histology per 1,000 women screened in 
2011 (Table 4.4; Figure 4.4). 
More recently, between 2010 and 2011, there was a decrease in high-grade abnormality 
detection from 7.8 to 7.1 for women under 20, and from 19.7 to 17.4 for women aged 20–24. 
This latter trend notably changed the peak age of high-grade histological abnormalities from 
women aged 20–24, where it has been for the life of the NCSP, to women aged 25–29. This 
decrease in high-grade abnormalities in younger women is likely due to younger girls 
vaccinated against HPV during the ‘catch-up’ program in 2007–2009, who are expected to 
experience fewer abnormalities (a trend noted in Brotherton et al., 2011) moving into the 
screening age range—visible in the under 20 age group several years ago, and now clearly 
contributing to the 20–24 age group in 2011.  
The decreases in the younger age groups occur despite an increase in the overall high-grade 
abnormality rate from 2007 to 2011, which appears to be due to an increase in the detection 
of high-grade abnormalities in women aged 25 to 39, a trend continued from 2010 to 2011 
(Table 4.4; Figure 4.4). 
 
Source: AIHW analysis of state and territory cervical cytology register data.  
Figure 4.4: High-grade abnormality detection rate by age, 2006, 2010 and 2011 
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High-grade abnormality detection rate by age 
In 2011, the high-grade abnormality detection rate was highest for women aged 25–29 at 19.4 
women with high-grade histology detected per 1,000 women screened. As noted earlier, this 
is a change from the historical peak age of 20–24. The detection rate was lower at 14.0 for 
women aged 30–34, further decreasing with increasing age to be just 1.1 for women aged  
65–69 (Table 4.4).  
High-grade abnormality detection by state and territory 
In 2011, the high-grade abnormality detection rate varied across states and territories 
between 6.2 and 11.6 per 1,000 women screened (Table 4.5). 
Table 4.5: High-grade abnormality detection rate in women aged 20–69, by state and territory, 2011 
 NSW Vic Qld WA SA Tas ACT NT Australia 
AS rate 9.2 7.7 8.7 8.0 7.5 9.5 6.2 11.6 8.4 
95% CI 8.9–9.4 7.4–7.9 8.4–9.0 7.6–8.4 7.1–8.0 8.6–10.4 5.4–7.1 10.0–13.4 8.3–8.6 
Note: Age-standardised (AS) rate is the number of women with a high-grade abnormality detected by histology per 1,000 women screened,  
age-standardised to the Australian population at 30 June 2001. 
Source: AIHW analysis of state and territory cervical cytology register data.  
Squamous abnormalities detected by histology in 2011 
In 2011, of the 38,122 abnormalities detected by histology in women aged 20–69, 36,996 were 
squamous in origin—14,504 low-grade, 21,941 high-grade, and 551 squamous cell carcinoma. 
This was 48.9 squamous abnormalities per 100 histology tests. 
A squamous abnormality is defined as a squamous result of HS02 Low-grade squamous 
abnormality, HS03.1 Cervical intraepithelial neoplasia (CIN) not otherwise specified (NOS), 
HS03.2 CIN II, HS03.3 CIN III, HS04.1 Microinvasive squamous cell carcinoma, or HS04.2 
Invasive squamous cell carcinoma, regardless of any endocervical result. 
Squamous abnormality trends 
The overall number of squamous abnormalities decreased from 39,786 in 2004 to 35,881 in 
2010, before increasing to 36,996 in 2011. As a per cent of all histology tests, this was similar 
for all years from 2004 to 2011, decreasing only very slightly over this time (Table 4.6).  
In 2011, 39.2% of squamous abnormalities were low-grade (HS02), with high-grade 
abnormalities (HS03)—incorporating CIN II and CIN III—the most frequent at 59.3%. 
Squamous cell carcinoma (HS04) was rarer at just 1.5% of all squamous abnormalities in 2011 
for women aged 20–69 (Table 4.6). 
Low-grade abnormalities have decreased substantially from 26.4 per 100 histology tests in 
2004 to 19.2 in 2011. This is likely a direct effect of the introduction of the current NHMRC 
Guidelines in 2006, which recommend repeat cytology rather than biopsy for a low-grade 
squamous intraepithelial lesion detected by cytology, a follow-on effect of which is likely to 
be a decrease in the proportion of histology tests detecting a low-grade abnormality. 
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Table 4.6: Squamous abnormalities detected by histology in women aged 20–69, by squamous 
category, 2004 to 2011 
Squamous category 
Year   
2004 2005 2006 2007 2008 2009 2010 2011 
HS02 Low-grade squamous abnormality   
Number 20,140 19,472 17,937 16,540 15,292 14,538 13,964   14,504 
Per 100 histology tests 26.4 25.8 24.7 23.1 21.0 20.0 19.3   19.2 
Per cent of squamous abnormalities 50.6 49.0 47.3 44.1 41.1 39.9 38.9 39.2 
HS03 High-grade squamous abnormality   
Number 19,176 19,705 19,508 20,437 21,411 21,379 21,389 21,941 
Per 100 histology tests 25.1 26.1 26.9 28.5 29.4 29.5 29.6 29.0 
Per cent of squamous abnormalities 48.2 49.6 51.5 54.5 57.5 58.7 59.6 59.3 
HS04 Squamous cell carcinoma   
Number 470 558 466 516 530 474 528 551 
Per 100 histology tests 0.6 0.7 0.6 0.7 0.7 0.7 0.7 0.7 
Per cent of squamous abnormalities 1.2 1.4 1.2 1.4 1.4 1.3 1.5 1.5 
All squamous abnormalities   
Number 39,786 39,735 37,911 37,493 37,233 36,391 35,881 36,996 
Crude rate 52.2 52.7 52.3 52.4 51.1 50.3 49.7 48.9 
AS rate 44.3 44.5 44.5 44.7 43.5 43.0 43.0 43.1 
95% CI 
43.8– 
44.8 
44.0– 
45.0 
44.0– 
45.0 
44.2– 
45.2 
43.1– 
44.0 
42.5–
43.4 
42.5– 
43.5 
42.6– 
43.5 
Notes 
1. HS03 High-grade squamous abnormality combines cervical intraepithelial neoplasia (CIN) not otherwise specified (NOS), CIN II and CIN III. 
2. Crude rate is the number of each squamous abnormality or all squamous abnormalities combined detected by histology as a proportion of 
the total number of histology tests; age-standardised (AS) rate is the number of all squamous abnormalities combined detected by histology 
as a proportion of the total number of histology tests age-standardised to the Australian population at 30 June 2001. 
Source: AIHW analysis of state and territory cervical cytology register data.  
High-grade abnormalities have increased concurrently with the decrease in low-grade 
abnormalities, from 25.1 to 29.0 per 100 histology tests, although this may be simply an 
artefact since, with fewer low-grade abnormalities, high-grade abnormalities will necessarily 
comprise an increasing proportion of all histology tests performed. 
Squamous cell carcinoma decreased in number, but not as a proportion of histology tests or 
squamous abnormalities between 2010 and 2011 (Table 4.6). 
The literature advocates that the distinction between the high-grade squamous abnormalities  
CIN II and CIN III is important to preserve. This is currently not possible nationally, as some 
states and territories receive data in a format that does not allow them to distinguish 
between the histology results of CIN II and CIN III. Therefore, CIN II and CIN III have been 
analysed separately using data only from those states and territories where these 
abnormalities could be distinguished (Table 4.7). 
In 2011, CIN II comprised 25.5% and CIN III 32.4% of the 16,329 squamous abnormalities in 
these states and territories, which equates to 11.2 and 14.2 per 100 histology tests 
respectively, for women aged 20–69. 
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Table 4.7: CIN II and CIN III in women aged 20–69, 2004 to 2011 
Squamous category 
Year  
2004 2005 2006 2007 2008 2009 2010 2011 
HS03.2 CIN II   
Number 3,818 3,904 3,909 4,104 4,377 4,574 4,338 4,157 
Per 100 histology tests 10.5 11.0 11.5 12.1 12.5 12.7 12.2 11.2 
Per cent of squamous 
abnormalities 22.6 23.8 24.7 25.5 25.9 26.7 26.6 25.5 
HS03.3 CIN III   
Number 4,236 4,314 4,350 4,753 5,340 5,373 5,127 5,293 
Per 100 histology tests 11.6 12.2 12.8 14.0 15.3 14.9 14.4 14.2 
Per cent of squamous 
abnormalities 25.1 26.3 27.5 29.6 31.6 31.3 31.5 32.4 
Source: AIHW analysis of state and territory cervical cytology register data.  
Between 2010 and 2011, there was a small decrease in the detection of CIN II from 4,338 to 
4,157 or 12.2 to 11.2 per 100 histology tests (from 10.1 to 9.6 age-standardised), with this 
decrease mostly seen in women aged 25–29 and 30–34. While there was a small increase in 
the detection of CIN III from 5,127 in 2010 to 5,293 in 2011, these represented a similar 
number per 100 histology tests (both crude and age-standardised). Despite this, there was a 
clear decrease in CIN III for women under 20 from 14.6 to 9.9 per 100 histology tests, and a 
smaller decrease for women aged 20–24 from 19.8 to 18.2. 
For all years, CIN III was more frequent than CIN II. 
 
  
A 
 
B  
 
Source: AIHW analysis of state and territory cervical cytology register data; data for figures are available in Table A1. 
Figure 4.5: CIN II (A) and CIN III (B) detected by histology by age, 2011 
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Comparing the age distribution of CIN II and CIN III reveals that these abnormalities share 
similar trends, the main difference being that CIN II is most frequent in women under 25, 
while CIN III peaks in women aged 25–29 and is far less common in women under 25 
(Figure 4.5).  
Consistent with this, CIN III was the more frequent high-grade abnormality for all age 
groups, apart from women under 20 and women aged 20–24, for which CIN II was more 
common (Figure 4.5). 
Squamous abnormalities by age 
Similar to squamous abnormalities detected by cytology, low-grade and high-grade 
squamous abnormalities detected by histology all peaked in younger women before 
decreasing with increasing age.  
However, low-grade abnormalities peaked in women under 20, thereafter decreasing 
steadily with increasing age in an almost straight line, whereas high-grade abnormalities 
peaked in women aged 25–59, remain high in the younger age groups (including under 20) 
up to the age of 30–34, and thereafter fall away rapidly (although as noted above, CIN II and 
CIN III differ in the age at which they peak, so overall high-grade abnormalities will be a 
combination of these two) (Figure 4.6).  
Although having far fewer occurrences, squamous cell carcinoma, rare in younger women, 
increased with age with a small peak from age 55–59 onwards (Figure 4.6). 
 
 
 
 
Note: HS02 = low-grade squamous abnormality; HS03 = high-grade squamous abnormality; HS04 = squamous cell carcinoma. 
Source: AIHW analysis of state and territory cervical cytology register data. 
Figure 4.6: Squamous abnormalities detected by histology in women by age, 2011 
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Endocervical abnormalities detected by histology in 2011 
In 2011, of the 38,122 abnormalities detected by histology in women aged 20–69, 1,126 were 
endocervical in origin—62 atypia, 735 high-grade, 283 adenocarcinoma, 33 adenosquamous 
carcinoma, and 13 other carcinoma of the cervix. This was 1.5 endocervical abnormalities per 
100 histology tests. 
An endocervical abnormality is defined as an endocervical result of HE02 Endocervical 
atypia, HE03.1 Endocervical dysplasia, HE03.2 Adenocarcinoma in situ, HE04.1 
Microinvasive adenocarcinoma, HE04.2 Invasive adenocarcinoma, HE04.3 Adenosquamous 
carcinoma* or HE04.4 Carcinoma of the cervix (other)* regardless of any squamous result. 
*Note that HE04.3 Adenosquamous carcinoma and HE04.4 Carcinoma of the cervix (other) 
are included as endocervical abnormalities for data reporting purposes, but that the former is 
not solely of endocervical origin, and the latter category comprises rarer carcinomas of other 
epithelial origin. 
Endocervical abnormality trends 
The overall number of endocervical abnormalities increased from 867 in 2004 to 1,126 in 
2011, with a concurrent increase in endocervical abnormalities per 100 histology tests from 
1.23% to 1.48% (Table 4.8).  
In 2011, 5.5% of endocervical abnormalities were atypia (HE02), 65.3% were high-grade 
abnormalities (HE03)—incorporating endocervical dysplasia and adenocarcinoma in situ, 
and 25.1% were adenocarcinoma. Adenosquamous carcinoma and other carcinoma of the 
cervix comprised 2.9% and 1.2% of endocervical abnormalities in 2011, respectively  
(Table 4.8).  
Endocervical atypia allows atypical endocervical cells that fall short of a high-grade 
abnormality to be captured (since a low-grade category for endocervical abnormalities 
detected by histology is not valid). However, this category is rarely used. Compared with 
2004 when there were 0.13 per 100 histology tests, the proportion of histology tests with the 
abnormality endocervical atypia in 2011 was 0.08 (Table 4.8). 
In contrast, high-grade endocervical abnormalities increased from 0.66 per 100 histology tests 
in 2004 to 0.97 in 2011. Adenocarcinoma, adenosquamous carcinoma, and other carcinoma of 
the cervix all had similar detection levels between 2004 and 2011 for women aged 20–69. 
Endocervical abnormalities by age 
Endocervical atypia, adenosquamous carcinoma and other carcinoma of the cervix are all 
very rare and contribute little to the overall trend in abnormalities.  
High-grade endocervical abnormalities (endocervical dysplasia and adenocarcinoma in situ 
combined) peaked in women aged 30–34, thereafter decreasing with increasing age until a 
second, lower peak in older women (Figure 4.7).  
Adenocarcinoma increased with age to a small peak in women aged 40–44, thereafter 
increasing with increasing age (Figure 4.7). 
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Table 4.8: Endocervical abnormalities detected by histology in women aged 20–69, by endocervical 
category, 2004 to 2011 
Endocervical category 
Year   
2004 2005 2006 2007 2008 2009 2010 2011 
HE02 Endocervical atypia   
Number 99 104 66 62 55 38 54 62 
Per cent of cytology tests 0.13 0.14 0.09 0.09 0.08 0.05 0.07 0.08 
Per cent of endocervical 
abnormalities 11.4 12.0 7.2 6.3 5.0 3.8 5.1 5.5 
HE03 High-grade endocervical abnormality   
Number 505 495 555 630 691 652 715 735 
Per cent of cytology tests 0.66 0.66 0.77 0.88 0.95 0.90 0.99 0.97 
Per cent of endocervical 
abnormalities 58.2 57.0 60.7 64.1 63.3 65.9 67.5 65.3 
HE04.1 & 4.2 Adenocarcinoma         
Number 229 235 257 245 311 263 248 283 
Per cent of cytology tests 0.30 0.31 0.35 0.34 0.43 0.36 0.34 0.37 
Per cent of endocervical 
abnormalities 26.4 27.1 28.1 24.9 28.5 26.6 23.4 25.1 
HE04.3 Adenosquamous carcinoma    
Number 22 19 15 25 21 20 21 33 
Per cent of cytology tests 0.03 0.03 0.02 0.03 0.03 0.03 0.03 0.04 
Per cent of endocervical 
abnormalities 2.5 2.2 1.6 2.5 1.9 2.0 2.0 2.9 
HE04.4 Carcinoma of the cervix (other)   
Number 12 15 21 21 14 16 21 13 
Per cent of cytology tests 0.02 0.02 0.03 0.03 0.02 0.02 0.03 0.02 
Per cent of endocervical 
abnormalities 1.4 1.7 2.3 2.1 1.3 1.6 2.0 1.2 
All endocervical abnormalities   
Number 867 868 914 983 1,092 989 1,059 1,126 
Crude rate 1.14 1.15 1.26 1.37 1.50 1.37 1.47 1.49 
AS rate 1.23 1.26 1.35 1.46 1.59 1.41 1.50 1.48 
95% CI 
1.14–
1.32 
1.17–
1.36 
1.26–
1.46 
1.36–
1.56 
1.49–
1.70 
1.32–
1.51 
1.40–
1.60 
1.39–
1.57 
Notes 
1. HE03 High-grade endocervical abnormality combines endocervical dysplasia and adenocarcinoma in situ.  
2. Crude rate is the number of each endocervical abnormality or of all endocervical abnormalities combined detected by histology as a 
proportion of the total number of histology tests; age-standardised (AS) rate is the number of all endocervical abnormalities combined 
detected by histology as a proportion of the total number of histology tests age-standardised to the Australian population at 30 June 2001. 
Source: AIHW analysis of state and territory cervical cytology register data.  
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Note: HE02 = endocervical atypia; HE03 = high-grade endocervical abnormality; HE04 = Adenocarcinoma (microinvasive and invasive combined) 
HE04.3 = Adenosquamous carcinoma; HE04.4 = carcinoma of the cervix (other). 
Source: AIHW analysis of state and territory cervical cytology register data. 
Figure 4.7: Endocervical abnormalities detected by histology in women by age, 2011 
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Indicator 5 Cytology-histology correlation 
What you need to know about the cytology-histology correlation  
Definition: The correlation between a squamous or endocervical cytology prediction and the 
most serious squamous or endocervical histology finding, where this histology occurs in the 
6-month period following the cytology. 
Rationale: Some cytology results will be followed by histology. Where this histology occurs 
within 6 months of cytology, a correlation between the cytology and histology result is 
presented as a measure of the accuracy of cytological predictions.  
Guide to interpretation: Correlation data are restricted to cytology tests for which a 
histology test is known to have occurred within 6 months. These do not include cytology 
tests not followed by histology, for which we cannot know the true disease state. 
Histology after a low-grade or a negative cytology test is a relatively rare occurrence, and is 
unlikely to be representative of negative and low-grade cytology in general. 
Colposcopy data are incomplete and therefore not reported, which means that some 
diagnostic information is missing from the correlation. 
Interpretation of data should take into consideration the counts provided. 
The most recent cytology-histology correlation data are for cytology tests performed in 2010. 
This small lag in data availability is because sufficient time needs to have passed to ascertain 
if histology was performed in the 6-month period after cytology tests performed in a 
particular calendar year. 
What the data tell us about the cytology histology correlation 
 Trends 
The positive predictive values of high-grade cytology performed in 2010 were similar to 
those for high-grade cytology performed in 2009—69.8% compared with 70.0% for  
high-grade squamous cytology, and 73.5% compared with 71.2% for high-grade 
endocervical cytology. 
 
Correlation between cytology and histology in 2010 
Of the cytology tests performed in 2010 that predicted a definite high-grade squamous 
intraepithelial lesion, 77.8% were confirmed to be high-grade disease on histology. 
The positive predictive value of all high-grade squamous cytology was 69.8% 
Of the cytology tests performed in 2010 that predicted adenocarcinoma in situ, 70.7% were 
confirmed to be high-grade disease on histology. 
The positive predictive value of all high-grade endocervical cytology was 73.5%.  
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More information about the cytology-histology correlation  
Where cytology is followed by histology (either to confirm the presence or absence of disease 
as predicted by the cytology sample, or for other clinical reasons such as to investigate 
symptoms even in the absence of predicted disease), correlation between the cytology 
prediction and the histology finding allows the accuracy of cytological predictions to be 
assessed, to allow a better understanding of the characteristics of the NCSP screening test.  
Follow-up of cytology tests should be according to the NHMRC Screening to prevent cervical 
cancer: guidelines for the management of asymptomatic women with screen detected abnormalities 
(NHMRC 2005), which means that most histology will occur after a cytology result of high-
grade or cancer. There will be exceptions, however, and these Guidelines do not cover 
management of symptomatic women. 
Note that a complete assessment of cytology would require all cytology results (including 
negative) to be followed up by histology, but this is neither feasible nor desirable. Rather, 
this assessment is restricted to cytology and histology results available on cervical cytology 
registers, and is intended to provide key measures that can be monitored annually to inform 
the NCSP of any early indications of alterations to the predictive ability of cervical cytology. 
Cautions 
Under current management guidelines, negative and low-grade cytology is not routinely 
followed up by histology (unless the low-grade abnormality persists). Thus, histology after a 
low-grade or a negative cytology test result is a relatively rare occurrence, and it is likely that 
these are a unique subset of cytology tests and are not representative of negative and low-
grade cytology as a rule, which means that these findings should not be extrapolated to low-
grade and negative cytology in general. 
In terms of completeness, a further consideration is the absence of colposcopy data. 
Colposcopy is an examination involving a special microscope that magnifies the cervix to 
allow the visualisation of an abnormality. A biopsy will often be taken at the time of 
colposcopy, which allows histological assessment. However, histology will not always result 
from a colposcopy—for instance if the colposcopy confirms a negative result, or if the 
woman is pregnant, a biopsy may not be performed. Colposcopy data are not systematically 
sent to cervical cytology registers in the same way as histology data, which means that some 
diagnostic information, particularly that for negative disease state, is missing from the 
correlation.  
Accuracy of the histology finding is also affected by the sample analysed; a biopsy may 
sample the wrong part of the cervix which may lead to an incorrect histology result, whereas 
a sample that allows the entire cervix to be assessed (for instance a hysterectomy that 
removes the entire cervix) is more likely to give an accurate result.  
Finally, it should be noted that the results presented here are based on a single cytology test 
in isolation, and are not placed within the context of cervical screening. Cervical cytology, 
like other screening tests, is not intended to be diagnostic, but aims to identify people who 
are more likely to have a cervical abnormality or cervical cancer, and therefore require 
further investigation from diagnostic tests. Further, the NCSP is an organised program of 
regular screening tests, and while a single cervical cytology test is not able to predict 
presence or absence of disease with absolute accuracy, repeated cervical cytology tests over 
time generate a far greater degree of accuracy.  
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Detailed analyses 
Proportion of squamous abnormalities followed by histology 
To provide context for the squamous correlation results, the proportion of squamous 
abnormalities detected in 2010 for which a squamous histology result occurred within 6 
months is shown in Table 5.1. 
The correlation data included in the analyses that follow are restricted to cytology tests for 
which a histology test is known to have occurred within 6 months. These do not include 
cytology tests not followed by histology, for which we cannot know the true disease state. 
Table 5.1: Number of squamous abnormalities detected in 2010, and proportion followed by 
squamous histology within 6 months, for women aged 20–69 
Cytology prediction Number detected 
Number followed  
by squamous histology 
Proportion followed  
by squamous histology (%) 
S2 Possible low-grade 43,485 7,071 16.3 
S3 Low-grade 34,311 7,924 23.1 
S4 Possible high-grade 12,088 8,782 72.7 
S5 High-grade 15,317 13,279 86.7 
S6 High-grade plus 313 276 88.2 
S7 Squamous cell carcinoma 178 155 87.1 
Source: AIHW analysis of state and territory cervical cytology register data.  
Correlation between squamous cytology and squamous histology 
Table 5.2 shows the correlation that exists between a squamous cytology prediction in 2010 
and the squamous histology finding within 6 months for women aged 20–69. 
Table 5.2: Correlation between squamous cytology and the most serious squamous histology 
within 6 months in women aged 20–69, cytology tests performed in 2010 
  Histology finding  
Cytology prediction 
HS02  
Low-grade 
HS03  
High-grade 
HS04  
Squamous cell  
carcinoma 
S1 Negative 3,241 (18.6%) 996 (5.7%) 36 (0.2%) 
S2 Possible low-grade 3,026 (42.8%) 1,340 (19.0%) 4 (0.1%) 
S3 Low-grade 4,059 (51.2%) 1,789 (22.6%) 1 (0.0%) 
S4 Possible high-grade 2,022 (23.0%) 4,755 (54.1%) 55 (0.6%) 
S5 High-grade 1,704 (12.8%) 10,331 (77.8%) 186 (1.4%) 
S6 High-grade plus 14 (5.1%) 185 (67.0%) 70 (25.4%) 
S7 Squamous cell carcinoma 2 (1.3%) 37 (23.9%) 111 (71.6%) 
Notes 
1. Numbers and per cent of each squamous cytology result category shown. 
2. For national consistency, the histology results of cervical intraepithelial (CIN) not otherwise specified (NOS), CIN II and CIN III are grouped 
together to form a broad high-grade abnormality category, and those of microinvasive and invasive squamous cell carcinoma are grouped 
together to form a broad squamous cell carcinoma category.  
Source: AIHW analysis of state and territory cervical cytology register data.  
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Low-grade squamous cytology 
Under the current management guidelines, low-grade cytology is not routinely followed up 
by histology unless the abnormality persists—indeed only 16% of possible low-grade and 
23% low-grade squamous abnormalities were followed by histology (Table 5.1). This means 
the following results should not be extrapolated to all low-grade cytology, since there may 
have been clinical reasons for performing histology within 6 months of a low-grade 
squamous cytology, which could bias these results towards a more serious abnormality than 
would be present in the majority of women with a cytology prediction of a low-grade 
abnormality.  
Of all cytology tests performed in 2010 that were followed by histology within  
6 months, 14,995 predicted a low-grade squamous abnormality—7,071 possible low-grade 
(S2) and 7,924 low-grade (S3) (Table 5.1). 
Of the 7,071 predicted possible low-grade squamous abnormalities (S2), 3,026 (42.8%) were 
found to be a low-grade squamous abnormality on histology; of the 7,924 predicted low-
grade squamous abnormalities (S3), 4,059 (51.2%) were found to be a low-grade squamous 
abnormality on histology (Table 5.2). 
Overall, 47.2% of low-grade squamous abnormalities predicted by cytology were found to be 
a true low-grade squamous abnormality on histology (the positive predictive value of low-
grade squamous cytology). Further, in these data squamous cytology predicted 50.4% of the 
true cases of low-grade squamous disease identified. 
Of particular note, almost no predictions of possible low-grade or low-grade cytology were 
found to be cancer on histology (Table 5.2). 
High-grade squamous cytology 
Of all cytology tests performed in 2010 that were followed by histology within  
6 months, 22,337 predicted a high-grade squamous abnormality—8,782 possible high-grade 
(S4), 13,279 high-grade (S5) and 276 high-grade with possible microinvasion/invasion (S6) 
(Table 5.1). 
Of the 8,782 predicted possible high-grade squamous abnormalities (S4), 4,755 (54.1%) were 
found to be a high-grade squamous abnormality on histology; of the 13,279 predicted high-
grade squamous abnormalities (S5), 10,331 (77.8%) were found to be a high-grade squamous 
abnormality on histology; and of the 276 predicted high-grade squamous abnormalities with 
possible microinvasion/invasion (S6), 185 (67.0%) were found to be a high-grade squamous 
abnormality on histology (Table 5.2). 
While the category high-grade squamous abnormality with possible 
microinvasion/invasion (S6) is classified as a high-grade squamous abnormality 
throughout this report, for the National Pathology Accreditation Advisory Council 
(NPAAC) performance measure calculations, this category is excluded from high-grades—a 
reflection that the majority of these are expected to be invasive malignancies, but are not 
coded definitively. Correlation data were considered when deciding the appropriate 
reporting grade for this category; with 67.0% found to be high-grade, and 25.4% found to be 
squamous cell carcinoma on histology, it was considered appropriate to continue to classify 
this category as high-grade in this report. Moving this category from high-grade to 
squamous cell carcinoma does not affect the overall positive predictive value of high-grade 
squamous cell abnormalities. 
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Overall, 69.8% of high-grade squamous abnormalities predicted by cytology were found to 
be a true high-grade squamous abnormality or squamous cell carcinoma on histology (the 
positive predictive value of high-grade squamous cytology—see Table 5.3), while 68.4% were 
found to be a true high-grade squamous abnormality. Further, in these data squamous 
cytology predicted 78.6% of the true cases of high-grade squamous disease identified.  
Squamous cell carcinoma cytology 
Of all cytology tests performed in 2010 that were followed by histology within 6 months, 155 
predicted squamous cell carcinoma (S7) (Table 5.1). Of these predicted abnormalities, 111 
(71.6%) were found to be squamous cell carcinoma on histology (Table 5.2). 
There were 352 abnormalities graded as squamous cell carcinoma on histology within 6 
months of cytology predictions other than squamous cell carcinoma, with 311 after high-
grade squamous abnormalities, 5 after low-grade squamous abnormalities, and 36 after 
negative squamous cytology (Table 5.2).  
Table 5.3: Positive predictive value (PPV) of high-grade squamous cytological abnormalities in 
women aged 20–69, most serious histology within 6 months of cytology performed in 2008, 2009 
and 2010 
 Cytology prediction 
 Possible high-grade S4 High-grade S5 High-grade plus S6 High-grade 
2008 53.8% (4,415/8,212) 78.4% (11,111/14,165) 92.2% (237/257)  69.6% (15,763/22,634) 
2009 55.2% (4,748/8,607) 78.9% (10,935/13,859) 90.5% (228/252) 70.0% (15,911/22,718) 
2010 54.8% (4,810/8,782) 79.2% (10,517/13,279) 92.4% (255/276) 69.8% (15,582/22,337)  
Note: The positive predictive value is calculated as the proportion of squamous cytology results of possible or definite high-grade that were 
confirmed on histology to be a high-grade squamous abnormality or squamous cell carcinoma.  
Source: AIHW analysis of state and territory cervical cytology register data.  
Proportion of endocervical abnormalities followed by histology 
To provide context for the endocervical correlation results, the proportion of endocervical 
abnormalities detected in 2010 for which an endocervical histology result occurred within 6 
months is shown in Table 5.4. 
The correlation data included in the analyses that follow are restricted to cytology tests for 
which a histology test is known to have occurred within 6 months. These do not include 
cytology tests not followed by histology, for which we cannot know the true disease state. 
Table 5.4: Number of endocervical abnormalities detected in 2010, and proportion followed by 
endocervical histology within 6 months, for women aged 20–69 
Cytology prediction 
Number of  
cytology tests 
Number followed  
by histology 
Proportion followed  
by histology (%) 
E2 Atypical endocervical cells of uncertain significance 714 219 30.7 
E3 Possible high-grade 435 213 49.0 
E4 Adenocarcinoma in situ 305 239 78.4 
E5 Adenocarcinoma in situ plus 33 23 69.7 
E6 Adenocarcinoma 82 43 52.4 
Source: AIHW analysis of state and territory cervical cytology register data.  
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Correlation between endocervical cytology and endocervical histology 
The correlation that exists between an endocervical cytology prediction in 2010 and the 
endocervical histology finding within 6 months for women aged 20–69 is shown in Table 5.5. 
This correlation may be affected by the recognised difficulties in sampling and interpreting 
endocervical cytology samples. 
The majority of endocervical cytology that is followed by histology within  
6 months is negative—a function of most abnormalities being squamous in origin with a 
concurrent negative endocervical component (since all cytology tests are allocated an ‘S’ and 
‘E’ code). This means that in the majority of cases the histology will be investigating a 
cytology prediction of a squamous abnormality, and not the negative endocervical cytology. 
Also important to realise when interpreting the correlation between endocervical cytology 
and histology is that abnormalities preceding adenocarcinoma are less well understood than 
are the abnormalities preceding squamous cell carcinoma, and interpretation of endocervical 
cells is more difficult (as can be the adequate sampling of these cells), all of which affect the 
correlation between endocervical cytology and endocervical histology. 
Table 5.5: Correlation between endocervical cytology and the most serious endocervical histology 
within 6 months in women aged 20–69, cytology tests performed in 2010 
  Histology finding  
Cytology prediction 
HE02  
Endocervical atypia 
HE03  
High-grade 
HE04.1&4.2  
Adenocarcinoma 
E1 Negative 50 (0.2%) 273 (1.2%) 94 (0.4%) 
E2 Atypical endocervical cells of uncertain significance 3 (1.4%) 49 (22.4%) 12 (5.5%) 
E3 Possible high-grade 2 (0.9%) 99 (46.5%) 21 (9.9%) 
E4 Adenocarcinoma in situ 2 (0.8%) 169 (70.7%) 43 (18.0%) 
E5 Adenocarcinoma in situ plus 0 (0.0%) 8 (34.8%) 9 (39.1%) 
E6 Adenocarcinoma 0 (0.0%) 9 (20.9%) 20 (46.5%) 
Notes 
1. Numbers and per cent of each endocervical cytology result category shown. 
2. For national consistency, the histology results of endocervical dysplasia and adenocarcinoma in situ are grouped together to form a broad 
high-grade abnormality category, and microinvasive and invasive adenocarcinoma are grouped to form a broad adenocarcinoma category.  
3. The histology results of adenosquamous carcinoma and carcinoma of the cervix (other) are excluded, since these are neither solely 
squamous or endocervical in origin, and thus would not necessarily be expected to correlate with cytology results of either cell type.  
Source: AIHW analysis of state and territory cervical cytology register data.  
Atypical endocervical cells of uncertain significance 
The cytology category, ‘atypical endocervical cells of uncertain significance’, is classified as a 
low-grade cytology abnormality, but it is not appropriate to correlate this with endocervical 
atypia (the histology equivalent of a low-grade endocervical abnormality) since this cytology 
prediction is not used to indicate the predicted presence of a low-grade endocervical 
abnormality (which is not a valid histology category), but rather is used to indicate that 
abnormal endocervical cells were identified in the sample but that the significance of these is 
uncertain (meaning that these could be indicative of a serious abnormality, or could be 
associated with a benign change such as inflammation). 
There were 714 cytology tests performed in 2010 that identified abnormal endocervical cells 
where the pathologist was uncertain of their significance; 219 (30.7%) of these were followed 
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by histology (Table 5.4). This means that the majority of cytology tests in which atypical 
endocervical cells of uncertain significance were identified, were not followed by histology. 
Of the 219 that were followed by histology within 6 months, 49 (22.4%) were found to be a 
high-grade endocervical abnormality on histology, and 12 (5.5%) were found to be 
adenocarcinoma on histology, with the majority (70.8%) of atypical endocervical cells of 
uncertain significance identified in the absence of endocervical disease (Table 5.5). 
High-grade endocervical cytology 
Of all cytology tests performed in 2010 that were followed by histology within  
6 months, 475 predicted a high-grade endocervical abnormality—213 possible high-grade 
(E3), 239 adenocarcinoma in situ (E4) and 23 adenocarcinoma in situ with possible 
microinvasion/invasion (E5) (Table 5.4). 
Of the 213 predicted possible high-grade endocervical abnormalities (E3), 99 (46.5%) were 
found to be a high-grade endocervical abnormality on histology. Of the 239 predicted 
adenocarcinoma in situ (E4), 169 (70.7%) were found to be a high-grade endocervical 
abnormality on histology. Of the 23 predicted adenocarcinoma in situ with possible 
microinvasion/invasion (E5), 8 (34.8%) were found to be a high-grade endocervical 
abnormality on histology (Table 5.5). 
The category adenocarcinoma in situ with possible microinvasion/invasion (E5) experiences 
similar disparity in classification to its squamous counterpart, however the very small 
numbers (8 found to be high-grade and 9 found to be adenocarcinoma) make qualification 
difficult, and thus this category will also continue to be classified as high-grade in this 
report. Moving this category from high-grade to adenocarcinoma does not have any great 
effect on the overall positive predictive values. 
Overall, 73.5% of high-grade endocervical abnormalities predicted by cytology were found 
to be a true high-grade endocervical abnormality or adenocarcinoma on histology (the 
positive predictive value of a high-grade endocervical cytology result—see Table 5.6), while 
58.1% were found to be a true high-grade endocervical abnormality. Further, in these data 
endocervical cytology predicted 45.5% of the true cases of high-grade endocervical disease 
identified. 
Table 5.6: Positive predictive value (PPV) of high-grade endocervical cytological abnormalities in 
women aged 20–69, most serious histology within 6 months of cytology performed in 2008, 2009 
and 2010 
 Cytology prediction 
 Possible high-grade  
E3 
Adenocarcinoma in situ 
E4 
Adenocarcinoma in situ plus 
E5 High-grade 
2008 49.3% (109/221) 92.2% (202/219) 96.0% (24/25) 72.0% (335/465) 
2009 54.1% (139/257) 89.2% (214/240) 78.6% (11/14) 71.2% (364/511) 
2010 56.3% (120/213) 88.7% (212/239) 73.9% (17/23) 73.5% (349/475) 
Note: The positive predictive value is calculated as the proportion of endocervical cytology results of possible or definite high-grade that were 
confirmed on histology to be a high-grade endocervical abnormality or adenocarcinoma (these are prone to variability due to small numbers).  
Source: AIHW analysis of state and territory cervical cytology register data.  
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Adenocarcinoma cytology 
Of all cytology tests performed in 2010 that were followed by histology within  
6 months, 43 predicted adenocarcinoma (E6) (Table 5.4). Of these predicted abnormalities, 20 
(46.5%) were found to be adenocarcinoma on histology (Table 5.5). 
There were 179 abnormalities graded as adenocarcinoma on histology within 6 months of 
cytology predictions other than adenocarcinoma, with 73 after high-grade endocervical 
cytology and 94 after negative endocervical cytology (Table 5.5). 
Additional analyses 
Cytology predictions preceding adenosquamous and other carcinomas of the cervix 
Adenosquamous and other carcinomas of the cervix were analysed separately, since—even 
though they are categorised as endocervical carcinomas for coding purposes—these do not 
fall into the category of either squamous or endocervical carcinoma.  
The cytology prediction preceding the histology finding of adenosquamous carcinoma or 
other carcinoma of the cervix is shown in Table 5.7. 
Table 5.7: Cytology prediction preceding a histology finding of adenosquamous carcinoma or other 
carcinoma of the cervix in women aged 20–69, cytology performed in 2010 
Cytology prediction  Adenosquamous carcinoma Carcinoma of the cervix (other) 
S1 Negative 4 15 
S2 Possible low-grade 0 2 
S3 Low-grade 0 0 
S4 Possible high-grade 2 2 
S5 High-grade 6 0 
S6 High-grade with possible invasion 4 1 
S7 Squamous cell carcinoma 3 2 
E1 Negative 9 16 
E2 Atypical endocervical cells of uncertain significance 1 0 
E3 Possible high-grade 0 0 
E4 Adenocarcinoma in situ 4 0 
E5 Adenocarcinoma with possible invasion 0 0 
E6 Adenocarcinoma 2 1 
Source: AIHW analysis of state and territory cervical cytology register data.  
Cytology predictions preceding CIN II versus CIN III 
The correlation between squamous cytology and squamous histology performed within  
6 months has been replicated in Table 5.8, including only data from states and territories that 
are able to distinguish between CIN II and CIN III. 
In these data, predicted possible low-grade (S2) or low-grade squamous abnormalities (S3), 
while both still more likely to be a low-grade squamous abnormality on histology, were 
more likely to be CIN II than CIN III (Table 5.8). 
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Predicted possible high-grade squamous abnormalities (S4) were equally likely to be low-
grade squamous abnormality or CIN II on histology (21.5% and 22.7%, respectively), with a 
slightly higher 29.3% of these found to be CIN III on histology. 
52.9% of predicted high-grade squamous abnormalities (S5) were found to be CIN III on 
histology, and 59.5% of predicted high-grade squamous abnormalities with possible 
microinvasion/invasion (S6) were found to be CIN III on histology. 
89.7% of predicted squamous cell carcinoma (S7) was found on histology to be either CIN III 
or squamous cell carcinoma (Table 5.8). 
Table 5.8: Correlation between squamous cytology and the most serious squamous histology 
within 6 months in women aged 20–69 showing CIN II and CIN III, cytology tests performed in 
2010 
 Histology finding 
Cytology prediction 
HS02  
Low-grade 
HS03.2  
CIN II 
HS03.3  
CIN III 
HS04  
Squamous cell  
carcinoma 
S1 Negative 1,422 (19.7%) 218 (3.0%) 188 (2.6%) 12 (0.2%) 
S2 Possible low-grade 1,708 (40.5%) 395 (9.4%) 286 (6.8%) 2 (0.0%) 
S3 Low-grade 2,082 (50.3%) 574 (13.9%) 298 (7.2%) 1 (0.0%) 
S4 Possible high-grade 1,024 (21.5%) 1,077 (22.7%) 1,393 (29.3%) 34 (0.7%) 
S5 High-grade 869 (12.3%) 1,697 (24.0%) 3,749 (52.9%) 99 (1.4%) 
S6 High-grade plus 5 (4.0%) 1 (0.8%) 75 (59.5%) 43 (34.1%) 
S7 Squamous cell carcinoma 1 (1.5%) 2 (2.9%) 9 (13.2%) 52 (76.5%) 
Notes 
1. Numbers and per cent of each squamous cytology result category shown. 
2. States and territories unable to distinguish between CIN II and CIN III were excluded from all data and calculations in this table. 
3. The high-grade category CIN NOS has been excluded from this table, but is a rare histology finding. 
Source: AIHW analysis of state and territory cervical cytology register data.  
NPAAC performance indicators 
The National Pathology Accreditation Advisory Council (NPAAC) Performance measures for 
Australian laboratories reporting cervical cytology (NPAAC 2006) includes recommended 
standards for the proportion of cytology specimens reported as definite high-grade (3a) and 
possible high-grade (3b) that are confirmed on histology within 6 months as high-grade 
abnormalities. 
Note that ‘S6 High-grade squamous intraepithelial lesion with possible 
microinvasion/invasion’ and ‘E5 Adenocarcinoma in situ with possible 
microinvasion/invasion’ have been included as definite high-grade intraepithelial 
abnormalities in the calculations for NPAAC Performance Measure 3a. Positive predictive 
values for ‘S5 High-grade squamous intraepithelial abnormality’ (Table 5.3) and ‘E4 
Adenocarcinoma in situ’ (Table 5.6) can be substituted for the below calculated values if it is 
desirable to exclude these from Performance measure 3a.   
Calculation of these performance measures using cytology-histology correlation data 
revealed that the proportion of definite high-grade squamous abnormalities on cytology 
confirmed to be high-grade or cancer on histology was 79.5% and the proportion of definite 
high-grade endocervical abnormalities on cytology confirmed to be high-grade or cancer on 
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histology was 87.4%, while the proportion of possible high-grade squamous abnormalities 
on cytology confirmed to be high-grade on histology was 54.8%, and the proportion of 
possible high-grade endocervical abnormalities on cytology confirmed to be high-grade on 
histology was 56.3%. 
Even though these were reported separately for squamous and endocervical abnormalities, 
which differs from the intended use of these performance measures, all of these would fall 
within the respective standards set for these measures (Box 5.1). 
 
Box 5.1: National Pathology Accreditation Advisory Council (NPAAC) Performance 
measures for Australian laboratories reporting cervical cytology 
Performance measure 3a 
Proportion of cytology specimens reported as a definite high-grade intraepithelial 
abnormality where cervical histology, taken within 6 months, confirms the abnormality as 
high-grade intraepithelial abnormality or malignancy. 
Recommended standard 
Not less than 65% of cytology specimens with a definite cytological prediction of a high-
grade intraepithelial abnormality are confirmed on cervical histology, which is performed 
within 6 months, as having a high-grade intraepithelial abnormality or malignancy. 
Calculated values for 2010 
Squamous cytology and histology  Endocervical cytology and histology 
10,772/13,555 = 79.5%   229/262 = 87.4% 
Performance measure 3b 
Proportion of cytology specimens reported as a possible high-grade intraepithelial 
abnormality where cervical histology, taken within 6 months, confirms the abnormality as 
high-grade intraepithelial abnormality or malignancy. 
Recommended standard 
Not less than 33% of cytology specimens with a cytological prediction of a possible high-
grade intraepithelial abnormality are confirmed on cervical histology, which is performed 
within 6 months, as having a high-grade intraepithelial abnormality or malignancy. 
Calculated values for 2010 
Squamous cytology and histology  Endocervical cytology and histology  
4,810/8,782 = 54.8%   120/213= 56.3% 
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Indicator 6 Incidence 
What you need to know about incidence 
Definition: The number of new cases of cervical cancer per 100,000 estimated resident 
female population in a 12-month period. 
Rationale: The National Cervical Screening Program (NCSP) aims to reduce the incidence of 
cervical cancer.  
Guide to interpretation: These data include both screen-detected cervical cancers (through 
the NCSP) and cervical cancers detected outside the screening program. 
Incidence of cervical cancer by state and territory, remoteness area, socioeconomic status and 
Indigenous status is reported over a 5-year period instead of a 12-month period to improve 
the stability and comparability of rates due to the small number of new cases in less 
populated areas and in Aboriginal and Torres Strait Islander women. 
The Australian Cancer Database is the source of cervical cancer incidence data.  
The most recent cervical cancer incidence data are for new cases diagnosed in 2009  
(note that 2009 incidence data include estimates for NSW and the ACT). 
What the data tell us about incidence 
 Trend 
Incidence of cervical cancer, after halving from 17.2 new cases per 100,000 women in 1991, 
has remained at around 9 new cases per 100,000 women from 2002 to 2009, for women aged 
20–69. 
 
2009 
In 2009 there were 631 new cases of cervical cancer in women aged 20–69, the target 
population of the NCSP, which equates to 8.9 new cases per 100,000 women (age-
standardised). There were 771 new cases, or 6.7 new cases per 100,000 women (age-
standardised) in women of all ages.  
 
2004–2008 
The incidence of cervical cancer was higher for women residing in Remote and very remote 
areas, and lower in women residing in areas of highest socioeconomic status. 
The incidence of cervical cancer in Aboriginal and Torres Strait Islander women from New 
South Wales, Queensland, Western Australia and the Northern Territory was significantly 
higher than non-Indigenous women from these states and territories, at 22.3 new cases per 
100,000 women compared with the non-Indigenous rate of 8.5 new cases per 100,000 
women for women aged 20–69 (both age-standardised). 
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More information on incidence  
Registration of cancer cases is required by law in each state and territory. Data are collected 
by state and territory cancer registries and compiled in a national database, the Australian 
Cancer Database (ACD), which is held by the Australian Institute of Health and Welfare 
(AIHW). The data include clinical and demographic information about people with newly 
diagnosed cancer.  
Incidence of cervical cancer measures the number of new cases of cervical cancer diagnosed 
each year, sourced from the ACD. Only primary cervical cancers are included—secondary 
cervical cancers and cervical cancers that are a reoccurrence of a primary cervical cancer are 
not counted. Note that incidence data refer to the number of new cases diagnosed and not 
number of women diagnosed (although it is rare for a woman to be diagnosed with more 
than one primary cervical cancer in the same year).  
The main data source for this chapter was the 2009 Australian Cancer Database. Note that, 
since 2009 incidence data include estimates for NSW and the ACT, data which require 
disaggregation (including by histological type) could only be presented to 2008. 
Detailed analyses 
Incidence of cervical cancer in 2009 
In 2009, there were 771 new cases of cervical cancer in Australian women. This is equivalent 
to 7.0 new cases for every 100,000 women in the population, which, when age-standardised 
to allow analysis of trends and differentials, equates to an incidence rate of 6.7 for 2009. 
Of the 771 new cases, 631 were in women aged 20–69, the target population of the NCSP. 
These 631 new cases represent 81.8% of all cervical cancers diagnosed in that year, and 8.9 
new cases for every 100,000 women in the population. When age-standardised to allow 
analysis of trends and differentials, this equates to an incidence rate of 8.9 per 100,000 
women aged 20–69. 
In the broader context of cancers diagnosed in Australian women (and excluding basal cell 
and squamous cell carcinoma of the skin), cervical cancer was the 12th most commonly 
diagnosed cancer in Australian women in 2009, and comprised 1.5% of all cancers diagnosed 
in women (AIHW & AACR 2012). Further, the mean age of diagnosis was 50.2 years, and the 
risk of diagnosis with cervical cancer was 1 in 198 by age 75 and 1 in 162 by age 85 (AIHW & 
AACR 2012). 
Incidence of cervical cancer trends 
The incidence of cervical cancer has decreased over time. For women aged 20–69, while 
incidence had been slowly decreasing before the organised national screening program, this 
halved between 1991 and 2009 from 17.2 to 8.9 new cases per 100,000 women. This historic 
low of 9 new cases per 100,000 women has been stable since 2002 (Figure 6.1; Table 6.1).  
For women aged 20–69, the overall decrease in the number of new cases was from 895 in 
1991 to 631 in 2009, a decrease of 29.5% (Table 6.1). 
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When interpreting cervical cancer incidence trends in relation to the NCSP, it is important 
to remember that opportunistic cervical screening occurred in Australia prior to the 
commencement of the national screening program in 1991, with some states trialling 
organised screening in the years leading up to 1991. Therefore it would be expected that 
some decreases in cervical cancer incidence would be apparent before 1991, particularly 
from the late 1980s onwards. 
Table 6.1: Incidence of cervical cancer, 1982 to 2009 
 New cases  AS rate 
Year of diagnosis 20–69 All ages  20–69 All ages 
1982 826 963  19.0 14.2 
1983 841 994  19.0 14.3 
1984 834 1007  18.4 14.2 
1985 896 1058  19.5 14.6 
1986 861 1019  18.6 13.9 
1987 904 1098  18.6 14.4 
1988 900 1065  18.1 13.6 
1989 908 1072  18.0 13.5 
1990 918 1088  18.0 13.5 
1991 895 1094  17.2 13.3 
1992 848 1027  16.0 12.2 
1993 848 1016  15.9 11.9 
1994 936 1143  17.0 13.1 
1995 777 962  13.9 10.7 
1996 759 939  13.4 10.3 
1997 658 809  11.4 8.7 
1998 701 873  11.9 9.2 
1999 661 800  11.0 8.3 
2000 598 769  9.9 7.8 
2001 588 742  9.5 7.4 
2002 560 691  8.9 6.8 
2003 579 730  9.1 7.1 
2004 585 727  9.1 6.9 
2005 607 737  9.3 6.9 
2006 588 719  8.8 6.7 
2007 624 752  9.2 6.9 
2008 641 780  9.3 7.0 
2009 631 771  8.9 6.7 
Note: Age-standardised rate is the number of new cases of cervical cancer per 100,000 women, age-standardised to the Australian population at 
30 June 2001. 
Source: AIHW Australian Cancer Database. 
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Note: Rates age-standardised to the Australian population as at 30 June 2001. 
Source: AIHW Australian Cancer Database. 
Figure 6.1: Incidence of cervical cancer in women aged 20–69, by year, 1982 to 2009 
Incidence of cervical cancer by age 
In 2009, the number of new cases of cervical cancer diagnosed in women aged 20–69 
comprised 81.2% of all cervical cancers. This is lower than 82.6% in 1999 and 84.5% in 1988. 
Analysis of 5-year age groups between 20 and 69 reveals that, in 2009, the highest incidence 
of cervical cancer was in women aged 50–54, at 12.0 new cases per 100,000 women (Table 
6.2). There is a second peak (not shown) of 15.1 new cases per 100,000 women for those aged 
85 and over. 
Table 6.2: Incidence of cervical cancer by age, 2009  
 Age group (years) 
 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 
New cases 12 54 85 85 67 89 87 59 51 44 
Crude rate 1.5 6.8 11.3 10.4 8.7 11.2 11.9 8.9 8.7 10.0 
Note: Crude rate is the number of new cases of cervical cancer per 100,000 women; rates based on less than 20 new cases should be interpreted 
with caution. 
Source: AIHW Australian Cancer Database. 
Historical age-specific trends reveal the effect of the cervical screening program on incidence. 
Calculated over a 5-year period to increase stability and comparability of rates, age-specific 
incidence is shown for 1985–1989, 1995–1999 and 2005–2009 in Figure 6.2.  
It was found that incidence was reduced across all age groups from 1985–1989 to 2005–2009. 
Further, in 1985–1989, before the NCSP was introduced, there was a clear second (and 
higher) peak in incidence in women from 60 years onwards, which has reduced (Figure 6.2). 
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Source: AIHW Australian Cancer Database. 
Figure 6.2: Incidence of cervical cancer in women, by age, 1985–1989, 1995–1999 and 2005–2009 
Incidence of cervical cancer by histological type 
While all cervical cancers share the same site code (C53 under ICD 10), there are a number of 
histological subtypes within the category of cervical cancer, with clear differences in clinical 
behaviour (Blomfield & Saville 2008). Histology codes for cancers are collected on the ACD, 
which allows the analysis of trends in cervical cancer incidence for different histological 
types. The histological types presented are based on the histological groupings for cervical 
cancer set out in Chapter 4 of Cancer incidence in five continents volume IX (Curado et al. 2007), 
with histological types characterised by the type of cell in which the cancer originates. Thus 
cervical cancer has been disaggregated into the broad histological types of carcinoma 
(cancers of epithelial origin), sarcoma (cancers originating in other cell types such as bone, 
muscle, or haematopoietic cells), and other specified and unknown malignant neoplasms 
(unusual cancers and cancers too poorly differentiated to be classified). Carcinoma has been 
further split into squamous cell carcinoma (which arise from the squamous cells that cover 
the outer surface of the cervix), adenocarcinoma (which arise from the glandular (columnar) 
cells in the cervical canal), adenosquamous carcinoma (which contains malignant squamous 
and glandular cells), and other carcinoma.  
This table differs slightly from that presented in Cancer incidence in five continents volume IX 
(Curado et al. 2007), with other specified and unspecified carcinomas grouped together, as 
are other specified and unspecified malignant neoplasms. Further, adenosquamous 
carcinoma has been listed as a separate group under carcinoma rather than included in 
‘other specified carcinoma’ as specified in Cancer incidence in five continents volume IX 
(Curado et al. 2007). The latter change is to allow the carcinoma histological groupings to 
match the cervical cancer types collected by the cervical cytology registries and reported 
under the Histology indicator. 
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Table 6.3: Incidence of cervical cancer in women aged 20–69, by histological type, 2008 
Type of cervical cancer 
New 
cases AS rate 
% of cervical 
cancers 
(% of 
carcinomas) 
1: Carcinoma 630 9.2 98.3 (100.0) 
1.1: Squamous cell carcinoma 419 6.1 65.4 (66.5) 
1.2: Adenocarcinoma 164 2.4 25.6 (26.0) 
1.3: Adenosquamous carcinoma 21 0.3 3.3 (3.3) 
1.4: Other specified and unspecified carcinoma 26 0.4 4.1 (4.1) 
2: Sarcoma 3 0.0 0.5 . . 
3: Other specified and unspecified malignant neoplasm 8 0.1 1.2 . . 
Total 641 9.4 100.0 . . 
Note: Age-standardised (AS) rate is the number of new cases per 100,000 women, age-standardised to the Australian population 
at 30 June 2001; rates based on less than 20 new cases should be interpreted with caution. 
Source: AIHW Australian Cancer Database. 
In 2008, of the 641 cervical cancers diagnosed in women aged 20–69, 630 (98.3%) were 
carcinomas, 3 (0.5%) were sarcomas, and 8 (1.2%) were classified as other and unspecified 
malignant neoplasms (Table 6.3). Within the carcinomas, squamous cell carcinoma 
comprised the greatest proportion at 65.4% of all cervical cancers, followed by 
adenocarcinomas at 25.6% of cervical cancers, and adenosquamous carcinomas at 3.3%, with 
other and unspecified carcinomas comprising 4.1% of all cervical cancers in 2008 in women 
aged 20–69 (Table 6.3). 
Trends in age-standardised incidence for women aged 20–69 for squamous cell carcinoma, 
adenocarcinoma, adenosquamous carcinoma and other carcinomas are shown in Figure 6.3. 
 
Source: AIHW Australian Cancer Database. 
Figure 6.3: Incidence of carcinoma of the cervix (squamous cell carcinoma, adenocarcinoma, 
adenosquamous carcinoma and other carcinoma) in women aged 20–69, by year, 1982 to 2008 
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Squamous cell carcinoma has shown the most dramatic change over this time, decreasing 
from 15.1 new cases per 100,000 women in 1982 to 12.4 in 1991, thereafter halving to 6.1 new 
cases per 100,000 women in 2008 (Figure 6.3). 
Incidence of adenocarcinoma appears to have increased in the late 1980s to around 3 new 
cases per 100,000 women, where it remained until a peak of 3.7 new cases per 100,000 
women in 1994. This is consistent with documented trends in Canada, the United States and 
the United Kingdom of increased incidence of adenocarcinoma from 1970 through to the 
mid-1990s, thought to represent a cohort effect as a result of increased risk of 
adenocarcinoma for women born in the early 1960s (Blomfield & Saville 2008). Incidence of 
adenocarcinoma was then found to decrease from the mid-1990s in countries with organised 
cervical screening programs (reviewed in Blomfield & Saville 2008), a trend mirrored in these 
data, with incidence of adenocarcinoma decreasing from 2.8 new cases per 100,000 women in 
1991 to 2.4 new cases per 100,000 women in 2008 (Figure 6.3).  
Incidence trends of adenosquamous and other carcinomas are more difficult to ascertain due 
to small numbers, but appear to increase around the introduction of the NCSP, thereafter 
decreasing to rates below these by 2008. 
As a result of these changes in incidence, the proportion of all carcinomas that each 
histological type comprises has changed over time. The proportion of carcinomas that are 
squamous in origin has decreased over time, from 81.5% in 1982 to 66.5% in 2008. In contrast, 
adenocarcinomas have comprised an increasingly large proportion since cervical screening, 
from 11.4% in 1982 to 26.0% in 2008. Adenosquamous, other specified and unspecified 
carcinomas between them comprise the remaining carcinomas (Figure 6.4). 
From these data it is clear that the observed decrease in cervical cancer incidence since the 
introduction of the NCSP in 1991 does not apply equally to all histological types of cervical 
cancer. 
The trend in squamous cell carcinomas illustrates the success of the NCSP in preventing 
these histological subtypes of cervical cancer through the detection of high-grade squamous 
abnormalities, with these readily identified by repeated cervical cytology (Blomfield & 
Saville 2008). As a result, squamous cell carcinomas now comprise 65% of cervical cancers, 
much reduced from its historical proportion of 95% (Blomfield & Saville 2008).  
In contrast, adenocarcinomas have not been reduced to the same degree as squamous cell 
carcinomas by cervical screening, with these glandular carcinomas now comprising a quarter 
of all cervical cancers—previously this was proportionately a rarer disease. The inability of 
cervical screening to reduce glandular cancers below the level reached a decade ago is 
recognised as a reflection of the difficulties in sampling glandular cells (Sasieni et al. 2009), 
with cervical cytology less effective at identifying glandular abnormalities (Blomfield & 
Saville 2008). Further, the cytological interpretation of abnormal glandular cells that are 
sampled (which occur much more infrequently than squamous abnormalities) is more 
difficult, and the progression from glandular abnormality to adenocarcinoma not well 
characterised (Sasieni et al. 2009; Wang et al. 2006). 
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Source: AIHW Australian Cancer Database. 
Figure 6.4: Squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma and other 
carcinoma in women aged 20–69, as a proportion of all carcinoma of the cervix, 1982 and 2008 
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Table 6.4: Incidence of carcinoma of the cervix (squamous cell carcinoma, adenocarcinoma, 
adenosquamous carcinoma and other carcinoma) in women aged 20–69, 1982 to 2008 
 New cases  AS rate 
Year of 
diagnosis SSC(a) AC(b) ASC(c) Other(d) 
 
SSC(a) AC(b) ASC(c) Other(d) 
1982 656 92 22 35  15.1 2.1 0.5 0.8 
1983 662 83 23 56  15.1 1.9 0.5 1.2 
1984 632 87 44 49  13.9 1.9 1.0 1.1 
1985 689 95 35 54  15.1 2.0 0.8 1.1 
1986 645 117 42 40  13.9 2.5 1.0 0.8 
1987 682 132 41 33  14.0 2.7 0.9 0.7 
1988 651 156 40 40  13.1 3.1 0.8 0.8 
1989 691 111 50 48  13.8 2.2 1.0 0.9 
1990 642 146 49 62  12.6 2.8 1.0 1.2 
1991 647 144 41 56  12.4 2.8 0.8 1.1 
1992 615 137 50 37  11.6 2.6 1.0 0.7 
1993 595 143 48 52  11.2 2.6 0.9 1.0 
1994 640 203 40 49  11.7 3.7 0.7 0.9 
1995 545 146 34 42  9.8 2.6 0.6 0.8 
1996 529 148 40 33  9.4 2.6 0.7 0.6 
1997 454 130 33 31  7.9 2.2 0.6 0.5 
1998 493 141 30 29  8.4 2.4 0.5 0.5 
1999 470 134 23 26  7.9 2.2 0.4 0.4 
2000 403 118 30 27  6.7 1.9 0.5 0.4 
2001 400 115 32 27  6.5 1.9 0.5 0.4 
2002 388 126 18 21  6.2 2.0 0.3 0.3 
2003 397 121 25 26  6.2 1.9 0.4 0.4 
2004 392 133 27 23  6.1 2.1 0.4 0.4 
2005 399 131 20 39  6.1 2.0 0.3 0.6 
2006 366 142 22 38  5.5 2.1 0.3 0.6 
2007 394 157 24 38  5.8 2.3 0.4 0.6 
2008 419 164 21 26  6.1 2.4 0.3 0.4 
(a) SSC = squamous cell carcinoma. 
(b) AC = adenocarcinoma. 
(c) ASC = adenosquamous carcinoma. 
(d) Other = other and unspecified carcinoma. 
Note: Age-standardised (AS) rate is the number of new cases of squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma and 
other carcinomas per 100,000 women age-standardised to the Australian population at 30 June 2001; rates based on less than 20 new cases 
should be interpreted with caution. 
Source: AIHW Australian Cancer Database. 
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Incidence of cervical cancer by state and territory 
In 2004–2008, incidence of cervical cancer for women aged 20–69 was relatively stable across 
states and territories, ranging between 7.9 and 14.5 new cases per 100,000 women (Table 6.5).  
Trends in state and territory incidence are shown in Figure 6.5.  
It should be noted that data for the least-populated jurisdictions are open to variation due to 
smaller numbers, even with 5 years of data combined. 
Table 6.5: Incidence of cervical cancer in women aged 20–69, by state and territory, 2004–2008 
 NSW Vic  Qld WA SA Tas ACT NT Australia  
New cases 982 661 691 334 210 76 44 47 3,045 
AS rate 8.9 7.9 10.6 10.2 8.5 9.7 8.0 14.5 9.1 
95% CI 8.4–9.5 7.3–8.5 9.8–11.4 9.1–11.4 7.4–9.8 7.6–12.2 5.8–10.7 10.5–19.4 8.8–9.5 
Note: Age-standardised (AS) rate is the number of new cases of cervical cancer per 100,000 women age-standardised to the Australian 
population at 30 June 2001. 
Source: AIHW Australian Cancer Database. 
 
 
Notes  
1. Rates age-standardised to the Australian population as at 30 June 2001. 
2. Bars on columns represent 95% confidence intervals. 
Source: AIHW Australian Cancer Database. 
Figure 6.5: Incidence of cervical cancer in women aged 20–69, by state and territory, 2004–2008 
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Incidence of cervical cancer by location of residence 
Incidence of cervical cancer is measured across remoteness areas and socioeconomic status of 
location of residence to assess any apparent differences. To increase the robustness and 
reliability of rates based on small numbers, incidence for Inner regional and Outer regional 
areas are reported together, as are Remote and Very remote areas. 
Incidence of cervical cancer in 2004–2008 differed little between Major cities and Inner and 
outer regional areas, these being 9.1 and 8.9 new cases per 100,000 women, respectively. 
Incidence in Remote and very remote areas, although not differing significantly from Inner 
regional areas, was significantly higher than incidence in Major cities (Table 6.6; Figure 6.6A). 
Table 6.6: Incidence of cervical cancer in women aged 20–69, by remoteness area, 2004–2008 
 Major cities Inner and outer regional Remote and very remote Australia 
New cases 2,094 849 87 3,045 
Rate 9.1 8.9 12.0 9.1 
95% CI 8.7–9.5 8.3–9.6 9.6–14.8 8.8–9.5 
Notes 
1. Women were allocated to a remoteness area using residential postcodes according to the 2006 Australian Standard Geographic 
Classifications. 
2. Age-standardised (AS) rate is the number of new cases of cervical cancers per 100,000 women age-standardised to the Australian 
population at 30 June 2001. 
Source: AIHW Australian Cancer Database. 
Higher incidence in Remote and very remote areas is likely be related to the proportionately 
high number of Indigenous women living in these areas, since Indigenous women have 
around twice the incidence of cervical cancer (see Figure 6.7 and Table 6.8 below). Further 
investigation of these incidence data found that, of all cervical cancers diagnosed in women 
residing in Remote and very remote areas, 45% were diagnosed in Aboriginal and Torres Strait 
Islander women, whereas only 5% of women in Inner and Outer regional areas diagnosed with 
cervical cancer were Indigenous, and 1% of those in Major cities were Indigenous women. 
Table 6.7: Incidence of cervical cancer in women aged 20–69, by socioeconomic status, 2004–2008 
 
(lowest) 
 1 2 3 4 
(highest) 
5 Australia  
New cases 685 635 609 566 534 3,045 
Rate 10.6 9.7 9.1 8.3 7.8 9.1 
95% CI 9.8–11.5 9.0–10.5 8.4–9.8 7.6–9.0 7.1–8.5 8.8–9.5 
Notes 
1. Women were allocated to a socioeconomic status using residential postcode according to the Australian Standard Geographic 
Classifications for 2006. 
2. Age-standardised (AS) rate is the number of new cases of cervical cancers per 100,000 women age-standardised to the Australian 
population at 30 June 2001. 
3. Australian total may not equal sum of the quintiles due to estimation of SES status variable  
Source: AIHW Australian Cancer Database. 
In 2004–2008, incidence was found to decrease with increasing socioeconomic status of 
residence, from 10.6 new cases per 100,000 women for women residing in areas of lowest 
socioeconomic status to 7.8 new cases per 100,000 women for women residing in areas of 
highest socioeconomic status (Table 6.7, Figure 6.6B). 
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Incidence of cervical cancer by Indigenous status 
The collection of reliable information by the state and territory cancer registries on the 
Indigenous status of individuals diagnosed with cancer is problematic, since primary cancer 
diagnosis information is sourced from pathology forms that do not have the capacity to 
record this information. The registries collect this information from additional sources such 
as hospital records and death records, which affect the completeness and correctness of these 
data. 
This means that reliable national data on the incidence of cancer for Aboriginal and Torres 
Strait Islander Australians are not available, because in some jurisdictions the level of 
identification of Indigenous status is not considered sufficient to enable analysis. In this 
report, data for four states and territories—New South Wales, Queensland, Western 
Australia and the Northern Territory—are considered of sufficient quality, and were used to 
examine the incidence of cervical cancer by Indigenous status. While the majority (around 
85%) of Australian Aboriginal and Torres Strait Islander people reside in these four 
jurisdictions (ABS 2009), the degree to which data for these jurisdictions are representative of 
data for all Aboriginal and Torres Strait Islander people is unknown. 
It was found that, over the 5-year period 2004–2008, Aboriginal and Torres Strait Islander 
women in New South Wales, Queensland, Western Australia and the Northern Territory 
aged 20–69 had a significantly higher incidence rate of cervical cancer compared with non-
Indigenous women from these states and territories at 22.3 new cases per 100,000 women 
compared with the non-Indigenous rate of 8.5 new cases per 100,000 women (Table 6.8; 
Figure 6.7).  
 
A 
 
B  
 
Note: Bars on columns represent 95% confidence intervals. 
Source: AIHW Australian Cancer Database. 
Figure 6.6: Incidence of cervical cancer in women aged 20–69, by geographic region (A) and by 
socioeconomic status (B), 2004–2008  
Number of new cases per 100,000 women
           0
           2
           4
           6
           8
          10
          12
          14
          16
M
aj
or
ci
tie
s
In
ne
r a
nd
ou
te
r r
eg
io
na
l
R
em
ot
e 
an
d
ve
ry
 re
m
ot
e
A
us
tra
lia
Number of new cases per 100,000 women
           0
           2
           4
           6
           8
          10
          12
          14
          16
1
(L
ow
es
t) 2 3 4 5
(H
ig
he
st
)
A
us
tra
lia
 78  Cervical screening in Australia 2010–2011 
 
Notes 
1. Rates age-standardised to the Australian population as at 30 June 2001. 
2. Bars on the columns represent 95% confidence intervals. 
Source: AIHW Australian Cancer Database. 
Figure 6.7: Incidence of cervical cancer in women aged 20–69 (New South Wales, Queensland, 
Western Australia, and Northern Territory), by Indigenous status, 2004–2008 
 
Table 6.8: Incidence of cervical cancer in women aged 20–69 (New South Wales, Queensland, 
Western Australia, and Northern Territory), by Indigenous status, 2004–2008 
  New South Wales, Queensland, Western Australia, and the Northern 
Territory(a) 
Australia(c) 
 Aboriginal and Torres Strait 
Islander Non-Indigenous Total(b)  
New cases 111 1,769 2,054 3,045 
Crude rate 20.0 8.6 9.7 9.1 
AS rate 22.3 8.5 9.7 9.1 
95% CI 18.2–27.0 8.2–9.0 9.3–10.1 8.8–9.5 
(a)  Data shown for ‘Aboriginal and Torres Strait Islander’, ‘Non-Indigenous’ and ‘Total’ are for New South Wales, Queensland, Western 
Australia and the Northern Territory only; data from these jurisdictions were considered to have adequate levels of Indigenous identification 
in cancer registration data at the time this report was prepared.  
(b) ‘Total’ may not equal the sum of ‘Aboriginal and Torres Strait Islander ‘and ‘Non-Indigenous’ due to the inclusion of the 'not stated' category.  
(c) Data shown for ‘Australia’ are for New South Wales, Victoria, Queensland, Western Australia, South Australia, Tasmania, the Australian 
Capital Territory and the Northern Territory. 
Notes 
1. Crude rate is the number of new cases of cervical cancer per 100,000 women; age-standardised rates are the number of cervical cancers 
detected per 100,000 women age-standardised to the Australian population at 30 June 2001. 
2. Some states and territories use an imputation method for determining Indigenous cancers, which may lead to differences between these 
data and those shown in jurisdictional cancer incidence reports. 
Source: Australian Cancer Database, AIHW. 
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Indicator 7 Mortality 
What you need to know about mortality 
Definition: The number of deaths from cervical cancer per 100,000 estimated resident female 
population in a 12-month period. 
Rationale: The National Cervical Screening Program (NCSP) aims to reduce mortality from 
cervical cancer. 
Guide to interpretation: These data include mortality from all cervical cancers, whether or 
not they were detected through the NCSP. 
Mortality from cervical cancer by state and territory, remoteness area, socioeconomic status 
and Indigenous status is reported over a 5-year period to improve the stability and 
comparability of rates due to the small number of deaths in less populated areas and in 
Aboriginal and Torres Strait Islander women. 
The National Mortality Database is the source of cervical cancer mortality data.  
The most recent cervical cancer mortality data are for deaths in 2010. 
What the data tell us about mortality 
 
 Trend 
Mortality from cervical cancer, after halving from 4.0 new cases per 100,000 women in 1991, 
has remained at around 2 new cases per 100,000 women from 2006 to 2010, for women aged 
20–69. 
 
2010 
In 2010 there were 152 deaths from cervical cancer in women aged 20–69, the target 
population of the NCSP, which equates to 2.0 deaths per 100,000 women (age-
standardised). There were 232 deaths, or 1.9 deaths per 100,000 women (age-standardised) 
in women of all ages. 
 
2006–2010 
Mortality where cervical cancer was the underlying cause was significantly higher in 
Aboriginal and Torres Strait Islander women (10.6 deaths per 100,000) from New South 
Wales, Queensland, Western Australia, South Australia and the Northern Territory 
compared with non-Indigenous women (1.9 deaths per 100,000) from these states and 
territories. 
 80  Cervical screening in Australia 2010–2011 
More information about mortality you might find useful 
Mortality statistics are one of the most comprehensively collected national data sets. 
Registration of death is a legal requirement in Australia and, as a result, the data set is 
considered to have high coverage and completeness. Registration of deaths is the 
responsibility of the Registrar of Births, Deaths and Marriages in each state and territory. The 
mortality data used here were provided by the Registries of Births, Deaths and Marriages, 
the Australian Bureau of Statistics and the National Coroners Information System. These 
data are maintained at the Australian Institute of Health and Welfare in the National 
Mortality Database.  
Mortality from cervical cancer measures the number of deaths each year for which cervical 
cancer was the underlying cause of death. Analyses are based on the year of death, except for 
2010 (the latest year for which mortality data are available), which is based on the year of 
registration of death. Note that about 5% of deaths are not registered until the year following 
the death (ABS 2012). Further, as noted in Appendix C, 2010 mortality data are preliminary 
and subject to revision. 
Detailed analyses 
Mortality from cervical cancer in 2010 
In 2010, there were 232 deaths from cervical cancer in Australian women. This is equivalent 
to 2.1 deaths for every 100,000 women in the population. When age-standardised to allow 
analysis of trends and differentials, this equates to a mortality rate of 1.9 for 2010. 
Of the 232 deaths, 152 were in women aged 20–69, the target population of the NCSP. These 
deaths represented 65.5% of all cervical cancer deaths in that year, and 2.0 deaths for every 
100,000 women (age-standardised). 
When compared with other cancers diagnosed in 2010, it was found that deaths from cervical 
cancer comprised 1.3% of all cancer deaths in women. Further, the mean age of death was 
62.2 years, and the risk of dying from cervical cancer was 1 in 728 by age 75 and 1 in 494 by 
age 85 (AIHW & AACR 2012). 
Mortality from cervical cancer trends 
Mortality from cervical cancer decreased over time.  
This decrease was evident prior to the introduction of the NCSP in 1991, being 5.5 deaths per 
100,000 women in 1982 and 4.8 deaths per 100,000 women in 1990. With opportunistic 
cervical screening occurring in Australia since the 1960s, some decreases in mortality are to 
be expected prior to the commencement of the NCSP.  
Mortality halved between 1991 and 2010, from 4.0 to 2.0 deaths per 100,000 women for 
women aged 20–69. This historic low of 2 deaths per 100,000 women has been stable since 
2002 (Figure 7.1; Table 7.1). The decrease in this rate was accompanied by a decrease in the 
number of deaths from 204 in 1991 to 152 in 2010 for women aged 20–69 (Table 7.1). 
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Table 7.1: Deaths and death rates from cervical cancer, 1982 to 2010 
 Deaths  AS rate 
Year 20–69 All ages  20–69 All ages 
1982 237 346  5.5 5.2 
1983 248 343  5.6 5.0 
1984 223 339  5.0 4.9 
1985 234 363  5.1 5.1 
1986 240 341  5.1 4.6 
1987 225 348  4.8 4.6 
1988 219 345  4.5 4.5 
1989 243 369  4.9 4.7 
1990 245 339  4.8 4.2 
1991 204 331  4.0 4.0 
1992 188 322  3.6 3.8 
1993 204 318  3.9 3.7 
1994 223 341  4.2 3.9 
1995 211 334  3.9 3.8 
1996 174 301  3.1 3.3 
1997 160 285  2.8 3.0 
1998 153 260  2.6 2.7 
1999 131 227  2.2 2.3 
2000 154 265  2.5 2.6 
2001 156 271  2.5 2.6 
2002 126 217  2.0 2.0 
2003 140 239  2.2 2.2 
2004 119 210  1.8 1.9 
2005 136 221  2.0 2.0 
2006 137 228  2.0 2.0 
2007 125 201  1.8 1.7 
2008 145 237  2.0 2.0 
2009 143 241  1.9 1.9 
2010 152 232  2.0 1.9 
Notes  
1. Deaths between 1982 and 2009 were derived by year of death; deaths in 2010 were derived by year of registration of death. Mortality data 
for 2009 and 2010 are revised and preliminary, and are subject to further revision. 
2. Age-standardised rate is number of deaths from cervical cancer per 100,000 women age-standardised to the Australian population at 30 
June 2001. 
3.  These data have not been adjusted for the additional deaths arising from outstanding registrations of deaths in Queensland in 2010. For 
more detail please refer to Technical note 3 in Causes of death, Australia, 2010 (ABS Cat. no. 3303.0). 
Source: AIHW analysis of National Mortality Database. 
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Notes:  
1. Deaths between 1982 and 2009 were derived by year of death; deaths in 2010 were derived by year of registration of death. Mortality data 
for 2009 and 2010 are revised and preliminary, respectively, and are subject to further revision. 
2. Rates age-standardised to the Australian population as at 30 June 2001. 
3.  These data have not been adjusted for the additional deaths arising from outstanding registrations of deaths in Queensland in 2010. For 
more detail please refer to Technical note 3 in Causes of death, Australia, 2010 (ABS Cat. no. 3303.0). 
Source: AIHW analysis of National Mortality Database. 
Figure 7.1: Mortality from cervical cancer, women aged 20–69, 1982 to 2010 
Mortality from cervical cancer by age 
In 2010, analysis of 5-year age groups revealed that mortality increased with age, from less 
than 1 death per 100,000 women for those aged 20–24 to 10.4 deaths per 100,000 women for 
those aged 85 and over. Within the target age group (20-69 years), women aged 55–59 had 
the highest mortality (32 deaths) and mortality rate (4.8 deaths per 100,000 women) (Table 
7.2).  
Table 7.2: Mortality from cervical cancer by age, 2010 
 Age group (years) 
 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 
Deaths 0 n.p. n.p. 19 16 12 26 32 19 22 
Crude rate 0.0 n.p. n.p. 2.3 2.1 1.5 3.5 4.8 3.1 4.8 
Notes 
1. Deaths in 2010 were derived using year of registration. Mortality data for 2010 are preliminary and are subject to further revision. 
2. Crude rate is the number of deaths from cervical cancer per 100,000 women; age-specific rates based on less than 20 deaths should be 
interpreted with caution. 
3. These data have not been adjusted for the additional deaths arising from outstanding registrations of deaths in Queensland in 2010. For 
more detail please refer to Technical note 3 in Causes of death, Australia, 2010 (ABS Cat. no. 3303.0). 
Source: AIHW analysis of National Mortality Database. 
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To stabilise rate comparisons over time, age-specific mortality rates in cervical cancer are 
presented over a 5-year period. The trend shows that mortality from cervical cancer has 
decreased across all age groups from 1986–1990 (prior to the introduction of the NCSP) to 
1996–2000 (just after its introduction), with the trend continuing through to 2006–2010 
(Figure 7.2). 
 
Notes:  
1. Deaths between 1986 and 2009 were derived by year of death; deaths in 2010 were derived by year of registration of death. Mortality data 
for 2009 and 2010 are revised and preliminary, respectively, and are subject to further revision. 
2. Rates age-standardised to the Australian population as at 30 June 2001. 
3. These data have not been adjusted for the additional deaths arising from outstanding registrations of deaths in Queensland in 2010. For 
more detail please refer to Technical note 3 in Causes of death, Australia, 2010 (ABS Cat. no. 3303.0). 
Source: AIHW analysis of National Mortality Database. 
Figure 7.2: Mortality from cervical cancer by age, 1986–1990, 1996–2000 and 2006–2010 
Mortality from cervical cancer by state and territory 
In 2006–2010, the mortality rate from cervical cancer for women aged 20–69 across the states 
and territories were relatively similar to the national rate of 1.9 deaths per 100,000 women 
(Table 7.3 and Figure 7.3).  
Table 7.3: Mortality from cervical cancer in women aged 20–69, by state and territory, 2006–2010 
 NSW Vic  Qld WA SA Tas ACT NT Australia  
Deaths 226 142 163 78 50 21 11 11 702 
AS rate 1.9 1.6 2.3 2.2 1.8 2.3 1.9 3.5 1.9 
95% CI 1.7–2.2 1.3–1.9 1.9–2.6 1.7–2.7 1.3–2.4 1.4–3.6 1.0–3.5 1.7–6.3 1.8–2.1 
Notes 
1. Deaths between 2006 and 2009 are derived from year of death; deaths in 2010 are derived from year of registration. Mortality data for 2009 
and 2010 are revised and preliminary, respectively, and are subject to further revisions.  
2. Age-standardised (AS) rate is the number of deaths from cervical cancer per 100,000 women, age-standardised to the Australian 
population at 30 June 2001; rates based on less than 20 deaths should be interpreted with caution. 
Source: AIHW analysis of National Mortality Database. 
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Notes  
1. Deaths between 2006 and 2009 were derived by year of death; deaths in 2010 were derived by year of registration of death. Mortality data 
for 2009 and 2010 are revised and preliminary, respectively, and are subject to further revision. 
2.  Rates age-standardised to the Australian population as at 30 June 2001. 
3. Bars on columns represent 95% confidence intervals. 
4. These data have not been adjusted for the additional deaths arising from outstanding registrations of deaths in Queensland in 2010. For 
more detail please refer to Technical note 3 in Causes of death, Australia, 2010 (ABS Cat. no. 3303.0). 
Source: AIHW analysis of National Mortality Database. 
Figure 7.3: Mortality from cervical cancer in women aged 20–69, by state and territory, 2006–2010 
Mortality from cervical cancer by location of residence 
Mortality from cervical cancer is measured across remoteness areas and socioeconomic 
status of location of residence. Due to small numbers, mortality from Inner regional and Outer 
regional areas are reported together, as are Remote and Very remote areas. 
Although mortality appeared to increase with increasing remoteness, mortality in Major cities 
did not differ significantly from that in Inner and outer regional areas (1.8 compared with 2.1 
deaths per 100,000 women). Mortality in Remote and very remote areas was, in contrast, 
significantly higher than mortality in both Major cities and Inner and outer regional areas, at  
6.1 deaths per 100,000 women (Table 7.4; Figure 7.4A). This death pattern is largely 
associated with the high proportion (45%) of Indigenous women living in remote and very 
remote areas compared with non-Indigenous women (2%) living in the same area.   
Similar to incidence, higher mortality in Remote and very remote areas is likely be related to the 
proportionately high number of Indigenous women living in these areas, since Indigenous 
women experience far greater mortality from cervical cancer (see Figure 7.5 and Table 7.6 
below). Further investigation of these mortality data found that, of all deaths from cervical 
cancer in women residing in Remote and very remote areas, 64% were Aboriginal and Torres 
Strait Islander women, whereas only 10% of cervical cancer deaths in Inner and Outer regional 
areas and 1% of those in Major cities occurred in Indigenous women. 
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Table 7.4: Mortality from cervical cancer in women aged 20–69, by remoteness area, 2006–2010 
 
Major cities 
Inner and outer 
regional 
Remote and very 
remote Australia 
Deaths 448 221 30 702 
AS rate 1.8 2.1 6.1 1.9 
95% CI 1.7–2.0 1.8–2.4 4.1–8.7 1.8–2.1 
Notes 
1. Women were allocated to a remoteness area using residential SLA according to the Australian Standard Geographic Classifications for 
2006. 
2. Deaths between 2006 and 2009 are derived from year of death; deaths in 2010 are derived from year of registration. Mortality data for 2009 
and 2010 are revised and preliminary, respectively, and subject to further revisions.  
3. Age-standardised (AS) rate is the number of deaths from cervical cancers per 100,000 women age-standardised to the Australian 
population at 30 June 2001. 
4. These data have not been adjusted for the additional deaths arising from outstanding registrations of deaths in Queensland in 2010. For 
more detail please refer to Technical note 3 in Causes of death, Australia, 2010 (ABS Cat. no. 3303.0). 
Source: AIHW analysis of National Mortality Database. 
 
  
A 
 
B  
 
Note: Bars on columns represent 95% confidence intervals. 
Source: AIHW analysis of National Mortality Database. 
Figure 7.4: Mortality from cervical cancer in women aged 20–69, by remoteness area (A) and by 
socioeconomic status (B), 2006–2010 
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Table 7.5: Mortality from cervical cancer in women aged 20–69, by socioeconomic status,  
2006–2010 
 1 (lowest) 2 3 4 5 (highest) Australia  
Deaths 166 134 130 123 86 702 
Rate 2.4 1.9 1.8 1.7 1.1 1.9 
95% CI 2.1–2.8 1.6–2.2 1.5–2.2 1.4–2.0 0.9–1.4 1.8–2.1 
Notes 
1. Women were allocated to a socioeconomic status using residential SLA according to the Australian Bureau of Statistics Socio-Economic 
Indexes for Areas (SEIFA) Index of Relative Socio-Economic Disadvantage for 2006. 
2. Deaths between 2006 and 2009 are derived from year of death; deaths in 2010 are derived from year of registration. Mortality data for 2009 
and 2010 are revised and preliminary, respectively, and subject to further revisions.  
3. Age-standardised (AS) rate is the number of deaths due to cervical cancers per 100,000 women age-standardised to the Australian 
population at 30 June 2001. 
4. These data have not been adjusted for the additional deaths arising from outstanding registrations of deaths in Queensland in 2010. For 
more detail please refer to Technical note 3 in Causes of death, Australia, 2010 (ABS Cat. no. 3303.0). 
Source: AIHW analysis of National Mortality Database. 
In 2006–2010, mortality was higher in women residing in areas of lowest socioeconomic 
status (2.4 deaths per 100,000 women) and lower in women residing in areas of highest 
socioeconomic status (at just over 1 death per 100,000 women) (Table 7.5, Figure 7.4B).  
Mortality from cervical cancer for Aboriginal and Torres Strait Islander women 
Information on Indigenous status on the National Mortality Database is considered of 
sufficient quality for the years 2006–2010 for five jurisdictions—New South Wales, 
Queensland, Western Australia, South Australia and the Northern Territory. The majority 
(around 90%) of Aboriginal and Torres Strait Islander people reside in these five jurisdictions 
(ABS 2009).  
In 2006–2010, the mortality rate from cervical cancer was significantly higher in Aboriginal 
and Torres Strait Islander women in New South Wales, Queensland, Western Australia, 
South Australia and the Northern Territory (10.6 deaths per 100,000 women) compared with 
non-Indigenous women from these states and territories (1.9 deaths per 100,000 women) 
(Table 7.6, Figure 7.5). This was true for women aged 20–69, and for women of all ages. This 
mirrors the incidence results for Aboriginal and Torres Strait Islander women in Indicator 6. 
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Notes  
1. Deaths between 2006 and 2009 are derived from year of death; deaths in 2010 are derived from year of registration. Mortality data for 2009 
and 2010 are revised and preliminary, respectively, and subject to further revisions.  
2.  Rates age-standardised to the Australian population as at 30 June 2001. 
3. Bars on columns represent 95% confidence intervals. 
Source: AIHW analysis of National Mortality Database. 
Figure 7.5: Mortality from cervical cancer in Aboriginal and Torres Strait Islander women aged 20–
69 (New South Wales, Queensland, Western Australia, South Australia and Northern Territory), 
2006–2010 
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Table 7.6: Mortality from cervical cancer in Aboriginal and Torres Strait Islander women aged 20–
69 (New South Wales, Queensland, Western Australia, South Australia and Northern Territory), 
2006–2010 
 New South Wales, Queensland, Western Australia, South Australia and  
the Northern Territory(a) 
Australia(c)  
 Aboriginal and Torres Strait 
Islander Non-Indigenous Total(b)  
Deaths 52 471 528 702 
Crude rate 8.3 2.0 2.1 2.0 
AS rate 10.6 1.9 2.1 1.9 
95% CI 7.8–14.1 1.7–2.0 1.9–2.2 1.8–2.1 
(a)  Data shown for ‘Aboriginal and Torres Strait Islander’, ‘Non-Indigenous’ and ‘Total’ are for New South Wales, Queensland, Western 
Australia, South Australia and the Northern Territory only; data from these jurisdictions were considered to have adequate levels of 
Indigenous identification in cancer mortality data at the time this report was prepared.  
(b) ‘Total’ may not equal the sum of ‘Aboriginal and Torres Strait Islander ‘and ‘Non-Indigenous’ due to the inclusion of the 'not stated' category.  
(c) Data shown for ‘Australia’ are for New South Wales, Victoria, Queensland, Western Australia, South Australia, Tasmania, the Australian 
Capital Territory and the Northern Territory. 
Notes 
1. Crude rate is the number of deaths from cervical cancer per 100,000 women; age-standardised rate is the number of deaths from cervical 
cancer per 100,000 women age-standardised to the Australian population at 30 June 2001. 
2. Deaths between 2006 and 2009 are derived from year of death; deaths in 2010 are derived from year of registration. Mortality data for 2009 
and 2010 are revised and preliminary, respectively, and subject to further revisions.  
Source: AIHW analysis of National Mortality Database. 
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Appendix A Additional data 
In Figure A.1, all symbols represent the average of the ABS estimated resident population for 
women aged 20–69 in 2010–2011, adjusted to include only women with an intact cervix using 
hysterectomy fractions derived from the AIHW National Hospital Morbidity Database. 
Darker symbols represent the proportion of women screened in 2010–2011. The single 
darkest symbol represents the proportion of women with a high-grade abnormality detected 
by histology. 
 
Source: AIHW analysis of state and territory cervical cytology register data.  
Figure A1: Women in the National Cervical Screening Program, 2010–2011
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Table A1: Data for performance indicators by age (to support figures in report body) 
   Age group (years)  
Figure Data shown <20 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70+ 
Figure 1.4 2-year participation 2010–2011(a) . . 42.6 51.9 58.1 60.3 61.6 63.0 62.6 60.3 57.7 50.4 . . 
Figure 1.4 3-year participation 2009–2011(a) . . 56.0 66.6 73.3 75.4 75.3 76.3 74.2 70.5 66.4 58.5 . . 
Figure 1.4 5-year participation 2007–2011(a) . . 76.2 85.4 90.9 90.5 88.0 87.5 83.0 78.1 71.6 66.0 . . 
Figure 3.1A Proportion of cytology tests 2.6 9.1 11.5 11.8 12.1 11.8 11.0 9.9 8.0 6.7 4.3 1.3 
Figure 3.1B Unsatisfactory cytology 2011(b) 2.3 2.3 2.3 2.1 2.0 1.9 1.8 1.9 2.2 2.2 2.1 2.6 
Figure 3.2A Negative cytology 2011(c) 84.1 84.3 87.9 90.9 92.8 93.8 94.6 95.3 95.8 96.1 96.3 94.9 
Figure 3.2B No endocervical component 2011(d) 18.6 18.1 17.6 17.1 17.7 19.3 21.7 24.0 27.4 30.5 32.9 36.3 
Figure 3.3A Low-grade abnormalities detected by cytology 2011(e) 11.9 10.5 6.9 4.8 3.7 3.3 2.8 2.2 1.5 1.3 1.2 1.6 
Figure 3.3B High-grade abnormalities detected by cytology 2011(f) 1.6 2.9 3.0 2.3 1.5 1.1 0.8 0.6 0.5 0.4 0.4 0.7 
Figure 4.1A Proportion of histology tests 2011 1.7 12.8 16.4 13.5 11.7 11.7 11.0 7.9 4.9 3.5 2.3 2.6 
Figure 4.1B Histology tests per 100 cytology tests 2011 2.5 5.2 5.2 4.2 3.6 3.6 3.7 3.0 2.3 1.9 2.0 7.3 
Figure 4.2 Negative histology 2011(g) 24.3 23.6 24.6 31.9 44.4 61.4 70.3 76.4 75.1 76.9 78.6 81.7 
Figure 4.3A Low-grade abnormalities detected by histology 2011(h) 37.3 31.5 25.0 22.8 19.6 15.7 12.9 9.5 9.8 8.0 7.8 3.1 
Figure 4.3B High-grade abnormalities detected by histology 2011(i) 37.0 43.6 48.7 43.6 33.5 19.7 13.0 9.5 8.6 8.5 6.7 3.9 
Figure 4.4A CIN II detected by histology 2011 20.7 21.1 18.3 14.8 11.1 7.0 4.7 3.3 3.1 1.7 2.4 0.7 
Figure 4.4B CIN III detected by histology 2011 9.9 18.2 25.3 22.8 16.9 8.3 5.3 4.0 4.6 4.3 3.3 1.7 
(a) Number of women participating as a per cent of the population, adjusted to include only women with an intact cervix. 
(b) Number of unsatisfactory cytology tests as a per cent of all cytology tests. 
(c) Number of negative cytology tests as a per cent of all cytology tests. 
(d) Number of cytology tests with no endocervical component as a per cent of all cytology tests. 
(e) Number of low-grade (S2, S3 and E2) cytology tests as a per cent of all cytology tests. 
(f) Number of high-grade (S4, S5, S6, E3, E4 and E5) cytology tests as a per cent of all cytology tests. 
(g) Number of negative histology tests as a per cent of all histology tests. 
(h) Number of low-grade (HS02 and HE02) histology tests as a per cent of all cytology tests. 
(i) Number of high-grade (HS03 and HE03) histology tests as a per cent of all cytology tests. 
Source: AIHW analysis of state and territory cervical cytology register data. 
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Appendix B National Cervical Screening 
Program information 
Table B1: Contacts and links for the state and territory and Australian Government components of 
the National Cervical Screening Program 
NSW Cervical Screening Program 
Tel: (02) 8374 5757 
Fax: (02) 8374 5700 
Email: cervicalscreening@cancerinstitute.org.au 
<http://www.csp.nsw.gov.au/> 
 
PapScreen Victoria 
Tel: (03) 9635 5000 
Fax: (03) 9635 5360 
Email: papscreen@cancervic.org.au 
<http://www.papscreen.org.au> 
 
Qld Cervical Screening Program 
Tel: (07) 3328 9467 
Fax: (07) 3328 9487 
Email: cssb@health.gov.au 
<http://www.health.qld.gov.au/cervicalscreening/> 
 
WA Cervical Cancer Prevention Program 
Tel: (08) 9323 6788 
Fax: (08) 9323 6711 
Email: cervicalcancer@health.wa.gov.au 
<http://www.health.wa.gov.au/cervical/home/> 
 
SA Cervix Screening Program 
Tel: (08) 8226 8181 
Fax: (08) 8226 8190 
Email: cervixscreening@health.sa.gov.au 
<http://www.sahealth.sa.gov.au/wps/wcm/connect/public+cont
ent/sa+health+internet/health+information/health+information+
for+the+consumer/pap+smears> 
Tasmanian Cervical Cancer Prevention Program 
Tel: (03) 6216 4300 
Fax: (03) 6216 4308 
Email: canscreen@dhhs.tas.gov.au 
 
<http://www.dhhs.tas.gov.au/cancerscreening/cervical_screeni
ng_register> 
ACT Cervical Screening Program 
Tel: (02) 6205 1545 
Fax: (02) 6205 5035 
Email: pap.register@act.gov.au 
<http://www.health.act.gov.au/paptest> 
 
Cervical Screen NT 
Tel: (08) 8922 6444 
Fax: (08) 8922 6455 
Email: wcpp.ths@nt.gov.au 
<http://www.health.nt.gov.au/Womens_Health/Well_Womens_
Cancer_Screening/index.aspx> 
 
Australian Government Department of Health and Ageing  
cancerscreening@health.gov.au 
 
<http://www.cancerscreening.gov.au/internet/screening/publis
hing.nsf/Content/cervical-about> 
Australian Institute of Health and Welfare  
screening@aihw.gov.au <http://www.aihw.gov.au/cervical-cancer-screening/> 
 92  Cervical screening in Australia 2010–2011 
Appendix C Data sources and 
classifications 
Data sources 
Data used in this report are derived from multiple sources and are summarised below. All 
data are based on calendar years.  
Table C1: Data sources for performance indicators in the Cervical screening in Australia report 
series 
Indicator Description Data source 
1 Participation in cervical screening State and territory cervical cytology registers 
2 Rescreening State and territory cervical cytology registers 
3 Cytology State and territory cervical cytology registers 
4 Histology State and territory cervical cytology registers 
5 Cytology-histology correlation State and territory cervical cytology registers 
6 Incidence of cervical cancer Australian Cancer Database, AIHW 
7 Mortality from cervical cancer National Mortality Database, AIHW 
National Cervical Screening Program data 
The National Cervical Screening Program (NCSP) has both national and state and territory 
components. Although policy is usually decided at a national level, coordination of 
screening activity is the responsibility of the individual state or territory. Data for 
participation, rescreening, cytology, histology and the cytology-histology correlation are 
sourced from the cervical cytology register in each state and territory and then compiled into 
national figures to allow national monitoring of the NCSP. These data include all women 
screened in each jurisdiction, except for Victoria and the Australian Capital Territory, for 
which immediate border residents are also included. 
See data quality statement for cervical screening data in Appendix D for further information. 
Incidence data 
Incidence data in this report come from the Australian Cancer Database (ACD, formerly the 
National Cancer Statistics Clearing House), a national collection of cancer statistics held and 
operated by the Australian Institute of Health and Welfare (AIHW). The ACD receives data 
from individual state and territory cancer registries on cancers diagnosed in residents of 
Australia and produces reports on national incidence. 
The Data Quality Statement for the ACD 2009 can be found on the AIHW website at 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/500417>. 
Data have been analysed using the year of diagnosis of cancer. This is a more accurate 
reflection of incidence during a particular year than year of registration data.  
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Mortality data 
Mortality data in this report come from the AIHW’s National Mortality Database, which is a 
national collection of de-identified information for all deaths in Australia. Information on the 
characteristics and causes of death of the deceased is provided by the Registrars of Births, 
Deaths and Marriages and coded nationally by the Australian Bureau of Statistics (ABS). 
Information on the cause of death is supplied by the medical practitioner certifying the 
death, or by a coroner. The data are updated each calendar year. 
The Data Quality Statement for the National Mortality Database can be found on the AIHW 
website at < http://meteor.aihw.gov.au/content/index.phtml/itemId/500078>. 
Analyses are based on the year of death, except for 2010 (the latest year for which mortality 
data are available), which is based on year of registration of death. Note that about 5% of 
deaths are not registered until the year following the death (ABS 2012). 
Mortality data for 2010 are preliminary and subject to revision. For more information about 
revisions to mortality data, refer to ABS (2012) Causes of death 2010 (Catalogue number 
3303.0).  
Population data 
The ABS estimated resident female population was used to calculate participation, incidence 
and mortality rates in this report.  
Participation rates were calculated using the average of the estimated resident female 
population for the 2-year, 3-year or 5-year reporting period. Denominators for participation 
rates were calculated using the average of the ABS estimated resident population for 2009 
and 2010 (2-year participation), the average for 2008, 2009 and 2010 (3-year participation) and 
the average of the ABS estimated resident population for 2006, 2007, 2008, 2009 and 2010 (5-
year participation). These average populations were adjusted for the estimated proportion of 
women who have had a hysterectomy using national hysterectomy fractions derived from 
the AIHW National Hospital Morbidity Database (NHMD). 
There may be some variation in published participation rates because of different sources of 
estimated resident population data between national reports and state and territory reports. 
Further, national denominators are adjusted for the estimated proportion of women who 
have had a hysterectomy using national hysterectomy fractions derived from the AIHW 
NHMD, whereas state and territory reports may use hysterectomy fractions derived from 
ABS National Health Surveys, or derived from health surveys conducted in their state or 
territory which may give more representative figures at the jurisdictional level. 
Incidence and mortality rates were calculated using the estimated resident population for 
single-year calculations, and the aggregate of the estimated resident populations for the five 
relevant years for five-year calculations. 
The age-standardised rates in this publication were calculated using the total estimated 
resident Australian population at June 2001.  
Hysterectomy fractions 
Hysterectomy fractions represent the proportion of women with an intact uterus (and cervix) 
at a particular age, and are the tool used to adjust the population for participation 
calculations. This is because women who have had a hysterectomy with their cervix removed 
are not at risk of cervical cancer and thus do not require screening, and since substantial 
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proportions (20–30%) of middle-aged and older women in Australia do not have an intact 
cervix, the population is adjusted to remove these women so that true participation in 
cervical screening can be more accurately estimated. 
Previously, the AIHW used hysterectomy fractions derived from self-reported information 
on hysterectomies collected in the 2001 National Health Survey (NHS) conducted by the 
ABS. However, hysterectomy incidence has fallen since 2001, which means the 2001 NHS 
hysterectomy fractions no longer allow accurate estimates. Thus the introduction of new 
performance indicators in the AIHW annual monitoring report, Cervical screening in Australia 
2008–2009 provided an appropriate opportunity to update the method by which 
hysterectomy fractions were estimated.  
The National Hospital Morbidity Database (NHMD) is based on summary records of patient 
separations, referring to episodes of care in public and private hospitals, and allows us to 
view relatively complete hysterectomy numbers and rates for financial years from the mid-
1990s. These data were used, with projections forward and backward where required, to 
generate estimates of current hysterectomy prevalence for women aged 20–69. Published 
hysterectomy incidence trends as well as data from the 1995, 2001 and 2004–05 NHS were 
drawn on to ensure accuracy in assumptions.  
The results of these combined approaches are robust hysterectomy fractions that reflect both 
historical and current hysterectomy trends, which can be used in the calculation of 
participation in cervical screening for the most recent participation data. 
The fractions themselves are similar to previous estimates taken from population health 
surveys with the proportion of women with an intact cervix remaining comparatively higher 
in most age groups—a reflection of the national trend of decreasing incidence of 
hysterectomies over time. These are shown next to the previously adopted hysterectomy 
fractions based on the 2001 NHS in Table C3, below. 
Table C2: National hysterectomy fractions, 2011 
 Percentage of women who have not had a hysterectomy 
Age group (years) Derived from NHS 2001 Modelled on NHMD 
20–24 100.0 100.0 
25–29 100.0 99.7 
30–34 98.9 98.8 
35–39 95.6 96.2 
40–44 90.6 91.6 
45–49 82.5 85.9 
50–54 76.5 81.0 
55–59 66.2 77.2 
60–64 68.9 73.6 
65–69 66.8 70.6 
Source: AIHW analysis of the National Hospital Morbidity Database.  
The incorporation of these new hysterectomy fractions, based on lower prevalence of 
hysterectomy procedures, into cervical screening participation calculations results in a slight 
decrease in the participation rate, as would be expected, since the population at risk (and 
therefore eligible for cervical screening) is larger. 
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Classifications 
Age 
The data in this report are stratified by the age of the woman at the time of the specified test 
(for the screening data), at the time of diagnosis (for the cancer incidence data) or at the time 
of death (for the cancer mortality data). 
State or territory 
The state or territory reported is the one where screening took place (for the screening data), 
where the diagnosis was made (for the cancer incidence data) or the place of usual residence 
(for the cancer mortality data). 
This means that it is possible for a woman to be double-counted in the screening data. If she 
was screened in one jurisdiction and then screened again less than 2 years later in another 
jurisdiction, both screens may be included in participation. This should, however, have a 
negligible effect on the reported participation. 
Remoteness area 
Remoteness areas are classified according to the ABS’s Australian Standard Geographic 
Classification (ASGC) Remoteness Structure (ABS 2006), which groups geographic areas into 
six categories. These categories, called Remoteness Areas (RAs), are based on Census 
Collection Districts and defined using the Accessibility/Remoteness Index for Australia 
(ARIA). ARIA is a measure of the remoteness of a location from the services provided by 
large towns or cities. Accessibility is judged purely on distance to one of the metropolitan 
centres. A higher ARIA score denotes a more remote location. The six RAs of the ASGC 
Remoteness Structure are listed in the table below (Table C4); the sixth ‘migratory’ area is not 
used in this report.  
Table C3: Remoteness areas for the ASGC 
Remoteness area  Collection districts within region 
Major cities of Australia  CDs with an average ARIA index value of 0 to 0.2 
Inner regional Australia  CDs with an average ARIA index value greater than 0.2 and less than or equal to 2.4 
Outer regional Australia CDs with an average ARIA index value greater than 2.4 and less than or equal to 5.92 
Remote Australia  CDs with an average ARIA index value greater than 5.92 and less than or equal to 10.53 
Very remote Australia  CDs with an average ARIA index value greater than 10.53 
Migratory  Areas composed of offshore, shipping and migratory CDs 
For participation and incidence, women were allocated to a remoteness area using their 
residential postcode supplied at the time of screening. Caution is required when examining 
differences across remoteness areas. First, postcodes used to allocate women may not 
represent their location of residence. Second, because these are based on the 2006 census, the 
accuracy of remoteness area classifications diminishes due to subsequent changes in 
demographics. Third, some postcodes (and hence women) are unable to be allocated to a 
remoteness area.  
For deaths, women were allocated to a remoteness area based on their assigned statistical 
local area.  
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Note that the methodology used to allocate women to numerators and denominators was 
refined for 2009–2010 participation data, which effects comparability with data prior to  
2009–2010. 
Socioeconomic status 
Socioeconomic status classifications are based on the ABS Index of Relative Socioeconomic 
Disadvantage (ABS 2008). Postal areas are assigned a score based on attributes such as low 
income, low educational attainment, high unemployment and jobs in relatively unskilled 
occupations. The score does not refer to the socioeconomic situation of a particular 
individual but instead refers to the postal area in which a person lives. A low score means a 
postal area has many low-income families, people with little training and high 
unemployment, and may be considered disadvantaged relative to other areas. Postal areas 
with high index scores may be considered less disadvantaged relative to other areas.  
Socioeconomic status groups based on the level of the index are used for analysis where 1 
(lowest) represents the most disadvantaged and 5 (highest) the least disadvantaged. 
For participation and incidence, women were allocated to a socioeconomic status using their 
residential postcode supplied at the time of screening. Caution is required when examining 
differences across socioeconomic status for several reasons. First, postcodes used to allocate 
women may not represent their location of residence. Second, because these are based on the 
2006 census, the accuracy of socioeconomic status classifications diminishes due to 
subsequent changes in demographics. Third, many postcodes (and hence women) are unable 
to be allocated to a socioeconomic status group. 
For mortality, women were allocated to a socioeconomic status based on their assigned 
statistical local area. 
Note that the methodology used to allocate women to numerators and denominators was 
refined for 2009–2010 participation data, which effects comparability with data prior to  
2009–2010. 
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Appendix D Data quality statement 
Data Quality Statement: Cervical screening data 
2010–2011 
Summary of key issues 
• All states and territories maintain a population-based cervical cytology register (also 
referred to as ’Pap test registers’ or ‘Pap smear registers’) to which all cervical cytology, 
histology, and human papillomavirus (HPV) DNA tests are reported. 
• State and territory cervical cytology registers were established to support the National 
Cervical Screening Program (NCSP) that commenced in 1991. 
• The AIHW compiles cervical screening data using aggregate data supplied from state 
and territory cervical cytology registers in order to monitor the NCSP annually. 
• Some duplication may occur where the same test is reported to the cervical cytology data 
in two or more jurisdictions. AIHW is unable to identify or resolve these instances, and 
the level of duplication is unknown, but believed to be small. 
• Cervical cytology register databases change every day, adding new records and 
improving the quality of existing records as new information becomes available. 
Description  
All states and territories have legislation that requires pathology laboratories to send all 
cervical tests to the relevant state or territory population-based cervical cytology register. 
Cervical screening programs in each state and territory interrogate their own cervical 
cytology register in accordance with detailed data specifications to supply aggregate data 
annually to the AIHW. These data are compiled into the only repository of national cervical 
screening data, although because these are aggregate and not unit record data, these data do 
not exist in a database per se, and cannot be interrogated further.  
Institutional environment 
The Australian Institute of Health and Welfare (AIHW) is a major national agency set up by 
the Australian Government under the Australian Institute of Health and Welfare Act 1987 to 
provide reliable, regular and relevant information and statistics on Australia’s health and 
welfare. It is an independent statutory authority established in 1987, governed by a 
management Board, and accountable to the Australian Parliament through the Health and 
Ageing portfolio. 
The AIHW aims to improve the health and wellbeing of Australians through better health 
and welfare information and statistics. It collects and reports information on a wide range of 
topics and issues, ranging from health and welfare expenditure, hospitals, disease and 
injury, and mental health, to ageing, homelessness, disability and child protection. 
The Institute also plays a role in developing and maintaining national metadata standards. 
This work contributes to improving the quality and consistency of national health and 
welfare statistics. The Institute works closely with governments and non-government 
organisations to achieve greater adherence to these standards in administrative data 
collections to promote national consistency and comparability of data and reporting. 
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One of the main functions of the AIHW is to work with the states and territories to improve 
the quality of administrative data and, where possible, to compile national datasets based on 
data from each jurisdiction, to analyse these datasets and disseminate information and 
statistics. 
The Australian Institute of Health and Welfare Act 1987, in conjunction with compliance to the 
Privacy Act 1988 (Cwth), ensures that the data collections managed by the AIHW are kept 
securely and under the strictest conditions with respect to privacy and confidentiality. 
For further information see the AIHW website <www.aihw.gov.au>. 
The AIHW has been receiving cervical screening data since 1989.  
Timeliness 
Cervical cytology data are available within about 6 months (there can be a lag of up to 6 
months in the transmission of test results from pathology laboratories to cervical cytology 
registers), and data for the previous calendar year are supplied in July each year (rescreening 
and correlation data lag behind, as the specifications for these require a specified period of 
time to pass before this can be accurately calculated). 
The current cervical screening data contains all cytology and histology tests performed in 
2011.  
Accessibility 
Cervical screening data are published annually in the report Cervical screening in Australia, 
available on the AIHW website http://www.aihw.gov.au/cervical-cancer-screening/where 
they can be downloaded without charge. Supplementary data tables that provide more 
detailed data are also provided to accompany each report, and these, too, are available on the 
AIHW website where they can be downloaded without charge. 
General enquiries about AIHW publications can be made to the Communications, Media and 
Marketing Unit on (02) 6244 1032 or via email to <info@aihw.gov.au>.  
Interpretability 
While many concepts in the report Cervical screening in Australia are easy to interpret, other 
concepts and statistical calculations are more complex and may be confusing to some users. 
All concepts are explained within the body of the report presenting these data, along with 
footnotes to provide further details and caveats. Appendix C provides additional detail on 
the data sources and classifications, and Appendix E provides details on the statistical 
methods used. 
Relevance 
Cervical screening data are highly relevant for monitoring trends in cervical screening 
participation and abnormality detection trends. The data are used for many purposes by 
policy-makers and researchers, but are supplied and analysed specifically to monitor and 
inform the NCSP. 
Accuracy 
All data provided by state and territory cervical screening programs, once analysed, are 
supplied back for verification. 
  Cervical screening in Australia 2009–2010 99 
Further, National Pathology Accreditation Advisory Council (NPAAC) Performance measures 
for Australian laboratories reporting cervical cytology exist which allow some cervical screening 
data compiled and reported by the AIHW to be compared with data that are also sourced 
from state and territory cervical cytology registers for a different purpose. 
Coherence 
Cervical screening data are reported and published annually by the AIHW. Changes in 
reporting practices over time are clearly noted throughout the reports. 
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Appendix E Statistical methods 
Comparisons and tests of statistical significance 
This report includes statistical tests of the significance of comparisons of rates between 
population groups. Any statistical comparison applied to one variable must take account of 
any other potentially relevant variables. For example, any comparison of participation by 
state must also take account of differences in the distribution of age and sex between the 
states. These other variables are known as ‘confounding’ variables. 
Crude rates 
A crude rate is defined as the number of events over a specified period of time (for example, 
a year) divided by the total population. For example, a crude cancer incidence rate is 
similarly defined as the number of new cases of cancer in a specified period of time divided 
by the population at risk. Crude mortality rates and cancer incidence rates are expressed in 
this report as number of deaths or new cases per 100,000 population. Crude participation 
rate is expressed as a percentage. 
Age-specific rates 
Age-specific rates are calculated by dividing the number of cases occurring in each specified 
age group by the corresponding population in the same age group expressed as a percentage 
or a number per 1,000 or 100,000 population. This rate may be calculated for particular age 
and sex groupings. For example: 
Age-specific cervical cancer incidence rate in females aged 50–54 years 
= (New cases aged 50–54 over Female population aged 50–54) times 100,000 
= (75 over 698,700) times 100,000 
= 10.7 per 100,000. 
Age-standardised rates (AS rates) 
Rates are adjusted for age to facilitate comparisons between populations that have different 
age structures, for example, between youthful and ageing communities. There are two 
different methods commonly used to adjust for age. This publication uses direct 
standardisation, in which the age-specific rates are multiplied by a constant population (the 
2001 Australian Standard Population unless otherwise specified). This effectively removes 
the influence of the age structure on the summary rate. 
It important to be aware that for some data presented in this report, indirect age 
standardisation would be more appropriate due to small numbers (most commonly for the 
Australian Capital Territory and the Northern Territory), but direct age standardisation has 
been used for consistency. This can result in relatively large differences between crude and 
age-standardised rates. In these cases, crude rates should also be considered when 
interpreting data. 
The method used for this calculation comprises that first, the age-specific rate is calculated 
(as shown above) for each age group. Second, the expected number of cases in each 5-year 
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age group is calculated by multiplying the age-specific rates by the corresponding standard 
population and dividing by the appropriate factor (that is, 100,000 for mortality and 
incidence rates, and 100 for participation). Third, to give the age-standardised rate, the 
expected number of cases in each group are summed, divided by the total of the standard 
population and multiplied by the appropriate factor (for example 100,000 for mortality and 
incidence rate, and 100 for participation). 
Confidence intervals 
Population numbers for incidence and mortality and screening have a natural level of 
variability for a single year above and below what might be expected in the mean over many 
years. The percentage variability is small for large population numbers but high for small 
numbers such as mortality in a young age group. One measure of the likely difference is that 
of standard error, which indicates the extent to which a population number might have 
varied by chance in only 1 year of data. In the 95% confidence interval, there are about 19 
chances in 20 that the difference will be less than two standard errors. 
There are several methods for calculating confidence intervals. The 95% confidence intervals 
(CIs) in this report were calculated using a method developed by Dobson et al. (1991). This 
method calculates approximate confidence intervals for a weighted sum of Poisson 
parameters. 
Interpretation of confidence intervals 
Where indicators include a comparison (such as between states and territories), a 95% 
confidence interval is presented along with the rates. This is because the observed value of a 
rate may vary due to chance, even where there is no variation in underlying value of the rate. 
The 95% confidence interval represents a range (interval) over which variation in the 
observed rate is consistent with this chance variation. In other words, there is a 95% 
confidence that the true value of the rate is somewhere within this range. 
These confidence intervals can be used as a guide to whether differences in a particular rate 
are consistent with chance variation. Where the confidence intervals do not overlap, the 
difference between rates is greater than that which could be explained by chance and is 
regarded as statistically significant. 
It is important to note that overlapping confidence intervals does not imply that the 
difference between two rates is definitely due to chance. Instead, an overlapping confidence 
interval represents a difference in rates that is too small to allow differentiation between a 
real difference and one that is due to chance variation. It can therefore only be stated that no 
statistically significant differences were found, and not that no differences exist. 
The approximate comparisons presented might understate the statistical significance of some 
differences, but they are sufficiently accurate for the purposes of this report. 
As with all statistical comparisons, care should be exercised in interpreting the results of the 
comparison. If two rates are statistically significantly different from each other, this means 
that the difference is unlikely to have arisen by chance. Judgment should, however, be 
exercised in deciding whether or not the difference is of any clinical significance. 
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Glossary 
Aboriginal: a person of Aboriginal descent who identifies as an Aboriginal and is accepted 
as such by the community in which he or she lives. 
Adenocarcinoma: a carcinoma arising from the glandular cells of the endocervical canal. 
Adenosquamous carcinoma: a carcinoma made up of malignant glandular cells and 
malignant squamous cells. 
Age-standardised rate: a method of removing the influence of age when comparing 
populations with different age structures. This is usually necessary because the rates of many 
diseases vary strongly (usually increasing) with age. The age structures of the different 
populations are converted to the same ‘standard’ structure, which allows comparison of 
disease rates. 
Atypia: abnormality in a cell (to a lower degree than dysplasia). 
Benign: not malignant. 
Biopsy: small sample of tissue that is taken to obtain a definitive diagnosis of an 
abnormality. 
Cancer death: a death where the underlying cause of death is indicated as cancer. Persons with 
cancer who die of other causes are not counted in the mortality statistics in this publication. 
Cancer (malignant neoplasm): a large range of diseases in which some of the body’s cells 
become defective, and begin to multiply out of control. These cells can invade and damage 
the area around them, and can also spread to other parts of the body to cause further 
damage. 
Carcinoma: a cancer of cells forming part of a surface or lining of an organ of the body. 
Cervical cancer: this term covers all cancers specific to the uterine cervix, including  
micro-invasive cervical cancer. Types of cervical cancers include squamous cell carcinoma, 
adenocarcinoma (including mucoepidermoid and adenoid carcinomas), adenosquamous, and 
other and unspecified carcinomas. Other malignant neoplasms of the uterine cervix are also 
included in the incidence of cervical cancer data.  
Cervical cytology: Microscope examination of exfoliated cervical epithelial cells.  
Cervical cytology register: a database that stores cervical cytology results and related test 
results for women in each state and territory of Australia. The term cervical cytology register 
is often used interchangeably with the terms Pap test register and Pap smear register. 
Cervical cytology registry: the component of each state and territory cervical screening 
program that maintains the cervical cytology register. The term cervical cytology registry is 
often used interchangeably with the terms Pap test registry and Pap smear registry. 
Cervical intraepithelial neoplasia (CIN): squamous cell carcinoma of the cervix is mostly 
preceded, over a period of years, by a spectrum of asymptomatic abnormalities known as 
cervical neoplasia (CIN) graded as CIN 1 (I) (mild dysplasia), CIN 2 (II) (moderate dysplasia) 
and CIN 3 (III) (severe dysplasia and carcinoma in situ). 
CIN: (see Cervical intraepithelial neoplasia). 
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Colposcopy: a detailed examination of the lower genital tract with a magnifying instrument 
called a colposcope. This method of non-invasive evaluation allows the clinician to more 
accurately assess a cytological abnormality by focusing on the areas of greatest abnormality 
and by sampling them with a biopsy to obtain a tissue diagnosis. 
Confidence interval (CI): a range determined by variability in data, within which there is a 
specified (usually 95%) chance that the true value of a calculated parameter lies. 
Cytology: the microscope evaluation of a sample of cells obtained from a tissue (or body 
fluid). The sample does not permit evaluation of the underlying structure of the tissue of 
origin (cf. histology). 
Dysplasia: abnormal appearance, development or growth patterns of cells. 
Ectocervix: outer surface of the cervix and its covering epithelium, visible on inspection of 
the cervix. 
Endocervix: internal canal of the uterine cervix and its epithelium, not usually visible on 
inspection of the cervix. 
Epithelium: tissue lining the outer layer of a body or lining a cavity (for example, vagina or 
mouth). 
Exfoliate: to break away or remove (shed) cells. In the context of this report it refers to the 
removal of cells from a person for the purpose of cervical cytology. 
High-grade abnormalities: in this report high-grade abnormalities are defined as CIN I/II, 
CIN II, CIN III (see CIN), endocervical dysplasia, and adenocarcinoma in situ. 
Histology: the microscope study of the minute and detailed structure and composition of 
tissues. 
Human papillomavirus (HPV): the virus that causes genital warts and which is linked in 
some cases to the development of more serious cervical cell abnormalities. 
Hysterectomy: refers to the surgical procedure whereby all or part of the uterus is removed. 
Hysterectomy fraction: the proportion of women who have not had their uterus removed by 
hysterectomy. 
ICD-10: International Classification of Diseases—a coding system used to identify the 
primary site of the malignancy. This classification is in its 10th revision. 
in situ: a Latin term meaning in place or position; undisturbed.  
Incidence: the number of new cases (for example, of an illness or event) occurring during a 
given period. 
Intraepithelial: the area within the layer of cell tissues forming the epidermis of a body 
cavity. These cells comprise contiguous cells having minimum intercellular substance. 
Invasive cancer: a tumour whose cells have the potential to spread to nearby healthy or 
normal tissue or to more distant parts of the body. 
Low-grade abnormalities: in this report low-grade abnormalities are defined as atypia, warty 
atypia (HPV effect), possible CIN, equivocal CIN, and CIN 1. 
Malignant: abnormalities in cells or tissues consistent with cancer. 
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Metastasis: the process by which cancerous cells are transferred from one part of the body to 
another, for example, via the lymphatic system or the bloodstream. 
Micro-invasive squamous cell carcinoma (micro-invasive cancer): a lesion in which the 
cancer cells can be visualised with the microscope (only) to have invaded just beyond the 
tissue layer they arose from, for example, the epithelium of the cervix, but they have not yet 
spread to other layers or tissues. 
Mortality: see Cancer death. 
Neoplasia: the new and abnormal development of cells that may be harmless (benign) or 
cancerous (malignant). 
New cancer case: a person who has a new cancer diagnosed for the first time. One person 
may have more than once cancer and therefore may be counted twice in incidence statistics if 
it is decided that the two cancers are not of the same origin. This decision is based on a series 
of principles set out in more detail in a publication by Jensen et al. (1991). 
Pap smear: a sample prepared for the study of exfoliated cells from the cervix. The terms Pap 
smear and Pap test are often used interchangeably. 
Pap test: a sample prepared for the study of exfoliated cells from the cervix. The terms Pap 
test and Pap smear are often used interchangeably. 
Screening: the performance of tests on apparently well people in order to detect a medical 
condition at an earlier stage than would otherwise be the case. 
Significant difference: where rates are referred to as significantly different, or one rate is 
deemed significantly higher or lower than another, these differences are statistically 
significant. Rates are deemed statistically significantly different when their confidence 
intervals do not overlap, since their difference is greater than what could be explained by 
chance. See ‘confidence intervals’ in Appendix E for more information. 
Squamous cells: thin and flat cells, shaped like soft fish scales. They line the outer surface of 
the cervix (ectocervix). They meet with columnar cells in the squamo-columnar junction. 
Abnormalities associated with squamous cells are the most likely abnormalities to be picked 
up by Pap tests. 
Squamous cell carcinoma: a carcinoma arising from the squamous cells of the cervix. 
Stroma: the supporting framework of on organ. 
The Institute: the Australian Institute of Health and Welfare. 
Tumour: an abnormal growth of tissue. Can be benign (not a cancer) or malignant (a cancer). 
Underlying cause of death: the condition, disease or injury initiating the sequence of events 
leading directly to death; that is, the primary, chief, main or principal cause. 
 
Note: terms in italics are defined elsewhere in the glossary. 
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Cervical screening in Australia 2010–2011 presents the latest 
national statistics monitoring the National Cervical Screening 
Program, which aims to reduce incidence, morbidity and 
mortality from cervical cancer. Around 57% of women in the 
target age group of 20–69 took part in the program, with 
more than 3.6 million women screened in 2010 and 2011. 
Cervical cancer incidence in this age group remains at a 
historical low of 9 new cases per 100,000 women, and deaths 
are also low, historically and by international standards, at 2 
deaths per 100,000 women.
